US20170103186A1 - Systems and methods for supporting patient use of a drug delivery device - Google Patents
Systems and methods for supporting patient use of a drug delivery device Download PDFInfo
- Publication number
- US20170103186A1 US20170103186A1 US15/315,954 US201515315954A US2017103186A1 US 20170103186 A1 US20170103186 A1 US 20170103186A1 US 201515315954 A US201515315954 A US 201515315954A US 2017103186 A1 US2017103186 A1 US 2017103186A1
- Authority
- US
- United States
- Prior art keywords
- patient
- drug delivery
- support group
- delivery device
- treatment regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 282
- 238000000034 method Methods 0.000 title claims abstract description 185
- 238000004891 communication Methods 0.000 claims abstract description 126
- 238000011269 treatment regimen Methods 0.000 claims abstract description 72
- 230000006855 networking Effects 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims description 96
- 230000015654 memory Effects 0.000 claims description 42
- 230000009471 action Effects 0.000 claims description 37
- 230000004044 response Effects 0.000 claims description 20
- 238000003860 storage Methods 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 11
- 238000009223 counseling Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 60
- 229950000128 lumiliximab Drugs 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 239000000825 pharmaceutical preparation Substances 0.000 description 25
- 230000004888 barrier function Effects 0.000 description 22
- 229940126534 drug product Drugs 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 108010074604 Epoetin Alfa Proteins 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000000429 assembly Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000000712 assembly Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100034980 ICOS ligand Human genes 0.000 description 8
- 229960003388 epoetin alfa Drugs 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- 108010029961 Filgrastim Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000010437 erythropoiesis Effects 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 229960001972 panitumumab Drugs 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 5
- 102100036509 Erythropoietin receptor Human genes 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 229940090047 auto-injector Drugs 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 108010002601 epoetin beta Proteins 0.000 description 5
- 229960004579 epoetin beta Drugs 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000005055 memory storage Effects 0.000 description 5
- 108010044644 pegfilgrastim Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010019673 Darbepoetin alfa Proteins 0.000 description 4
- 108010008165 Etanercept Proteins 0.000 description 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 101710093458 ICOS ligand Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 239000003173 antianemic agent Substances 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 108010030868 epoetin zeta Proteins 0.000 description 4
- 229950005185 epoetin zeta Drugs 0.000 description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- 102000044389 human CD22 Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940071846 neulasta Drugs 0.000 description 3
- 229940029345 neupogen Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 108010017584 romiplostim Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229950007296 cantuzumab mertansine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960005029 darbepoetin alfa Drugs 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940089118 epogen Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 108010013846 hematide Proteins 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- 229950001869 mapatumumab Drugs 0.000 description 2
- 229940029238 mircera Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229950001212 volociximab Drugs 0.000 description 2
- 229950008250 zalutumumab Drugs 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002691 anti-thymic effect Effects 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229950007940 bixalomer Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940065770 humatrope Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229940116949 sensipar Drugs 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229950009578 vidupiprant Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- G06F19/3468—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31501—Means for blocking or restricting the movement of the rod or piston
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31568—Means keeping track of the total dose administered, e.g. since the cartridge was inserted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
- A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
-
- G06F19/325—
-
- G06F19/3418—
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
- A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
Definitions
- the present disclosure generally concerns systems and methods for encouraging a patient to use a drug delivery device in accordance with a treatment regimen.
- Drugs can be administered through the use of drug delivery devices, such as autoinjectors or on-body injectors or infusers. These devices may replace older delivery systems using the combination of a syringe and a vial containing the drug or medicament, or a pre-filled syringe. Autoinjectors and on-body injectors may be used to automate the injection and delivery or administration process, thereby simplifying the process for certain patient groups or sub-groups for which use of the syringe/vial combination or pre-filled syringe systems is disadvantageous, whether because of physiological or psychological impediments.
- drug delivery devices such as autoinjectors or on-body injectors or infusers. These devices may replace older delivery systems using the combination of a syringe and a vial containing the drug or medicament, or a pre-filled syringe.
- Autoinjectors and on-body injectors may be used to automate the injection and delivery or administration process, thereby simplifying
- patients may experience challenges in being adherent or compliant with a treatment regimen. For example, certain patients may not perform the injections according to the treatment regimen, having forgotten to perform the injection at all. Other patients may perform the injections, but then be unable to remember whether they performed the injections because they become distracted before they are able to record that they did so. Some patients may elect not to perform the injections because of misunderstandings or miscommunications of when or how the medication will affect the patient's disease or symptoms, especially where the effects are not felt by the patient until a considerable portion of the treatment regimen has been performed.
- Some patients may be more likely to follow a treatment regimen if they are provided with support and/or encouragement from others (e.g., a healthcare provider, a caregiver, a family member, a friend, another individual with a similar medical condition, etc.). However, the people who would potentially be willingly to provide such support and/or encouragement may be unaware that the patient has failed to follow the treatment regimen.
- others e.g., a healthcare provider, a caregiver, a family member, a friend, another individual with a similar medical condition, etc.
- the present disclosure sets forth various systems and methods to support patient use of a drug delivery device and facilitate compliance with a treatment regimen.
- a social networking based method of providing a patient with support may include associating the patient with at least one support group.
- the method may also include receiving data representative of at least one of a condition or an operational state of a drug delivery device associated with the patient.
- the method may further include determining if the patient is compliant with a treatment regimen based on the condition or the operational state of the drug delivery device.
- the method may include transmitting a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
- a support system for a patient includes a drug delivery system and an external computing device.
- the drug delivery system may include a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within the patient, one or more sensors, and a first communication module configured to transmit a report representative of at least one of a condition or an operational state of the drug delivery device.
- the external computing device may include a second communication module configured to receive the report, a processor, and a memory coupled to the processor and configured to store non-transitory, computer-executable instructions.
- the non-transitory, computer-executable instructions may cause the processor to: (i) associate the patient with the at least one support group; (ii) store, in the memory, a predefined criteria for determining compliance with a treatment regimen; (iii) compare the report with the predefined criteria to determine if the patient is compliant with the treatment regimen; and (iv) in response to a determination that the patient is not compliant with the treatment regimen, control the second communication module to transmit a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
- a non-transitory, computer-readable storage medium having computer-executable instructions that, when executed at one or more processors of a support system for a patient, cause the one or more processors to: (i) associate the patient with at least one support group; (ii) receive data representative of at least one of a condition or an operational state of a drug delivery device associated with the patient; (iii) determine if the patient is compliant with a treatment regimen based on the condition or the operational state of the drug delivery device; and (iv) in response to a determination that the patient is not compliant with the treatment regimen, transmit a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
- FIG. 1 is a schematic diagram of a drug delivery system according an embodiment of the disclosure in communication with one or more computing devices and one or more networks;
- FIG. 2 is a block diagram of a method of operating the drug delivery system illustrated in FIG. 1 according to an embodiment of the disclosure
- FIGS. 3A-3C is a block diagram of a method of operating the drug delivery system illustrated in FIG. 1 according to another embodiment of the disclosure;
- FIG. 4 is a block diagram of a method of operating a computing device such as is illustrated in FIG. 1 according to an embodiment of the disclosure, the computing device in communication with a drug delivery system operating according to one of the methods disclosed herein, for example;
- FIG. 5 is a schematic illustration of an embodiment of a system including a drug delivery device, a local computing device, and a remote computing device interconnected with communication links and networks;
- FIG. 6 is a flow diagram of an embodiment of a method for supporting a paitent's use of a drug delivery device.
- the present disclosure is directed to methods and systems for providing a patient under medical care with a social support network. More particularly, the present disclosure relates to monitoring patient use of a drug delivery device with sensors or other means and linking the patient to a support group who can encourage the patient to comply with a treatment regimen (e.g., a therapeutic regimen).
- a treatment regimen e.g., a therapeutic regimen.
- the systems and methods described herein may leverage the capabilities of social networking services (e.g., Facebook, Twitter, etc.) to identify a support group from which the patient is likely to take advice.
- the presently disclosed methods and systems therefore may increase the likelihood of patient use of the drug delivery device in accordance with a treatment regimen.
- the systems and methods may involve the determination of one or more states, which states may be determined through the use of one or more sensors in combination with one or more controllers.
- the sensors may rely on mechanical, electrical or chemical sensing mechanisms, and the controllers may be mechanical, electrical or electro-mechanical.
- the states may relate to the operation of the drug delivery device, or to the condition of the drug delivery device.
- the system and methods may use the state determination to control the operation of the drug delivery device, and/or may communicate the state determination to other devices, such as third-party servers that may collect, process and/or further disseminate the state determinations received from the system including the drug delivery device, the one or more sensors, and the one or more controllers.
- the systems and methods may communicate the state determination to local computing devices, such as a mobile computing device (e.g., cell phone).
- a drug delivery system may include a drug delivery device having a reservoir (which may also be referred to as a primary container, e.g. a syringe, vial or cartridge).
- the reservoir may contain a drug, which may also be referred to as a medication or a medicament.
- the drug may be, but is not limited to various biologicals such as peptides, peptibodies, or antibodies.
- the drug may be in a fluid or liquid form, although the disclosure is not limited to a particular state (e.g., no differentiation is intended between a solution, a gel, or a lyophilized product for example).
- the drug delivery device also includes delivery cannula having a first end connected to or connectable in fluid communication with the reservoir and a second end to be inserted within a patient.
- delivery cannula or “cannula” is hereby defined to mean a tube that can be inserted into the body for the delivery of fluid.
- a cannula may include a rigid or semi-rigid needle or blunt cannula, or may be in a flexible form, by example and not by way of limitation.
- the cannula may be integrated with the other elements of the drug delivery device, or the cannula may be separate from the other elements of the drug delivery until immediately prior to use.
- the drug delivery device may further include an inserter to introduce the second end into the patient, although this is not required according to each embodiment of the disclosure.
- the inserter may or may not be withdrawn back into the device, thereby leaving the cannula in a patient.
- the device may be characterized as an autoinjector or an on-body injector or infuser (the reference to injector intended to include also a reference to an infuser, to the extent that a difference is suggested).
- Autoinjectors may be single-use devices, administering a single dose during a single application of the device to the user's skin, although autoinjectors are not limited to only single-use devices—they may be multi-use devices as well.
- On-body injectors may be multi-use devices, administering multiple doses during one or more applications of the device to the user's skin, although on-body devices may also be used as single-use devices.
- Either autoinjectors or on-body injectors may have assemblies or sub-assemblies that are reusable, in that the assemblies may be used and re-used by refilling the reservoir, by removing an empty reservoir and replacing it with a filled reservoir, or by replacing the cannula, for example.
- the system or method according to the disclosure will determine one or more states relative to the drug delivery device.
- the system or method may determine if the drug delivery device is in one or more operational states (i.e., a state relating to the operation of the drug delivery device to deliver the drug to the patient).
- operational states i.e., a state relating to the operation of the drug delivery device to deliver the drug to the patient.
- a non-exhaustive list of the general operational states may include (i) packaged/ready for distribution; (ii) packaged/distributed; (iii) unpackaged/ready for administration; (iv) sterile barrier removed; (v) device applied; (vi) cannula injected (or inserted); (vii) drug delivery initiated; (viii) drug delivery completed; and (ix) device removed.
- the system or method may determine specific operational states within each of the general operational states; for example, the system or method may determine if plunger has been moved from a first end of a bore (defining a drug reservoir) to a second end of the bore to determine if the drug delivery device is in the “drug delivery complete” state.
- the system or method may determine if the drug delivery device is in one or more condition states (i.e., a state relating to the condition of the drug delivery device, not necessarily related to the operation of the drug delivery device to deliver the drug to the patient).
- condition states may include (i) age (e.g., taken with respect to a manufacturing date or an expiration date); (ii) sterility/contamination; (iii) temperature; (iv) temperature history; and (iv) orientation.
- the determination of a condition state may be considered as part of the determination of an operational state; for example, the determination of the temperature state may be considered as part of the determination of the “ready for administration” state.
- the operational and condition states may be determined separately.
- the sensors may be particular to a condition state to be determined: for example, a thermocouple disposed adjacent to the reservoir may be used to determine the temperature state of the drug delivery device.
- the sensors may be particular to an operational state to be determined: for example, a switch may be coupled to a needle guard to determine when a needle cap has been removed to determine the “sterile barrier removed” operational state, the switch being open when the needle cap is disposed over the second end of the cannula and the switch being closed when the needle guard is not disposed over the second end of the cannula.
- thermocouple may be used to determine the temperature condition state of the device (or more particularly, the drug), and/or the thermocouple may be used to determine the “ready for administration” operational state.
- the system or method may use the determined states to control the operation of the drug delivery device.
- the system may include a controller that is coupled to the sensor and may be coupled to one or more of the assemblies or subassemblies of the drug delivery device described above, or to one or more additional assemblies or subassemblies of the drug delivery device.
- the controller may be adapted structurally or programmed (if electrical or electro-mechanical) to activate or to inhibit these assemblies or subassemblies in accordance with the determined states.
- the drug delivery device may include a lockout that limits or completely inhibits the operation of the injector, and the controller may activate the lockout in a reversible fashion if the temperature state of the drug delivery device (and in particular, the drug in the reservoir) is below a threshold state.
- the system or method may communicate the determined state(s) to another device or system, which communication may be performed in conjunction with use of the determined state(s) to control the operation of the drug delivery device.
- the system or method may communicate the determined state(s) with a networked device using a communication link.
- a networked device is intended to include any device that communicates with at least one other device over a communication link, and might include communication with a device such as mobile device (e.g., cell phone or mobile computing device) using a Bluetooth connection or a computing device using a Wi-Fi connection, for example.
- the networked device may communicate the determined states to other computing devices remote from the drug delivery system over the network that includes the networked device such as a server.
- the system communicates directly with the network (i.e., without an intermediate networked device—the system would be a networked device) or directly with a remote computing device such as a server (using, for example, a 3G antenna).
- the state information communicated over network may then be used, for example, to determine if a patient is in compliance, or if a class of drug delivery devices is exhibiting a systemic malfunction.
- the state information may be used in other manners as well.
- the systems and methods may also include control of the drug delivery device according to information relating to the identity of the drug, the drug delivery device, or the user, and/or communication of this identity information.
- Identity information relating to the drug may include a drug name, a drug concentration, dose information, a lot number or serial number, and a date of manufacture and/or expiration.
- Identity information relating to the drug delivery device may include a device type (e.g., autoinjector, on-body injector), a lot number or serial number, and a date of manufacture.
- Identity information relating to the user may include a patient name, demographic information, and patient subgroup information. This information may be referred to as “static” information, in contrast to the state information discussed above.
- FIG. 1 illustrates a drug delivery system 100 according to an embodiment of the disclosure.
- the drug delivery system 100 may be associated with a patient 102 , who may use the drug delivery system 100 , to inject a drug as part of a treatment regimen (e.g., a therapeutic regimen).
- the drug delivery system 100 includes, but is not limited to, the drug delivery device describe below in more detail.
- the drug delivery system 100 may communicate with a computing device 104 (e.g., a server) via one or more intermediate computing devices and/or one or more networks.
- the server 104 may communicate with the drug delivery system 100 , the patient 102 , and one or more computing devices (with their associated parties) via one or more intermediate computing devices and/or one or more networks.
- the server 104 may communicate directly with the drug delivery system 100 , using a 3G or 4G antenna, for example.
- the drug delivery system 100 is illustrated as communicating with a mobile computing device 110 (e.g., a smartphone, a smartwatch, a smart wearable device, a tablet computer, etc.) via a first communication link 112 , and with a computing device 114 (e.g., a personal computer or a dedicated hub) via a second communication link 116 .
- Both links 112 , 116 may operate according to, for example, a near field communication protocol, Bluetooth, and/or Bluetooth Low Energy.
- the mobile computing device 110 may communicate with a cellular network 118 via a communication link 120
- the other computing device 114 may communicate with a hard-wired network (e.g., local area network or wide area network) 122 via a communication link 124 .
- These networks 118 , 122 may also communicate with the server 104 .
- the networks 118 , 122 may facilitate communication between the server 104 and one or more parties associated with the patient 102 , such as his or her caregiver 130 , support giver 132 (e.g., a family member, a friend, individual using a similar drug and/or drug delivery device as the patient 102 ), a healthcare provider 134 , via their mobile computing devices (e.g., smartphones, smartwatches, smart wearable devices, tablet computers, etc.) and/or another computing devices.
- the server 104 may also be in communication with one or more computing devices (e.g., servers) associated with one or more additional parties associated with the patient 102 .
- a healthcare system server 140 a payment server 142 , a pharmacy server 144 , a distributor server 146 , and a governmental agency server 148 are illustrated in communication with the server 104 via the network 122 . It will also be recognized that the networks 118 , 122 may be in communication with each other.
- the server 104 may be used to provide social networking based support for the user 102 of the drug delivery system 100 , as described below in more detail with reference to FIGS. 4 and 5 .
- FIGS. 3A-3C illustrate a method 300 that may be viewed as illustrating some of the mixed operational and condition state monitoring that may occur in a method and system according to the disclosure.
- the method 300 may also be viewed as illustrating how the one or more sensors may be used to determine the state changes described above.
- the method 300 may be viewed as providing disclosure of operational and conditions state monitoring and communication of that information not illustrated in FIG. 2 .
- the method 300 may begin with the drug delivery device in the package, and the method waits at block 302 until it is determined that the package has been opened.
- the device may optionally be locked until such time as the system conducts one or more validations, verifications or checks to ensure that the device is ready to administer, the sterile barrier has been removed and/or the device has been (correctly) applied (see blocks 220 , 226 , 232 of method 220 in FIG. 2 ).
- the method 300 may determine if the drug delivery device is adapted or programmed to carry out the validation, verification or check.
- a determination may be made at block 304 if the drug delivery device is adapted or programmed to check the sterility of the drug delivery device; in particular, the validation or verification may be related to a sterile barrier disposed at the second end of the cannula. If the drug delivery device is adapted or programmed to perform the sterility check, the method 300 may proceed to block 306 , where it is determined if the sterile barrier is disposed over or about the second end of the cannula, for example.
- the method may proceed to block 308 where the user is instructed to remove the barrier.
- the method 300 may then determine at block 310 if the barrier has been removed. When it is determined that the barrier has been removed, a sterility timer may be started, the expiration of which may result in the drug delivery device being placed into or remaining in a locked state, preventing use of the drug delivery device.
- the method 300 may proceed to block 312 , wherein the delivery device is locked (e.g., a lock or lock-out device is actuated) or the delivery device remains in a locked state if the device was previously locked.
- the locking of the delivery device at block 312 may be irreversible.
- the lock may be reversed once it is determined that the drug product (e.g., the drug product reservoir) has been replaced at block 314 . If the drug product is not replaced, or in those embodiments where the drug product cannot be replaced (i.e., the lock is irreversible), information regarding the failed sterility check may be communicated by the system.
- the method 300 continues to block 316 .
- a determination is made if the drug delivery device is capable of performing visual and/or environmental inspections. If the device is so adapted, the method proceeds to block 318 , wherein the determination is made if the visual inspection and/or environmental conditions are within desired thresholds.
- the method may proceed to blocks 312 , 314 . If the determination is made that the visual inspection and/or environmental conditions are within desired thresholds, then the method 300 may proceed to block 320 .
- the system may also communicate the information to local and/or remote devices. If the system is enabled to permit heating or cooling, then the method proceeds to block 336 , where the device may be locked or remain locked, heating or cooling may be initiated, and the user may be alerted. Whether passive or active heating or cooling (blocks 334 , 336 ), the method 300 may continue to block 338 , where delivery is delayed to provide time for the heating or cooling to occur before the method returns to block 330 . According to certain embodiments, the method 300 may terminate after block 330 (in case of excessive temperature, for example) and may communicate that information to local and/or remote devices.
- the temperature check performed at block 330 may involve an evaluation of the temperature history of the drug product to determine the range and duration of temperatures experienced by the drug product in the past (e.g., during storage, distribution, etc.). If the temperature history of the drug product is unacceptable due to, for example, the drug product being exposed to elevated temperatures for several days during shipment, the controller 350 may lockout the drug delivery device 302 so that it cannot be used to deliver the drug product to a patient, and additionally, may control the communication module 352 to transmit a report to the local computing device 304 or the remote computing device 306 representative of the unacceptability of drug product's temperature history.
- the controller may begin a timer that runs until the temperature falls back below the threshold temperature. If the duration of the timer exceeds a predefined time limit, the controller 350 may lockout the drug delivery device 302 and control the communication module 352 to transmit a report representative of the unacceptability of drug product's temperature history.
- the method may continue to block 340 , where a determination is made if the device is enabled to determine that the device is properly positioned on or oriented relative to the patient. If the device is so adapted, then the method proceeds to block 342 , and a determination is made whether the device is properly disposed or oriented.
- knowledge of the orientation of the device may be useful in providing a successful injection. For example, self-administration into the abdomen would most likely result in an orientation of an autoinjector axis approximately horizontal.
- the method proceeds to block 344 , and the device may be locked and the user instructed to reposition or reorient the device.
- the method 300 may then proceed to block 346 wherein a time delay is provided for the user to reposition the device before the method 300 returns to block 342 for a further determination relative to the position of the device.
- the method may proceed to block 348 , and any locks or lockouts that may have been actuated are removed (or the device is unlocked).
- the method 300 continues at block 350 , wherein a determination is made whether the system is enabled to determine if the delivery has been triggered. If the determination is made that the system is so adapted, then the method proceeds to block 352 , and a determination is made if the device has been activated or triggered. If the determination is made at block 352 that the device has not been triggered, then the method 300 may proceed to block 354 and the system may instruct the user to trigger the device. According to other embodiments, the drug delivery device may wait for a predetermined and/or preprogrammed time delay to occur before triggering the device automatically upon the completion of the time delay.
- the method 300 may optionally determine if a timer has elapsed at block 355 to reduce the risk of contamination and infection, for example.
- the timer may be started upon the determination that the barrier has been properly removed at block 310 (or may be started upon the determination that the barrier has been removed, according to still further embodiments), and if the method 300 does not determine that the device has been triggered within a certain amount of time from that event, the method 300 may return to block 312 , for example, as illustrated in FIGS. 3B and 3A .
- the method proceeds to block 356 , where the user may be notified of the triggering of the device and/or the date, time and location of the delivery may be stored or recorded. Optionally, this information may also be communicated to local and/or remote devices in communication with the system. The method 300 then continued to FIG. 3C .
- a needle shield e.g., needle shield 526 described below
- a delivery cannula e.g., delivery cannula 514 described below
- a plunger e.g., plunger 531 descrbied below
- the method 300 proceeds to block 376 , where the system indicates to the user that the delivery is complete. Furthermore, the method 300 communicates information regarding the drug delivery, the drug delivery device, and the drug product to local and/or remote devices at block 378 . For example, the information may include that certain operational states occurred and the timing of the operational states. The method 300 may also verify that the device was correctly positioned throughout, where the system is enabled to make this determination. The method 300 may also pass to block 378 if the system is not enabled to determine if the administration of the drug product is complete, the assumption made that the drug delivery device having been determined to have passed through one or more of the preceding operational states necessarily leads to the conclusion that the delivery was completed.
- the device need not determine each and every state or perform each and every action illustrated in FIG. 3A-3C . Rather, it will be recognized that one of ordinary skill in the art may omit or eliminate the determination of certain states or performance of certain actions, so as to result in a system that may control the device based on or communicate a subset of the states described.
- the possible methods of operating one or more computing devices in communication with the drug delivery system is now discussed in the context of a method 400 illustrated in FIG. 4 .
- the method 400 may be carried out by a single computing device, such as the server 104 illustrated in FIG. 1 , or the remote computing device 506 described below in connection with FIG. 5 .
- the actions discussed with respect to FIG. 4 may be carried out by multiple computing devices, such as the mobile device 110 and/or the computing device 114 in conjunction with the server 104 illustrated in FIG. 1 , or the local computing device 504 and the remote computing device 506 illustrated in FIG. 5 .
- the method 400 begins at block 402 with a determination as to whether a report has been received from the drug delivery system. If no report has been received, the method 400 waits at block 402 Once it is determined that a report has been received at block 402 , the method 400 proceeds to block 404 .
- the report received from the drug delivery system is used to update one or more records.
- the one or more computing devices adapted or programmed to carry out the method 400 may perform the actions of retrieving the one or more records from storage in one or more memory storage devices, writing the information received from the drug delivery device into the one or more records, and then storing the one or more records in the one or more memory storage devices.
- the one or more memory storage devices may be part of the one or more computing devices, may be separate from the one or more computing devices, or may include one or more of the memory storage devices that are part of the one or more computing devices and one or more memory storage devices that are separate from the one or more computing devices (i.e., the record is stored at the computing device and in backup storage separate and possibly remote from the computing device).
- the report may be used to update one or more records.
- the patient record may be used, for example, to track the compliance of the individual patient (e.g., patient 102 ) with his or her regimen(s).
- the drug delivery system record may be used to store information regarding the drug delivery system throughout the life of the drug delivery system.
- the drug delivery system record may be accessed by the drug delivery system manufacturer or the drug provider for quality control purposes (e.g., to monitor individual instances of the drug delivery system for faults or failures attributable for to the drug delivery system, or to track the environmental condition histories of one or more drug delivery systems for patterns that may assist in determining improvements in the design, packaging, shipment or handling of the drug delivery systems).
- quality control purposes e.g., to monitor individual instances of the drug delivery system for faults or failures attributable for to the drug delivery system, or to track the environmental condition histories of one or more drug delivery systems for patterns that may assist in determining improvements in the design, packaging, shipment or handling of the drug delivery systems.
- the computing device adapted or programmed to carry out the method 400 may be adapted or programmed to carry out one or more actions based on the information in the report received from the drug delivery system.
- the computing device may be adapted or programmed to carry out an action at block 406 .
- This action may require not only the information received in the report and/or stored previously in the record updated at block 404 , but may require additional information such as from other patient records, drug system delivery records and/or drug records.
- the determination may be made at block 408 that these other records need to be accessed, and the information retrieved at block 410 (e.g., by retrieving these other records from the patient, drug delivery system and drug databases and reading the information from these records once retrieved). The action may then be carried out at block 412 .
- the one or more computing devices adapted or programmed to carry out the method 400 may be adapted or programmed to use the information received in the report to prepare a compliance history for the patient, which compliance history tracks uses of instances of the drug delivery system by the individual patient relative to his or her treatment regimen to determine how successful the patient has been in following the treatment regimen and which compliance history may be stored in the patient record.
- the one or more computing devices may determine if a pharmacy should be contacted to order delivery of additional drug delivery devices for the individual patient, and may generate a communication to be sent to the pharmacy to order the delivery of additional drug delivery systems.
- the one or more computing devices may determine if a reminder should be sent to the patient, via the mobile device 110 for example, to improve or support compliance with the individual patient's treatment regime, in which case the one or more computing devices may generate a communication to be sent to the patient or user of the device. Further, the one or more computing devices may determine that the operation of the drug delivery device should be modified because of a conditional state received from the drug delivery device, for example. For example, the one or more computing devices may determine that the drug delivery system should be locked to prevent its use because of the temperature history of the drug in the drug delivery system, for example.
- the one or more computing devices may generate a communication, in the form of a signal for example, to be sent to the drug delivery system to lock the drug delivery device that is part of the drug delivery system.
- a communication in the form of a signal for example, to be sent to the drug delivery system to lock the drug delivery device that is part of the drug delivery system.
- the method 400 may proceed to blocks 414 , 416 , 418 where determinations are made if the computing device should make contact with other parties (block 414 ), interact with the patient (or user, if not the same as the patient) (block 416 ) or control the drug delivery device that is part of the drug delivery system (block 418 ).
- the action taken at block 412 may involve the generation of communications or signals to be sent to third parties, such as the pharmacy, to the patient, or to the drug delivery device.
- the one or more computing devices may carry out the actions of block 420 , 422 , 424 as dictated by the determinations made at blocks 414 , 416 , 418 .
- the one or more computing devices may carry out the actions of blocks 420 , 422 , 424 even if it is determined that no action need be taken at block 406 .
- the one or more computing devices may forward certain information to third parties 420 based solely on the receipt of the information in a report from the drug delivery device, such that there is no need to separately determine that an action need be taken in regard to the information received (i.e., the communication is automatically sent based on the fact that the information has been received, with the one or more computing devices acting as a repeater station for such information).
- the receipt of information from the drug delivery device may also prompt communications to be sent to the patient/user or control signals to be sent to the drug delivery system without a separate determination that such action need be taken, the communication or control signal being sent simply because certain information and/or reports were received from the drug delivery system.
- the method 400 may return to block 402 to await the next report.
- the one or more computing devices may perform the actions of the method 400 in parallel for each of the reports received from different instances of the drug delivery system, or may perform this steps in sequence for each report. If performed in parallel, the one or more computing devices may determine if action is to be taken in regard to one report, while the one or more computing devices may be interacting with another patient in regard to the information contained in the report received from that patient.
- the one or more computing devices carrying out the method 400 need not be adapted or programmed to carry out each of the actions described above according to every embodiment of the one or more computing devices.
- one of the one or more computing devices may be adapted or programmed to update records for each patient and to determine if an interaction with that patient is required, while another of the one or more computing devices may be adapted or programmed to update records for each drug delivery device and to determine is a control signal should be sent to the drug delivery device, while another one of the one or more computing devices does not update any record, but is adapted or programmed to access, for example, a patient record and determine if the pharmacy needs to be contacted to order additional instances of the drug delivery system for the patient associated with the patient record accessed and to generate the communication if the order of additional instances of the system is required.
- the methods 200 , 300 , and 400 touch only a fraction of the possible state and identity information that may be used to control and/or monitor the drug delivery device and that may be communicated between the drug delivery system and the one or more computing devices, as well as how that information is used by the drug delivery system and the one or more computing devices. Additional embodiments are possible according to the disclosure.
- a non-limiting matrix of state and identity information may include the following:
- This information may be used to control the drug delivery system or device, to be communicated to other computing devices, or otherwise to be used, and an exemplary listing of certain additional uses is included below.
- the listing and additional comments below is not intended to supersede, but to augment the discussion above, and is intended to be non-limiting.
- the drug delivery system or the one or more computing devices may make a determination regarding the authenticity of the drug and its compliance with manufacturing standards. Such a determination may be made by the drug delivery device at block 220 of method 200 or block 318 of method 300 , or by the one or more computing devices at block 406 of method 400 , for example. The determination may be made based on the temperature, shock or vibration exposure, and/or light exposure of the drug delivery device/drug (or a history of one or more of these conditions) and color and/or turbidity of the drug (as determined by an optical inspection). This determination may result in control of the drug delivery device to either lock or unlock the device, according to the determination made. See blocks 220 , 222 , 224 of method 220 , blocks 318 , 312 , 314 of method 300 , and blocks 406 - 412 and 418 , 424 of method 400 .
- the drug delivery system or the one or more computing devices may make a determination whether the drug is appropriate for the patient. See block 220 of method 200 , block 322 of method 300 , and block 406 - 412 of method 400 .
- the determination may be made based on one or more of the items of device of patient identity information listed above, and may also result in control of the drug delivery device to either lock or unlock the device, according to the determination made. See blocks 220 , 222 , 224 of method 220 , blocks 322 , 324 , 326 of method 300 , and blocks 406 - 412 and 418 , 424 of method 400 .
- the drug delivery system or the one or more computing devices may make a determination whether the dose has been correctly administered. This determination may be carried out after determining that the drug is appropriate for the patient and/or that the drug is authentic (e.g., not counterfeit) and is in compliance with manufacturing standards. See the preceding paragraphs.
- the determination whether the dose has been correctly administered may depend on one or more of the types of operational state information listed above. See blocks 220 - 260 of method 200 , and blocks 328 - 378 of method 300 . This information may be used to update the patient record, determine the patient compliance or therapy progress, and may prompt communication with the pharmacy regarding a refill, or with the payer (e.g., insurance company) to authorize payment for the drug delivery device. See blocks 404 - 414 of method 400 , and servers 142 , 144 of FIG. 1 .
- the drug delivery system or the one or more computing devices may use the information to make a determination regarding the operational state of the drug delivery device, and to generate instructional messages to guide the user through the actions required for the proper use of the drug delivery device.
- the determination may be based on any of the operational state information listed above, and the instructions generated may be dictated by the actions that need to be performed after the operational state that has just occurred. Implementation of interactive instructions that follow the changing states of the drug delivery device may help the user have confidence in administration of the drug.
- the drug delivery system or the one or more computing devices may use the information to make a determination that the patient needs more medication (a refill). See blocks 406 - 412 of method 400 .
- the determination may be based in part on the drug identity information, such as the prescribed treatment regime, and in part on the operational state information, such as where the drug delivery has been completed.
- the one or more computing devices may generate a communication that is sent to the payer and/or pharmacy to request a prescription refill. See blocks 414 , 420 of method 400 .
- the drug delivery system or the one or more computing devices may use the information to make a determination that the injection was not performed correctly. See blocks 406 - 412 of method 400 .
- the determination may be based in part on operational state information, in comparison with information that may be collected and stored regarding conventional norms in operation.
- a comparison between the determined, reported or received operational states may permit a determination to be made that the injection was not performed correctly. For example, the determination, reporting or receipt of operational state information indicating that the drug delivery is complete without operation state information indicating that device was triggered, that the device was applied to the patient, and/or that the cannula was inserted may indicate that the drug delivery device has failed to perform correctly, is faulty or was operated incorrectly.
- the drug delivery system or the one or more computing devices may use the information to make a determination that patient's condition is improving.
- the determination may be based in part on patient identity information, such as point-of-care diagnostics performed on the patient (e.g., blood glucose test or other testing) or self-analysis reporting, and in part on the determination, reporting or receipt of operational state information, such as where the drug delivery has been completed.
- the determination may rely upon an overall trend as opposed to individual determinations or reports, as it is believed that data or reporting trends are usually more indicative of improvement in a patient's condition than the patient's condition as determined at individual instances for serious diseases.
- the information gathered regarding the patient and the operational state of the drug delivery system/device may be combined with combined with therapy compliance history. This determination may result in individualized interventions to be generated, which interventions (such as encouraging messages and other forms of positive reinforcement) may increase persistence in therapy.
- the drug delivery system or the one or more computing devices may use the information to make a determination of the time of day (or week, month, etc.) that the patient usually takes their medication. This determination may be based, in part, on the patient record in which time information is associated with operational state information, such as relates to the triggering of the drug delivery device or the completion of the drug delivery. This determination may also rely on device identity information, such as the prescribed treatment regimen. Based on this determination, the one or more computing devices may generate a reminder communication that is sent, for example, to the mobile device 110 to alert the patient that the time is approaching for them to administer their next dose.
- the one or more computing devices may also generate a personalized intervention, such as a message of encouragement to be used as a positive reinforcement.
- the drug delivery system or the one or more computing devices may use the information to make a determination where the patient usually takes their medication. This determination may be based, in part, on the patient record in which geographic position information is associated with operational state information, such as relates to the triggering of the drug delivery device or the completion of the drug delivery. This determination may also rely on device identity information, such as the prescribed treatment regimen. Based on this determination, the one or more computing devices may generate a reminder communication that is sent, for example, to the mobile device 110 to alert the patient that the time is approaching for them to administer their next dose when they are at or near the geographic location where the patient usually uses the drug delivery system.
- the one or more computing devices may also generate a personalized intervention, such as a message of encouragement to be used as a positive reinforcement.
- the determinations regarding the usual time and location of the use of the drug delivery device may be combined, and the one or more computing devices may generate a message only when the patient or user is at or near their usual location of use at or near the time they usually use the drug delivery device.
- the drug delivery system or the one or more computing devices may use the information to make a determination that other people nearby are taking the same medication. See blocks 406 - 412 of method 400 .
- This determination may be made based on the drug identity information and the patient identity information, in combination with the drug delivery system geographic location information.
- This determination may prompt a communication with the patient (see blocks 416 , 422 of method 400 ) regarding local support networks of persons with similar conditions and/or taking similar drugs or medication to permit the patient to receive support and encouragement from such networks.
- the determination may prompt a communication with the local support network(s) (see blocks 414 , 420 of method 400 ) requesting them to support and encourage to the patient.
- the determination may prompt a personalized intervention communication to be sent to the patient (again, see blocks 416 , 422 of method 400 ).
- the drug delivery system or the one or more computing devices may use the information to make a determination whether the patient is not in compliance with their treatment regimen. See blocks 406 - 412 of method 400 .
- the determination may be based in part on the drug identification information, such as the prescribed treatment regime, in part on condition state information, such as the passage of time, and in part on the operational state information, such as where the drug delivery device is removed from the packaging but where no additional operational state information is determined, reported or received during the passage of time from the removal from packaging operational state.
- the drug delivery system and/or the one or more computing devices may determine that an interaction with the patient should be generated, such as an alert may be displayed or sent to patient. See blocks 416 , 422 of method 400 .
- the drug delivery system and/or one or more computing devices may determine that a communication should be generated to be displayed or sent to a healthcare provider, caregiver, support giver and/or payer to encourage adherence to the treatment regime. See blocks 414 , 420 of method 400 .
- FIGS. 5 and 6 Described below with reference to FIGS. 5 and 6 are embodiments of a system and method for implementing the patient support network mentioned above in connection with FIG. 4 .
- FIG. 5 illustrates an embodiment of a system 500 including a drug delivery device 502 , a local computing device 504 and a remote computing device 506 . While the system 500 includes both a local computing device 504 and a remote computing device 506 , not all embodiments according to this disclosure include both a local computing device 504 and a remote computing device 506 . Also, any one of the drug delivery device 502 , the local computing device 504 and the remote computing device 506 may be substituted for a corresponding element of FIG. 1 . For example, the drug delivery device 502 , the local computing device 504 , and the remote computing device 506 may be substituted for, respectively, the drug delivery system 100 , the mobile device 110 , and the server 104 of FIG. 1 .
- the drug delivery device 502 may be in the form of an autoinjector, and thus is adapted for hand-held use and application against the skin of the patient.
- the drug delivery device 502 includes a housing 510 in which are disposed assemblies or structures that introduce a delivery cannula into the patient, and that eject a drug or medicament from a reservoir 512 through the delivery cannula into the patient.
- the same assemblies or structures that introduce the delivery cannula into the patient may also eject the drug or medicament from the reservoir through the delivery cannula into the patient.
- the drug delivery device 502 may also include assemblies or structures that connect the delivery cannula to the reservoir, that withdraw the delivery cannula into the housing 510 through an opening in the housing 510 (not illustrated), or that deploy other structures that will prevent contact with the delivery cannula once the delivery cannula has been removed from the patient. Even additional assemblies and structures are possible.
- the specific embodiment of the drug delivery device 502 discussed below is thus by way of example and not by way of limitation.
- the drug delivery device 502 includes a reservoir 512 and a delivery cannula 514 having a first end 516 (e.g., a proximal end) that may be connected or connectable in fluid communication with the reservoir 512 and a second end 518 (e.g., a distal end) that may be inserted into a patient.
- the delivery cannula 514 may be, for example, a rigid needle having a beveled edge that may be sized such that the second end 518 of the needle 514 is received under the skin so as to deliver a subcutaneous injection of the medicament within the reservoir 512 .
- the first end 516 of the needle 514 may be disposed through a wall 520 of the reservoir 512 , and thus be connected in fluid communication with the reservoir 512 .
- the first end 516 of the needle 514 may be disposed only partially through the wall 520 (which wall 520 may be a resalable septum or stopper, for example) such that the first end of the needle 514 may not be connected in fluid communication until the second end 518 of the needle 514 is inserted into the patient.
- the first end 516 of the needle 514 may thus be described as connectable in fluid communication with the reservoir 512 , although it will be recognized that there are other mechanisms by which the first end 516 of the needle 514 may be connectable, but not connected, in fluid communication with the reservoir 512 .
- the drug delivery device 502 includes a shield 522 (e.g., a needle shield) that may be deployed at least after the injection has been completed to limit access to the second end 518 of the needle 514 .
- the shield 522 may have a biasing element 524 (such as a spring) that extends the shield 522 from the housing 510 such that a distal end 526 of the shield 522 extends beyond the second end 518 of the needle 514 except when the shield 522 is disposed against the skin and the insertion of the needle 514 is actuated.
- the insertion of the needle 514 may be actuated according to certain embodiments of the drug delivery device 502 by disposing the distal end 526 of the shield 522 on or against the skin of the patient.
- the drug delivery device 502 may also include a lock 528 (e.g., a ratchet) that is coupled to the shield 522 and configured to limit or prevent movement of the shield 522 relative to the housing 510 of the drug delivery device 502 such that the distal end 526 of the shield 522 extends from the housing 510 a sufficient distance to limit or prevent contact with the second end 518 of the needle 514 , for example, after the needle 514 has been removed or separated from the skin of the patient.
- a lock 528 e.g., a ratchet
- the lock 528 may be coupled to a controller (e.g., controller 550 described in more detail below) which can selectively activate or deactivate the lock 528 based on different types of information regarding the drug delivery device 502 , including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above.
- a controller e.g., controller 550 described in more detail below
- the lock 528 may be configured to limit or prevent movement of the needle shield 522 relative to the housing 510 .
- the lock 528 may be configured to allow movement of the needle shield 522 relative to the housing 510 .
- the drug delivery device 502 also includes at least one drive 530 that may be used to insert the second end 518 of the needle 514 into the skin of the patient, and to eject the drug or medicament from the reservoir 512 through the delivery cannula 514 into the patient.
- the drive 530 may include one or more springs, according to certain embodiments.
- the drive 530 may include a source of pressurized gas or a source of a material that undergoes a phase change, such that the escaping gas or phase changing material provides a motive force that may be applied to the reservoir 512 to eject the drug therefrom.
- the drive 530 may include an electromechanical system, such as may include a motor for example, although such an electromechanical system may be more appropriate for the on-body autoinjector or infuser described above.
- an electromechanical system such as may include a motor for example, although such an electromechanical system may be more appropriate for the on-body autoinjector or infuser described above.
- Other embodiments of the drive 530 are also possible.
- the drive 530 may be coupled to a plunger 531 and/or a stopper 532 (e.g., a wall) disposed in the reservoir 512 to move that stopper 532 in a distal direction toward the delivery cannula 514 .
- the stopper 532 may be a stopper that is fixed to a distal end of the plunger 531 and received within a bore 534 .
- the plunger 531 in conjunction with the drive 530 , may move the stopper 532 along a longitudinal axis of the drug delivery device 502 through the bore 534 from a proximal end of the bore 534 to a distal end of the bore 534 , and thereby eject the medicament from the reservoir 512 .
- the drive 530 may also cooperate with the stopper 532 and/or the bore 534 to move the reservoir 512 relative to the housing 510 so as to move the second end 518 of the needle 514 relative to the housing 510 and into the patient. According to those embodiments wherein the drive 530 cooperates with the stopper 532 , this may occur before the first end 516 of the needle 514 is in fluid communication with the reservoir 512 .
- the drive may include one component (e.g., first spring) that cooperates with the bore 534 to move the reservoir 512 and needle 514 relative to the housing 510 , and a second component (e.g., second spring) that cooperates with the stopper 532 to move the stopper 532 relative to the bore 534 .
- first spring e.g., first spring
- second spring e.g., second spring
- the drug delivery device 502 may also include a lock 535 that is coupled to the plunger 531 and configured to limit or prevent movement of the plunger 531 relative to the housing 510 of the drug delivery device 502 so that the stopper 532 cannot be advanced to discharge the medicament from the reservoir 512 to the patient.
- the lock 535 may be coupled to a controller (e.g., controller 550 described in more detail below) which can selectively activate or deactivate the lock 535 based on different types of information regarding the drug delivery device 502 , including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above.
- the lock 535 When the lock 535 is activated by the controller 550 , the lock 535 may be configured to limit or prevent movement of the plunger 531 relative to the housing 510 . When the lock 535 is deactivated by the controller 550 , the lock 528 may be configured to allow movement of the plunger 531 relative to the housing 510 .
- the drive 530 may be associated with an actuator 540 .
- the actuator 540 may activate the drive 530 to cause the drive 530 to insert the needle 514 and eject the drug from the reservoir 512 through the needle 514 into the patient.
- the actuator 540 may, according to certain embodiments, be the needle shield 522 , as explained above. According to other embodiments, such as the one illustrated in FIG. 5 , the actuator 540 may be a button that may be manually depressed by the user or patient once the drug delivery device 502 is placed disposed on or against the patient's skin.
- a lock 541 may be coupled to the actuator 540 and configured to limit or prevent movement of the actuator 540 so that the actuator 540 cannot be used to activate the drive 530 .
- the lock 541 may be coupled to a controller (e.g., controller 550 described in more detail below) which can selectively activate or deactivate the lock 541 based on different types of information regarding the drug delivery device 502 , including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above.
- a controller e.g., controller 550 described in more detail below
- the lock 541 may be configured to limit or prevent movement of the actuator 540 relative to the housing 510 .
- the lock 541 may be configured to allow movement of the actuator 540 relative to the housing 510 .
- the drug delivery device 502 may also include a removable sterile barrier 544 that is disposed about one or more of a distal end of the housing 510 , the needle shield 522 , and the second end 518 of the delivery cannula 514 .
- the removable sterile barrier 544 may be removably attached to the distal end of the housing 510 as shown in FIG. 5 .
- the removable sterile barrier 544 may form an interference or snap fit with the distal end of the housing 510 . A frictional force associated with the interference or snap fit may be overcome by manually pulling the removable sterile barrier 544 in a direction away from a housing 510 .
- the removable sterile barrier 544 when attached to the drug delivery device 502 , may reduce the risk of contamination of the delivery cannula 514 and other elements disposed within the drug delivery device 502 .
- the drug delivery device 502 may include a heating element 546 coupled to the exterior of the reservoir 512 and configured to warm the medicament inside the reservoir 512 through, for example, conductive heating.
- the heating element 546 may be coupled to the controller 550 so that the controller 550 can selectively activate or deactivate the heating element 546 based on different types of information regarding the drug delivery device 502 , including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above.
- the heating element 546 may include an electrically conductive coil that is wrapped around the exterior of the reservoir 512 .
- a cooling element (not illustrated) may be coupled to the reservoir 512 and controllable by the controller 550 in a manner similar to the heating element 546 .
- the drug delivery device 502 may also include an output unit 547 coupled to the housing 510 and configured to notify the patient or user of information related to the drug delivery device 502 .
- the output unit 547 may be coupled to the controller 550 so that the controller 550 can selectively activate or deactivate the output unit 547 based on different types of information regarding the drug delivery device 502 , including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above.
- the output unit 547 may be any device suitable for conveying information to the patient or user including a display (e.g., a liquid crystal display), a touchscreen, a light (e.g., a light emitting diode), a vibrator (e.g., an electro-mechanical vibrating element), a speaker, and/or an alarm, among other devices.
- a display e.g., a liquid crystal display
- a touchscreen e.g., a liquid crystal display
- a light e.g., a light emitting diode
- a vibrator e.g., an electro-mechanical vibrating element
- speaker e.g., a speaker, and/or an alarm, among other devices.
- the drug delivery device 502 may also include an input unit 548 coupled to the housing 510 and configured to allow a user or patient to input information (e.g., password information) to be used by the controller 550 .
- the input unit 548 , the output unit 547 , and even the fingerprint sensor 565 may be a single device such as a touchscreen.
- the input unit 548 may be a separate device from the output unit 547 such as a keyboard or button.
- the reservoir 512 , the biasing element 524 , the locks 528 , 535 , 541 , the plunger 531 , the stopper 532 , and the drive 530 , and the heating element 546 are disposed within the housing 510 , along with at least part of the delivery cannula 514 .
- a controller 550 Also disposed within the housing 510 is a controller 550 , a communication module 552 (e.g., a wireless transmitter), and at least one sensor or switch.
- a temperature sensor 560 e.g., a temperature sensor 560 , a skin sensor 562 , at least one orientation sensor 564 , and a fingerprint sensor 565 .
- the sensors 560 , 562 , 564 , and 565 may each generate sensor data (e.g., raw or unprocessed data) related to a respective measured property or aspect of the drug delivery device 502 .
- the sensor data may be representative of at least one of a condition or operational state of the drug delivery device 502 .
- the drug delivery device 502 includes a switch 566 .
- the controller 550 is coupled to the communication module 552 , the locks 528 , 535 , 541 , the sensors 560 , 562 , 564 , 565 , the heating element 546 , the fingerprint sensor 565 , the output unit 547 , the input unit 548 , and the switch 566 .
- the controller 550 may be configured to process the sensor data generated by the sensors 560 , 562 , 564 , and 565 to determine a condition and/or operational state of the drug delivery device 502 .
- the controller 550 , the communication module 552 , one or more of the sensors 560 , 562 , 564 , 565 and the switch 566 may be packaged together as a single module, or each component may be fabricated separately and coupled once the components are disposed within the housing 510 .
- each electrical component may be integrated into the structure of the device 502 associated with that electrical component (e.g., the sensors 562 and 564 may be integrated into the shield 522 ).
- the controller 550 , the communication module 552 , one or more of the sensors 560 , 562 , 564 , 565 , and/or the switch 566 may be packaged together inside the removable sterile barrier 544
- the controller 550 may include at least one processor 570 (e.g., a microprocessor) and a memory 572 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.).
- the controller 550 may also include or be coupled to a power supply, e.g. a battery.
- the processor 570 may be programmed to carry out the actions that the controller 550 is adapted to perform and the memory 572 may include one or more tangible non-transitory readable memories having executable, computer-readable, non-transitory instructions stored thereon, which instructions when executed by the at least one processor 570 may cause the at least one processor 570 to carry out the actions that the controller 550 is adapted to perform.
- the controller 550 may include other circuitry that carries out the actions that the controller is adapted to perform.
- the memory 572 may store the identity information discussed above.
- the identity information may be stored in the memory 572 prior to the start of execution of any of the methods discussed above.
- the identity information may include, by way of example and not by way of limitation, a unique identifier, the name of the drug, the dosage, an expiration date, and information regarding the identity of the patient for whom the drug was prescribed. With this information, the controller 550 or a local computing device (e.g., a smartphone) may make a determination regarding the patient that is about to receive the drug, and provide appropriate informational and/or instructional prompts.
- the identity information may be contained in a QR code label or RFID tag associated with the drug delivery device 502 .
- the communication module 552 may be any of a number of different communication modules used to communicate with a local computing device (e.g., a smartphone) and/or a remote computing device (e.g., a server operated by the device manufacturer).
- the communication module 552 may be a Bluetooth and/or Bluetooth Low Energy module that is on-board with the controller 550 .
- the communication module 552 is used to transmit information from the drug delivery device 502 to the local computing device 504 .
- other wireless protocols may be used by the communication module 552 , such as radio-frequency identification (RFID), Zigbee, Wi-Fi, near field communication (NFC), and others.
- RFID radio-frequency identification
- NFC near field communication
- the communication may be sent along a hardwired connection, rather than using the electromagnetic (EM) spectrum.
- EM electromagnetic
- a communication transmitted and/or received between the module 552 , the local computing device, and/or the remote computing device may be in the form of a hardwired signal or EM signal or a
- the temperature sensor 560 may be disposed proximate to the reservoir 512 so that the temperature of the drug in the reservoir 512 may be determined. Alternatively, the temperature sensor 560 may simply be disposed in the housing 510 , so that an approximate temperature of the drug in the reservoir 512 and of the drug delivery device 502 generally may be determined. According to an embodiment, the temperature sensor 560 may be an on-board temperature sensor 560 attached to the processor 570 .
- the skin sensor 562 may be attached to or associated with the shield 522 to determine when the drug delivery device 502 is disposed on or against the patient's skin.
- the skin sensor 562 is a pressure sensor.
- the skin sensor 562 may be a capacitance sensor, resistance sensor, or inductance sensor.
- the skin sensor 562 or the switch 566 (which is attached to or associated with the actuator 540 ) may be used to determine when the drug delivery device 502 is activated or actuated, depending on the design and operation of the drug delivery device 502 that is used to actuate the drive 530 , in accordance with the discussion above.
- a signal from the skin sensor 560 is used to determine that the drug delivery device 502 has been activated even when the shield 522 is not used as the actual actuator, the underlying assumption being that the movement of the shield 522 is necessarily related to the actuation of the device 502 .
- the orientation sensors 564 may be associated with the shield 522 (or that portion of the housing 510 adjacent the shield 522 ) and the controller 550 (which may be, as illustrated, disposed at the other end of the drug delivery device 502 or the housing 510 from the shield 522 ).
- the orientation sensors 564 may be magnetometers, for example.
- the orientation sensor 564 associated with the controller 550 may be an on-board magnetometer.
- the orientation sensors 564 may be used to determine the orientation of the drug delivery device 502 (in particular, the housing 510 ) relative to the injection site (or more particularly, relative to the placement of the drug delivery device 502 on or against the patient's skin).
- the local computing device 504 may be in the form of at least one computing device including at least one processor 620 (e.g., microprocessor) and a memory 622 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.).
- the at least one processor 620 and the memory 622 may be incorporated into a controller 623 of the local computing device 504 and/or may be configured separately.
- the remote computing device 506 may be in the form of at least one computing device including at least one processor 624 (e.g., microprocessor) and memory 626 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.).
- the at least one processor 624 and the memory 626 may be incorporated into a controller 627 of the local computing device 504 and/or may be configured separately.
- the processors 620 , 624 may be programmed to carry out actions described below relative to the method of FIG.
- the memories 622 , 626 may include one or more tangible, non-transitory computer-readable memories having computer-executable instructions stored thereon, which instructions when executed by the processors 622 , 624 may cause the processors 622 , 624 to carry out the actions described below relative to the method of FIG. 6 .
- the computer-executable instructions may be included in a software application (e.g., a mobile software application, also commonly referred to as a “mobile app”) stored in the memory 622 of the local computing device 504 .
- the software application may be installed on local computing device 504 as one or more downloaded files, such as an executable package installation file downloaded from a suitable application store via a connection to the Internet. Examples of package download files may include downloads via the iTunes store, the Google Play Store, the Windows Phone Store, downloading a package installation file from another computing device, etc.
- the software application may be developed for a mobile operating system such as AndroidTM or iOS®, developed by Google and Apple, respectively.
- the application may be initiated by a user selecting an icon shown on a home screen of a display 632 (e.g., a touchscreen) of the local computing device 504 .
- Various displays including messages received from a support group, may be generated in the application and displayed to a user and/or patient via the display 632 of the local computing device 504 .
- the local computing device 504 may carry out the actions of FIG. 6 independent of the remote computing device 506 . According to other embodiments, the local computing device 504 may carry out certain of the actions of FIG. 6 , while the remote computing device 506 carries out other of the actions of FIG. 6 .
- the processor(s) 620 may control components of the local computing device 504 permitting communication with the controller 550 and/or the user, but may not make the determinations as to the content of those communications, the determinations relative to the content of the communications being made at the remote computing device 506 .
- the local computing device 504 is a mobile computing device (e.g., a smartphone, a smartwatch, a smart wearable device, a personal computer, a laptop computer, or a tablet computer, etc.) while the remote computing device 506 is a server.
- the local computing device 504 can include generally any computing device capable of processing data and being synched to and in communication with the drug delivery device 502 such as, for example, a smart wearable device, a personal computer, a laptop computer, a smart television, a smart appliance, a smart automobile, a networked computer, etc.
- the local computing device 504 may be a dedicated device such as a hub or gateway that can establish a communication link with the communication module 552 and potentially the remote computing device 506 , where communication with the remote computing device 506 is necessary or desirable.
- the local computing device 504 may further include a communication module 630 for wireless communication with the communication module 552 of the drug delivery device 502 , for example by using Bluetooth or Bluetooth Low Energy protocol. Alternatively, other wireless protocols may be used by the communication module 552 , such as radio-frequency identification (RFID), Zigbee, Wi-Fi, near field communication (NFC), and others.
- the local computing device 504 may also include the display 632 (e.g., a touchscreen) to be used to display information (e.g., instructional prompts and/or informational prompts) to the user.
- the local computing device 504 may include other output devices other than the display 632 to communicate with the user, such as a speaker 634 for example.
- the speaker 634 may be controlled by the processor(s) 620 to provide an audible form of the instructions displayed in written form on the display 632 .
- the local computing device 504 may also include one or more communication modules, which may be the same as or different from the communication module 630 , that may be used to communicate with one or more networks 640 , 642 .
- the network 640 may be a wireless radio frequency network, such as a cellular mobile device network
- the network 642 may be a network of computing devices, such as the Internet.
- the networks 640 , 642 may be in communication with each other, such that the local computing device 504 may communicate with the remote computing device 506 over the network 640 , the network 642 or a combination of the networks 640 , 642 .
- the remote computing device 624 may include a communication module 636 to receive communications from the networks 640 , 642 .
- each of the local computing device 504 and the remote computing device 506 is separate from, and spaced apart from, the drug delivery device 502 , and therefore each may be considered to be an “external computing device” relative to the drug delivery device 502 .
- FIG. 6 illustrated is a flow diagram of one embodiment of a method 700 of providing social support to a patient associated with the drug delivery device 502 .
- the memory 622 of the local computing device 504 and/or the memory 626 of the remote computing device 506 may store one or more computer-executable instructions that, when executed by the processor 620 of the local computing device 504 and/or the processor of the 624 of the remote computing device 506 , cause the processor 620 of the local computing device 504 and/or the processor of the 624 of the remote computing device 506 to carry out the actions described below relative to the method 700 .
- the method 700 may leverage social networking services (e.g., Facebook, Twitter, etc.) that provide access to groups of users who are already connected, or who can easily be connected, to the patient.
- social networking services e.g., Facebook, Twitter, etc.
- the patient may be more likely to comply with a treatment regimen (e.g., a therapeutic regimen) for treating a medical condition of the patient with drug delivery device 502 .
- the method 700 may begin with associating the patient with a support group or multiple support groups (see block 710 ).
- the support group may be a group of people and/or organizations having an interest in the patient complying with the treatment regimen.
- the support group may include a healthcare provider (e.g., a doctor, nurse, etc.), a caregiver, a family member, a friend, a medical device manufacturer, an insurance company, and/or another individual using a similar drug delivery device and/or having a similar medical condition.
- the support group may be a pre-existing online community of individuals connected through a social networking service, such as a Facebook group.
- the support group may consist of the patient's Facebook friends.
- the association of the patient with the support group may be accomplished in a variety of different manners.
- the patient may select (via, for example, a mobile application executing on the local computing device 504 ) a pre-existing group (e.g., the patient's Facebook friends) to be the support group.
- the patient's selection may be transmitted to the remote computing device 506 which subsequently associates the patient with the patient-selected support group.
- the remote computing device 506 may register identity information about the patient (e.g., age, height, weight, medical condition, etc.) and then associate the patient with individuals sharing similar identity information.
- the associating the patient with a support group may include initially collecting data (e.g., GPS data) from the local computing device 504 about the geographic location of the patient and/or the drug delivery device 502 . Based on this data, the remote computing device 506 may choose individuals who are physically near the geographic location of the patient as the support group.
- the geographic-based method of associating the patient with a support group may be combined with any of the foregoing methods of association, such that the geographic location of the patient is only one factor in the selection of an appropriate support group.
- the patient may be presented with map of nearby support groups from which the patient can selected a desired support group.
- the method 700 may involve receiving, at the local computing device 504 and/or at the remote computing device 506 , data representative of a condition and/or an operational state of the drug delivery device 502 (see block 720 ).
- the data may be in the form of one or more of the reports similar to those described above in connection with the method 200 and/or the method 300 .
- the drug delivery device 502 may transmit sensor data, collected by the sensors onboard the drug delivery device 502 , to the local computing device 504 , which in turn, may analyze the sensor data to generate a report representative of a condition and/or an operational state of the drug delivery device 502 and then transmit that report to the remote computing device 506 .
- the sensor data may be transmitted directly to the remote computing device 506 , which may then analyze the sensor data to determine the condition and/or operational state of the drug delivery device 502 .
- the drug delivery device 502 may analyze the sensor data and generate the report representative the condition and/or an operational state of a drug delivery device 502 , and then transmit that report to the local computing device 504 and/or the remote computing device 506 .
- the local computing device 504 and/or the remote computing device 506 may analyze the data to determine if the patient has complied with a treatment regimen (see block 730 ). This determination may involve a comparison of the data representative of the condition and/or the operational state of the drug delivery device 502 with a predefined criteria stored in the memory 622 of the local computing device 504 and/or the memory 626 of the remote computing device 506 .
- the predefined criteria may specify, for example, the frequency with which the patient is to receive an injection of a medicament, the amount or dose of medicament to be received by the patient, the temperature of the medicament at the time of injection, the type of medicament to be received by the patient, and/or the sequence in which a medicament is to be injected along with other medicaments.
- the predefined criteria may indicate that the patient is to receive an injection of the medicament every day before noon.
- compliance with the treatment regimen may be involve a determination that the operational state of the drug delivery device 502 corresponds to the drug delivery device 502 having completed delivery of the medicament to the patient. Judging whether delivery of the medicament to the patient has been successful may accomplished in a manner consistent with the method 200 and/or the method 300 .
- successful drug delivery may be determined if both the needle shield 522 has been moved in the distal direction relative to the delivery cannula 514 and the plunger 531 has completed its delivery stroke by moving from its proximal position to its distal position.
- Other conditions or states that may be considered to confirm successful delivery of the medicament to the patient include an indication that the actuator 540 has been triggered (e.g., depressed) and/or the amount of medicament remaining in the reservoir 512 .
- the method 700 may return to block 720 , where the local computing device 504 and/or the remote computing device 506 waits for the reception of new data representative of at least one of a condition or an operational state of a drug delivery device 502 .
- the local computing device 504 and/or the remote computing device 506 may transmit a communication to the support group associated with the patient requesting the support group to send a message of praise or congratulation to the patient.
- the local computing device 504 and/or the remote computing device 506 may transmit a communication to the support group associated with the patient in order to initiate an intervention with the patient (see block 740 ).
- the communication may be sent through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.).
- the communication may request the support group to counsel the patient about the treatment regimen. In some embodiments, the request may suggest that the support group send a message to the patient encouraging the patient to comply with the treatment regimen.
- the request may include pre-written message and/or an ideogram (e.g., an emoji) which can be sent, on demand, by a member of the support group to the patient.
- the request may ask the support group to actively intervene by, for example, meeting with the patient in-person, physically assisting the patient with their use of the drug delivery device, and/or actually administering the medicament to the patient with the drug delivery device. Active intervention may be especially beneficial for patients suffering from dementia and other forms of cognitive decline.
- the message asking the support group to intervene may include an indication of the patient's limited cognitive abilities so that the support group appreciates the patient's vulnerability to forget their medication schedule.
- the method 700 may include the local computing device 504 and/or the remote computing device 506 receiving a communication from the support group providing the requested counseling (see block 750 ).
- the communication may in the form of a message sent through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.).
- the message may include words of encouragement, coaching, advice, a reminder, or any other communication likely to urge the patient to comply with the treatment regimen.
- the method 700 may forward the communication to the patient (block 760 ). This may involve displaying the communication on the display 632 of the local computing device 504 and/or generating a sound with the speaker 634 of the local computing device 504 .
- the support provided to the patient by the method 700 is reactive support since it is provided in response to the patient's failure to comply with the treatment regimen.
- the methods and systems disclosed herein may be configured to provide the patient with proactive support. This type of support reduces the likelihood that the patient will fail to comply with the treatment regimen by taking preventative measures before a violation of the treatment regimen occurs.
- the local computing device 504 and/or the remote computing device 506 may evaluate the treatment region to determine if the patient is scheduled to receive a dose of the medicament in the near future (e.g., tomorrow, tonight, in the next hour, etc.).
- the local computing device 504 and/or the remote computing device 506 may transmit a communication to the support group associated with the patient.
- This communication may include a request for support group to remind the patient to take their upcoming dose of the medicament. Similar to the method 700 , these steps may be performed by executing non-transitory, computer-executable instructions included in a mobile software application, or other module, stored in the memory 622 of the local computing device 504 and/or the memory 626 of the remote computing device 506 .
- members of the support group may send one or more messages through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.) to the patient reminding him or her to take their medication.
- a social networking service e.g., email, SMS message, push notification, telephone, etc.
- the patient may be less likely to miss a scheduled dose of the medicament.
- the local computing device 504 and/or the remote computing device 506 may be configured to receive a request from the patient for help and/or support, and in response to that request, automatically contact an appropriate individual or organization.
- a mobile software application executing on the local computing device 504 may display a help button or icon that, when selected by the patient, causes the local computing device 504 to transmit a help request to a healthcare provider (e.g., doctor, nurse practitioner, nurse, etc.), caregiver, medical device manufacturer, support group, or any other individual or organization capable helping the patient.
- a healthcare provider e.g., doctor, nurse practitioner, nurse, etc.
- the help request may solicit technical support for proper use of the drug delivery device, emotional support, information about the medicament and its side effects, and/or any other type of support.
- selecting the help button may cause the smartphone to automatically call a support hotline, call a member of a support group, and/or open a website (e.g., a website including a list a frequently asked questions) in a web browser executing on the smartphone. Accordingly, the patient may be able to obtain immediate support for his or her questions or concerns.
- the methods and systems disclosed herein have several technical effects on the process of monitoring the use of a drug delivery device and ensuring patient compliance with a treatment regimen.
- One technical effect is the computer-implemented determination of the condition and/or operational state of the drug delivery device and the automatic distribution of this information to a social network for further processing and/or notification of a support group. Accordingly, a caregiver is not required to manually determine, or manually notify a support group of, the condition and/or operational state of the drug delivery device to ensure patient compliance.
- Another technical effect is that the presently disclosed systems and methods streamline the process of identifying an appropriate support group for the patient.
- the systems and methods may automatically associate the patient with a support group located geographically nearby the patient and/or a support group including members with whom the patient has a personal and/or professional relationship. Automating the process of associating the patient with a support group reduces the search burden on the patient or caregiver.
- the patient may be associated with a support group based upon the patient's pre-existing social networking based relationships (e.g., Facebook friendships), which may further simplify the process of identifying appropriate members for the support group.
- Yet another technical effect of the presently disclosed methods and systems is that they automatically send a help request to the support group in response to a determination of the patient's non-compliance with the treatment regimen.
- the systems and methods provide a relatively simplistic trigger for notifying the support group, which can help minimize the amount of data processing needed to alert the support group. While the foregoing mentions several technical effects associated with the invention, other technical effects will be readily apparent to one of ordinary skill in the art upon a review of this disclosure.
- the above description describes various systems and methods for use with a drug delivery device. It should be clear that the system, drug delivery device or methods can further comprise use of a medicament listed below with the caveat that the following list should neither be considered to be all inclusive nor limiting.
- the medicament will be contained in a reservoir.
- the reservoir is a primary container that is either filled or pre-filled for treatment with the medicament.
- the primary container can be a cartridge or a pre-filled syringe.
- the drug delivery device or more specifically the reservoir of the device may be filled with colony stimulating factors, such as granulocyte colony-stimulating factor (G-CSF).
- G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim).
- the drug delivery device may be used with various pharmaceutical products, such as an erythropoiesis stimulating agent (ESA), which may be in a liquid or a lyophilized form.
- ESA erythropoiesis stimulating agent
- An ESA is any molecule that stimulates erythropoiesis, such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa
- An ESA can be an erythropoiesis stimulating protein.
- erythropoiesis stimulating protein means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor.
- Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor.
- Erythropoiesis stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, pegylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1/hematide), and mimetic antibodies.
- Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoetin, erythropoietin agonist variants, and peptides or antibodies that bind and activate erythropoietin receptor (and include compounds reported in U.S. Publication Nos. 2003/0215444 and 2006/0040858, the disclosures of each of which is incorporated herein by reference in its entirety) as well as erythropoietin molecules or variants or analogs thereof as disclosed in the following patents or patent applications, which are each herein incorporated by reference in its entirety: U.S. Pat. Nos.
- Examples of other pharmaceutical products for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab); other biological agents such as Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim , G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet).
- antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab); other biological agents such as Enbrel® (et
- the device may also be used with a therapeutic antibody, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
- a therapeutic antibody for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
- the pharmaceutical product may be in liquid form, or reconstituted from lyophilized form.
- proteins are the specific proteins set forth below, including fusions, fragments, analogs, variants or derivatives thereof:
- OPGL specific antibodies, peptibodies, and related proteins, and the like also referred to as RANKL specific antibodies, peptibodies and the like
- fully humanized and human OPGL specific antibodies particularly fully humanized monoclonal antibodies, including but not limited to the antibodies described in PCT Publication No. WO 03/002713, which is incorporated herein in its entirety as to OPGL specific antibodies and antibody related proteins, particularly those having the sequences set forth therein, particularly, but not limited to, those denoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including the OPGL specific antibodies having either the light chain of SEQ ID NO:2 as set forth therein in FIG. 2 and/or the heavy chain of SEQ ID NO:4, as set forth therein in FIG. 4 , each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- IL-4 receptor specific antibodies particularly those that inhibit activities mediated by binding of IL-4 and/or IL-13 to the receptor, including those described in PCT Publication No. WO 2005/047331 or PCT Application No. PCT/US2004/37242 and in U.S. Publication No.
- Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in U.S. Publication No. 2004/097712, which is incorporated herein by reference in its entirety in parts pertinent to IL1-R1 specific binding proteins, monoclonal antibodies in particular, especially, without limitation, those designated therein: 15CA, 26F5, 27F2, 24E12, and 10H7, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the aforementioned publication;
- Ang2 specific antibodies, peptibodies, and related proteins, and the like including but not limited to those described in PCT Publication No. WO 03/057134 and U.S. Publication No. 2003/0229023, each of which is incorporated herein by reference in its entirety particularly in parts pertinent to Ang2 specific antibodies and peptibodies and the like, especially those of sequences described therein and including but not limited to: L1(N); L1(N) WT; L1(N) 1K WT; 2xL1(N); 2xL1(N) WT; Con4 (N), Con4 (N) 1K WT, 2xCon4 (N) 1K; L1C; L1C 1K; 2xL1C; Con4C; Con4C 1K; 2xCon4C 1K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8-8(N); TN8-14 (N); Con 1 (N), also including anti-
- WO 2003/030833 which is incorporated herein by reference in its entirety as to the same, particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565; AbF1AbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12; AblA1; AblF; AblK, AblP; and AblP, in their various permutations as described therein, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- NGF specific antibodies, peptibodies, and related proteins, and the like including, in particular, but not limited to those described in U.S. Publication No. 2005/0074821 and U.S. Pat. No. 6,919,426, which are incorporated herein by reference in their entirety particularly as to NGF-specific antibodies and related proteins in this regard, including in particular, but not limited to, the NGF-specific antibodies therein designated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- IGF-1 receptor specific antibodies such as those described in PCT Publication No. WO 06/069202, which is incorporated herein by reference in its entirety as to IGF-1 receptor specific antibodies and related proteins, including but not limited to the IGF-1 specific antibodies therein designated L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37,
- anti-IGF-1R antibodies for use in the methods and compositions of the present invention are each and all of those described in:
- B7RP-1 B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like
- B7RP-1 also is referred to in the literature as B7H2, ICOSL, B7h, and CD275
- B7RP-specific fully human monoclonal IgG2 antibodies particularly fully human IgG2 monoclonal antibody that binds an epitope in the first immunoglobulin-like domain of B7RP-1, especially those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells in particular, especially, in all of the foregoing regards, those disclosed in U.S. Publication No. 2008/0166352 and PCT Publication No.
- WO 07/011941 which are incorporated herein by reference in their entireties as to such antibodies and related proteins, including but not limited to antibodies designated therein as follow: 16H (having light chain variable and heavy chain variable sequences SEQ ID NO:1 and SEQ ID NO:7 respectively therein); 5D (having light chain variable and heavy chain variable sequences SEQ ID NO:2 and SEQ ID NO:9 respectively therein); 2H (having light chain variable and heavy chain variable sequences SEQ ID NO:3 and SEQ ID NO:10 respectively therein); 43H (having light chain variable and heavy chain variable sequences SEQ ID NO:6 and SEQ ID NO:14 respectively therein); 41H (having light chain variable and heavy chain variable sequences SEQ ID NO:5 and SEQ ID NO:13 respectively therein); and 15H (having light chain variable and heavy chain variable sequences SEQ ID NO:4 and SEQ ID NO:12 respectively therein), each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- IL-15 specific antibodies, peptibodies, and related proteins, and the like such as, in particular, humanized monoclonal antibodies, particularly antibodies such as those disclosed in U.S. Publication Nos. 2003/0138421; 2003/023586; and 2004/0071702; and U.S. Pat. No. 7,153,507, each of which is incorporated herein by reference in its entirety as to IL-15 specific antibodies and related proteins, including peptibodies, including particularly, for instance, but not limited to, HuMax IL-15 antibodies and related proteins, such as, for instance, 146B7;
- IFN gamma specific antibodies peptibodies, and related proteins and the like, especially human IFN gamma specific antibodies, particularly fully human anti-IFN gamma antibodies, such as, for instance, those described in U.S. Publication No. 2005/0004353, which is incorporated herein by reference in its entirety as to IFN gamma specific antibodies, particularly, for example, the antibodies therein designated 1118; 1118*; 1119; 1121; and 1121*.
- the entire sequences of the heavy and light chains of each of these antibodies, as well as the sequences of their heavy and light chain variable regions and complementarity determining regions, are each individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication and in Thakur et al.
- Specific antibodies include those having the heavy chain of SEQ ID NO:17 and the light chain of SEQ ID NO:18; those having the heavy chain variable region of SEQ ID NO:6 and the light chain variable region of SEQ ID NO:8; those having the heavy chain of SEQ ID NO:19 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:10 and the light chain variable region of SEQ ID NO:12; those having the heavy chain of SEQ ID NO:32 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:30 and the light chain variable region of SEQ ID NO:12; those having the heavy chain sequence of SEQ ID NO:21 and the light chain sequence of SEQ ID NO:22; those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:
- TALL-1 specific antibodies such as those described in U.S. Publication Nos. 2003/0195156 and 2006/0135431, each of which is incorporated herein by reference in its entirety as to TALL-1 binding proteins, particularly the molecules of Tables 4 and 5B, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publications;
- PTH Parathyroid hormone
- TPO-R Thrombopoietin receptor
- TRAIL-R2 specific antibodies, peptibodies, related proteins and the like such as those described in U.S. Pat. No. 7,521,048, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TRAIL-R2;
- Activin A specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Publication No. 2009/0234106, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind Activin A;
- TGF-beta specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Pat. No. 6,803,453 and U.S. Publication No. 2007/0110747, each of which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TGF-beta;
- Amyloid-beta protein specific antibodies including but not limited to those described in PCT Publication No. WO 2006/081171, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind amyloid-beta proteins.
- One antibody contemplated is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6 as disclosed in the foregoing publication;
- c-Kit specific antibodies including but not limited to those described in U.S. Publication No. 2007/0253951, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind c-Kit and/or other stem cell factor receptors;
- OX40L specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Publication No. 2006/0002929, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind OX40L and/or other ligands of the OX40 receptor; and
- Activase® (alteplase, tPA); Aranesp® (darbepoetin alfa); Epogen® (epoetin alfa, or erythropoietin); GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (alemtuzumab, anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti- ⁇ 4 ⁇ 7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cet
- Tysabri® (natalizumab, anti- ⁇ 4integrin mAb); Valortim® (MDX-1303, anti-B. anthracis protective antigen mAb); ABthraxTM; Vectibix® (panitumumab); Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portion of human IgG1 and the extracellular domains of both IL-1 receptor components (the Type I receptor and receptor accessory protein)); VEGF trap (Ig domains of VEGFR1 fused to IgG1 Fc); Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2R ⁇ mAb); Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal
- sclerostin antibody such as but not limited to romosozumab, blosozumab, or BPS 804 (Novartis).
- therapeutics such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA.
- a monoclonal antibody that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), e.g. U.S. Pat. No. 8,030,547, U.S. Publication No.
- talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers.
- oncolytic HSV include, but are not limited to talimogene laherparepvec (U.S. Pat. Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669); OrienX010 (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143); G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002), Cancer Gene Ther., 9(12):967-978).
- TIMPs are endogenous tissue inhibitors of metalloproteinases (TIMPs) and are important in many natural processes.
- TIMP-3 is expressed by various cells or and is present in the extracellular matrix; it inhibits all the major cartilage-degrading metalloproteases, and may play a role in role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions.
- the amino acid sequence of TIMP-3, and the nucleic acid sequence of a DNA that encodes TIMP-3 are disclosed in U.S. Pat. No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated by reference herein. Description of TIMP mutations can be found in U.S. Publication No. 2014/0274874 and PCT Publication No. WO 2014/152012.
- CGRP human calcitonin gene-related peptide
- bispecific T cell engager antibody e.g. Blinotumomab
- Blinotumomab can be used in the device.
- included can be an APJ large molecule agonist e.g., apelin or analogues thereof in the device. Information relating to such molecules can be found in PCT Publication No. WO 2014/099984.
- the medicament comprises a therapeutically effective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody.
- TSLP anti-thymic stromal lymphopoietin
- anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Pat. Nos. 7,982,016, and 8,232,372, and U.S. Publication No. 2009/0186022.
- anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Pat. No. 8,101,182.
- the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated as AS within U.S. Pat. No. 7,982,016.
Abstract
Description
- The priority benefit of U.S. Provisional Patent Application No. 62/007,007, filed Jun. 3, 2014, is claimed, and the entire contents thereof are expressly incorporated herein by reference.
- The present disclosure generally concerns systems and methods for encouraging a patient to use a drug delivery device in accordance with a treatment regimen.
- Drugs can be administered through the use of drug delivery devices, such as autoinjectors or on-body injectors or infusers. These devices may replace older delivery systems using the combination of a syringe and a vial containing the drug or medicament, or a pre-filled syringe. Autoinjectors and on-body injectors may be used to automate the injection and delivery or administration process, thereby simplifying the process for certain patient groups or sub-groups for which use of the syringe/vial combination or pre-filled syringe systems is disadvantageous, whether because of physiological or psychological impediments.
- Despite the automation provided by drug delivery devices, patients may experience challenges in being adherent or compliant with a treatment regimen. For example, certain patients may not perform the injections according to the treatment regimen, having forgotten to perform the injection at all. Other patients may perform the injections, but then be unable to remember whether they performed the injections because they become distracted before they are able to record that they did so. Some patients may elect not to perform the injections because of misunderstandings or miscommunications of when or how the medication will affect the patient's disease or symptoms, especially where the effects are not felt by the patient until a considerable portion of the treatment regimen has been performed.
- Some patients may be more likely to follow a treatment regimen if they are provided with support and/or encouragement from others (e.g., a healthcare provider, a caregiver, a family member, a friend, another individual with a similar medical condition, etc.). However, the people who would potentially be willingly to provide such support and/or encouragement may be unaware that the patient has failed to follow the treatment regimen.
- To address one or more of the challenges or needs mentioned above, the present disclosure sets forth various systems and methods to support patient use of a drug delivery device and facilitate compliance with a treatment regimen.
- According to an aspect of the disclosure, provided is a social networking based method of providing a patient with support. The method may include associating the patient with at least one support group. The method may also include receiving data representative of at least one of a condition or an operational state of a drug delivery device associated with the patient. The method may further include determining if the patient is compliant with a treatment regimen based on the condition or the operational state of the drug delivery device. Furthermore, in response to a determination that the patient is not compliant with the treatment regimen, the method may include transmitting a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
- According to another aspect of the disclosure, a support system for a patient includes a drug delivery system and an external computing device. The drug delivery system may include a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within the patient, one or more sensors, and a first communication module configured to transmit a report representative of at least one of a condition or an operational state of the drug delivery device. The external computing device may include a second communication module configured to receive the report, a processor, and a memory coupled to the processor and configured to store non-transitory, computer-executable instructions. When executed by the processor, the non-transitory, computer-executable instructions may cause the processor to: (i) associate the patient with the at least one support group; (ii) store, in the memory, a predefined criteria for determining compliance with a treatment regimen; (iii) compare the report with the predefined criteria to determine if the patient is compliant with the treatment regimen; and (iv) in response to a determination that the patient is not compliant with the treatment regimen, control the second communication module to transmit a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
- According to a further aspect of the disclosure, provided is a non-transitory, computer-readable storage medium having computer-executable instructions that, when executed at one or more processors of a support system for a patient, cause the one or more processors to: (i) associate the patient with at least one support group; (ii) receive data representative of at least one of a condition or an operational state of a drug delivery device associated with the patient; (iii) determine if the patient is compliant with a treatment regimen based on the condition or the operational state of the drug delivery device; and (iv) in response to a determination that the patient is not compliant with the treatment regimen, transmit a communication to the at least one support group requesting the at least one support group to counsel the patient about the treatment regimen.
-
FIG. 1 is a schematic diagram of a drug delivery system according an embodiment of the disclosure in communication with one or more computing devices and one or more networks; -
FIG. 2 is a block diagram of a method of operating the drug delivery system illustrated inFIG. 1 according to an embodiment of the disclosure; -
FIGS. 3A-3C is a block diagram of a method of operating the drug delivery system illustrated inFIG. 1 according to another embodiment of the disclosure; -
FIG. 4 is a block diagram of a method of operating a computing device such as is illustrated inFIG. 1 according to an embodiment of the disclosure, the computing device in communication with a drug delivery system operating according to one of the methods disclosed herein, for example; -
FIG. 5 is a schematic illustration of an embodiment of a system including a drug delivery device, a local computing device, and a remote computing device interconnected with communication links and networks; and -
FIG. 6 is a flow diagram of an embodiment of a method for supporting a paitent's use of a drug delivery device. - In general, the present disclosure is directed to methods and systems for providing a patient under medical care with a social support network. More particularly, the present disclosure relates to monitoring patient use of a drug delivery device with sensors or other means and linking the patient to a support group who can encourage the patient to comply with a treatment regimen (e.g., a therapeutic regimen). The systems and methods described herein may leverage the capabilities of social networking services (e.g., Facebook, Twitter, etc.) to identify a support group from which the patient is likely to take advice. The presently disclosed methods and systems therefore may increase the likelihood of patient use of the drug delivery device in accordance with a treatment regimen.
- The systems and methods may involve the determination of one or more states, which states may be determined through the use of one or more sensors in combination with one or more controllers. The sensors may rely on mechanical, electrical or chemical sensing mechanisms, and the controllers may be mechanical, electrical or electro-mechanical. By way of example and not by way of limitation, the states may relate to the operation of the drug delivery device, or to the condition of the drug delivery device. The system and methods may use the state determination to control the operation of the drug delivery device, and/or may communicate the state determination to other devices, such as third-party servers that may collect, process and/or further disseminate the state determinations received from the system including the drug delivery device, the one or more sensors, and the one or more controllers. In addition or in the alternative, the systems and methods may communicate the state determination to local computing devices, such as a mobile computing device (e.g., cell phone).
- A drug delivery system according to the disclosure may include a drug delivery device having a reservoir (which may also be referred to as a primary container, e.g. a syringe, vial or cartridge). The reservoir may contain a drug, which may also be referred to as a medication or a medicament. The drug may be, but is not limited to various biologicals such as peptides, peptibodies, or antibodies. The drug may be in a fluid or liquid form, although the disclosure is not limited to a particular state (e.g., no differentiation is intended between a solution, a gel, or a lyophilized product for example). The drug delivery device also includes delivery cannula having a first end connected to or connectable in fluid communication with the reservoir and a second end to be inserted within a patient. As used herein, the term “delivery cannula” or “cannula” is hereby defined to mean a tube that can be inserted into the body for the delivery of fluid. A cannula may include a rigid or semi-rigid needle or blunt cannula, or may be in a flexible form, by example and not by way of limitation. The cannula may be integrated with the other elements of the drug delivery device, or the cannula may be separate from the other elements of the drug delivery until immediately prior to use. According to certain embodiments, the drug delivery device may further include an inserter to introduce the second end into the patient, although this is not required according to each embodiment of the disclosure. The inserter may or may not be withdrawn back into the device, thereby leaving the cannula in a patient.
- Considering the foregoing description of the drug delivery device, the device may be characterized as an autoinjector or an on-body injector or infuser (the reference to injector intended to include also a reference to an infuser, to the extent that a difference is suggested). Autoinjectors may be single-use devices, administering a single dose during a single application of the device to the user's skin, although autoinjectors are not limited to only single-use devices—they may be multi-use devices as well. On-body injectors may be multi-use devices, administering multiple doses during one or more applications of the device to the user's skin, although on-body devices may also be used as single-use devices. Either autoinjectors or on-body injectors may have assemblies or sub-assemblies that are reusable, in that the assemblies may be used and re-used by refilling the reservoir, by removing an empty reservoir and replacing it with a filled reservoir, or by replacing the cannula, for example.
- As noted above, the system or method according to the disclosure will determine one or more states relative to the drug delivery device.
- For example, the system or method may determine if the drug delivery device is in one or more operational states (i.e., a state relating to the operation of the drug delivery device to deliver the drug to the patient). A non-exhaustive list of the general operational states may include (i) packaged/ready for distribution; (ii) packaged/distributed; (iii) unpackaged/ready for administration; (iv) sterile barrier removed; (v) device applied; (vi) cannula injected (or inserted); (vii) drug delivery initiated; (viii) drug delivery completed; and (ix) device removed. The system or method may determine specific operational states within each of the general operational states; for example, the system or method may determine if plunger has been moved from a first end of a bore (defining a drug reservoir) to a second end of the bore to determine if the drug delivery device is in the “drug delivery complete” state.
- Furthermore, the system or method may determine if the drug delivery device is in one or more condition states (i.e., a state relating to the condition of the drug delivery device, not necessarily related to the operation of the drug delivery device to deliver the drug to the patient). A non-exhaustive list of condition states may include (i) age (e.g., taken with respect to a manufacturing date or an expiration date); (ii) sterility/contamination; (iii) temperature; (iv) temperature history; and (iv) orientation. The determination of a condition state may be considered as part of the determination of an operational state; for example, the determination of the temperature state may be considered as part of the determination of the “ready for administration” state. Alternatively, the operational and condition states may be determined separately.
- These states may be determined through the use of one or more sensors. The sensors may be particular to a condition state to be determined: for example, a thermocouple disposed adjacent to the reservoir may be used to determine the temperature state of the drug delivery device. The sensors may be particular to an operational state to be determined: for example, a switch may be coupled to a needle guard to determine when a needle cap has been removed to determine the “sterile barrier removed” operational state, the switch being open when the needle cap is disposed over the second end of the cannula and the switch being closed when the needle guard is not disposed over the second end of the cannula. Sensors may be used to determine both a condition state and an operational state: for example, the thermocouple may be used to determine the temperature condition state of the device (or more particularly, the drug), and/or the thermocouple may be used to determine the “ready for administration” operational state.
- The system or method may use the determined states to control the operation of the drug delivery device. For example, the system may include a controller that is coupled to the sensor and may be coupled to one or more of the assemblies or subassemblies of the drug delivery device described above, or to one or more additional assemblies or subassemblies of the drug delivery device. The controller may be adapted structurally or programmed (if electrical or electro-mechanical) to activate or to inhibit these assemblies or subassemblies in accordance with the determined states. For example, the drug delivery device may include a lockout that limits or completely inhibits the operation of the injector, and the controller may activate the lockout in a reversible fashion if the temperature state of the drug delivery device (and in particular, the drug in the reservoir) is below a threshold state.
- The system or method may communicate the determined state(s) to another device or system, which communication may be performed in conjunction with use of the determined state(s) to control the operation of the drug delivery device. For example the system or method may communicate the determined state(s) with a networked device using a communication link. In this sense, a networked device is intended to include any device that communicates with at least one other device over a communication link, and might include communication with a device such as mobile device (e.g., cell phone or mobile computing device) using a Bluetooth connection or a computing device using a Wi-Fi connection, for example. The networked device may communicate the determined states to other computing devices remote from the drug delivery system over the network that includes the networked device such as a server. According to certain embodiments of the present disclosure, the system communicates directly with the network (i.e., without an intermediate networked device—the system would be a networked device) or directly with a remote computing device such as a server (using, for example, a 3G antenna). The state information communicated over network, may then be used, for example, to determine if a patient is in compliance, or if a class of drug delivery devices is exhibiting a systemic malfunction. The state information may be used in other manners as well.
- The systems and methods may also include control of the drug delivery device according to information relating to the identity of the drug, the drug delivery device, or the user, and/or communication of this identity information. Identity information relating to the drug may include a drug name, a drug concentration, dose information, a lot number or serial number, and a date of manufacture and/or expiration. Identity information relating to the drug delivery device may include a device type (e.g., autoinjector, on-body injector), a lot number or serial number, and a date of manufacture. Identity information relating to the user may include a patient name, demographic information, and patient subgroup information. This information may be referred to as “static” information, in contrast to the state information discussed above.
- As to the communication of the information, and in particular relative to the identity information discussed immediately above, it will be recognized that not all information may be useful, desired, or even accessible to every different party whether for convenience, patient privacy or data security concerns.
-
FIG. 1 illustrates adrug delivery system 100 according to an embodiment of the disclosure. Thedrug delivery system 100 may be associated with apatient 102, who may use thedrug delivery system 100, to inject a drug as part of a treatment regimen (e.g., a therapeutic regimen). Thedrug delivery system 100 includes, but is not limited to, the drug delivery device describe below in more detail. Thedrug delivery system 100 may communicate with a computing device 104 (e.g., a server) via one or more intermediate computing devices and/or one or more networks. In turn, theserver 104 may communicate with thedrug delivery system 100, thepatient 102, and one or more computing devices (with their associated parties) via one or more intermediate computing devices and/or one or more networks. As is also illustrated inFIG. 1 , theserver 104 may communicate directly with thedrug delivery system 100, using a 3G or 4G antenna, for example. - For example, the
drug delivery system 100 is illustrated as communicating with a mobile computing device 110 (e.g., a smartphone, a smartwatch, a smart wearable device, a tablet computer, etc.) via afirst communication link 112, and with a computing device 114 (e.g., a personal computer or a dedicated hub) via asecond communication link 116. Bothlinks mobile computing device 110 may communicate with acellular network 118 via acommunication link 120, while theother computing device 114 may communicate with a hard-wired network (e.g., local area network or wide area network) 122 via acommunication link 124. Thesenetworks server 104. - The
networks server 104 and one or more parties associated with thepatient 102, such as his or hercaregiver 130, support giver 132 (e.g., a family member, a friend, individual using a similar drug and/or drug delivery device as the patient 102), ahealthcare provider 134, via their mobile computing devices (e.g., smartphones, smartwatches, smart wearable devices, tablet computers, etc.) and/or another computing devices. Theserver 104 may also be in communication with one or more computing devices (e.g., servers) associated with one or more additional parties associated with thepatient 102. For example, ahealthcare system server 140, apayment server 142, apharmacy server 144, adistributor server 146, and agovernmental agency server 148 are illustrated in communication with theserver 104 via thenetwork 122. It will also be recognized that thenetworks - In some embodiments, the
server 104 may be used to provide social networking based support for theuser 102 of thedrug delivery system 100, as described below in more detail with reference toFIGS. 4 and 5 . -
FIGS. 3A-3C illustrate amethod 300 that may be viewed as illustrating some of the mixed operational and condition state monitoring that may occur in a method and system according to the disclosure. Themethod 300 may also be viewed as illustrating how the one or more sensors may be used to determine the state changes described above. Furthermore, themethod 300 may be viewed as providing disclosure of operational and conditions state monitoring and communication of that information not illustrated inFIG. 2 . - Referring first to
FIG. 3A , themethod 300 may begin with the drug delivery device in the package, and the method waits atblock 302 until it is determined that the package has been opened. At this point, the device may optionally be locked until such time as the system conducts one or more validations, verifications or checks to ensure that the device is ready to administer, the sterile barrier has been removed and/or the device has been (correctly) applied (seeblocks method 220 inFIG. 2 ). Before conducting each of the one or more validations, verifications or checks, themethod 300 may determine if the drug delivery device is adapted or programmed to carry out the validation, verification or check. For example, a determination may be made atblock 304 if the drug delivery device is adapted or programmed to check the sterility of the drug delivery device; in particular, the validation or verification may be related to a sterile barrier disposed at the second end of the cannula. If the drug delivery device is adapted or programmed to perform the sterility check, themethod 300 may proceed to block 306, where it is determined if the sterile barrier is disposed over or about the second end of the cannula, for example. - If it is determined at
block 306 that the barrier is in place, then the method may proceed to block 308 where the user is instructed to remove the barrier. Themethod 300 may then determine atblock 310 if the barrier has been removed. When it is determined that the barrier has been removed, a sterility timer may be started, the expiration of which may result in the drug delivery device being placed into or remaining in a locked state, preventing use of the drug delivery device. - If it is determined at
block 306 that the barrier is not in place (i.e., the barrier has been prematurely removed), themethod 300 may proceed to block 312, wherein the delivery device is locked (e.g., a lock or lock-out device is actuated) or the delivery device remains in a locked state if the device was previously locked. According to certain embodiments, the locking of the delivery device atblock 312 may be irreversible. According to other embodiments, including the embodiment illustrated inFIGS. 3A-3C , the lock may be reversed once it is determined that the drug product (e.g., the drug product reservoir) has been replaced atblock 314. If the drug product is not replaced, or in those embodiments where the drug product cannot be replaced (i.e., the lock is irreversible), information regarding the failed sterility check may be communicated by the system. - If (i) the determination is made at
block 304 that the system is adapted to validate, verify or check the sterility of the device, (ii) the determination is made atblock 306 that the barrier is in place and atblock 310 that the barrier subsequently has been removed, or (iii) the determination is made atblock 306 that the barrier is not in place but the determination is made atblock 314 that the drug product had been replaced, themethod 300 continues to block 316. Atblock 316, a determination is made if the drug delivery device is capable of performing visual and/or environmental inspections. If the device is so adapted, the method proceeds to block 318, wherein the determination is made if the visual inspection and/or environmental conditions are within desired thresholds. If the determination is made that the visual inspection and/or environmental conditions are outside desired thresholds, then the method may proceed toblocks method 300 may proceed to block 320. - At
block 320, a determination is made whether the drug delivery system is able to confirm the user identity. If the drug delivery system is so adapted, then themethod 300 continues to block 322, and the determination is made if the user identity matches the authorization for the use of the drug delivery device. If the user is not identified as an authorized user atblock 322, then themethod 300 continues to block 324, where the drug delivery device is locked or remains locked, and block 326, where the information regarding the attempted unauthorized use is communicated to local and/or remote devices. If the user is identified as an authorized user, then themethod 300 proceeds toFIG. 3B and block 328. - At
block 328, a further determination is made as to whether the drug delivery system is enabled to confirm the temperature of the drug product. If the system is so adapted, then themethod 300 continues to block 330. Atblock 330, a determination is made if the drug product temperature is within a range for predictable delivery (neither too high nor too low). If the determination is made atblock 330 that the temperature is not within the range for predictable delivery, then themethod 300 continues to block 332, wherein a determination is made if the device is capable of heating or cooling the drug product to bring the temperature of the product within the range. If the system is not so adapted, then the method proceeds to block 334, where the device may be locked or remain locked to allow passive heating or cooling to occur and the user may be alerted. Optionally, the system may also communicate the information to local and/or remote devices. If the system is enabled to permit heating or cooling, then the method proceeds to block 336, where the device may be locked or remain locked, heating or cooling may be initiated, and the user may be alerted. Whether passive or active heating or cooling (blocks 334, 336), themethod 300 may continue to block 338, where delivery is delayed to provide time for the heating or cooling to occur before the method returns to block 330. According to certain embodiments, themethod 300 may terminate after block 330 (in case of excessive temperature, for example) and may communicate that information to local and/or remote devices. - In some embodiments, the temperature check performed at
block 330 may involve an evaluation of the temperature history of the drug product to determine the range and duration of temperatures experienced by the drug product in the past (e.g., during storage, distribution, etc.). If the temperature history of the drug product is unacceptable due to, for example, the drug product being exposed to elevated temperatures for several days during shipment, thecontroller 350 may lockout thedrug delivery device 302 so that it cannot be used to deliver the drug product to a patient, and additionally, may control thecommunication module 352 to transmit a report to thelocal computing device 304 or theremote computing device 306 representative of the unacceptability of drug product's temperature history. In some embodiments, upon a determination that the temperature of the drug product exceeds a threshold temperature, the controller may begin a timer that runs until the temperature falls back below the threshold temperature. If the duration of the timer exceeds a predefined time limit, thecontroller 350 may lockout thedrug delivery device 302 and control thecommunication module 352 to transmit a report representative of the unacceptability of drug product's temperature history. - Returning to
FIG. 3B , if the determination is made atblock 328 that the device is not adapted to perform a temperature check or atblock 330 that the temperature of the drug product is within the desired range, then the method may continue to block 340, where a determination is made if the device is enabled to determine that the device is properly positioned on or oriented relative to the patient. If the device is so adapted, then the method proceeds to block 342, and a determination is made whether the device is properly disposed or oriented. In this regard, depending on the preferred insertion site, knowledge of the orientation of the device may be useful in providing a successful injection. For example, self-administration into the abdomen would most likely result in an orientation of an autoinjector axis approximately horizontal. - If the device is not properly disposed, then the method proceeds to block 344, and the device may be locked and the user instructed to reposition or reorient the device. The
method 300 may then proceed to block 346 wherein a time delay is provided for the user to reposition the device before themethod 300 returns to block 342 for a further determination relative to the position of the device. Alternatively, if the device is properly disposed, then the method may proceed to block 348, and any locks or lockouts that may have been actuated are removed (or the device is unlocked). - The
method 300 continues atblock 350, wherein a determination is made whether the system is enabled to determine if the delivery has been triggered. If the determination is made that the system is so adapted, then the method proceeds to block 352, and a determination is made if the device has been activated or triggered. If the determination is made atblock 352 that the device has not been triggered, then themethod 300 may proceed to block 354 and the system may instruct the user to trigger the device. According to other embodiments, the drug delivery device may wait for a predetermined and/or preprogrammed time delay to occur before triggering the device automatically upon the completion of the time delay. According to still other embodiments, themethod 300 may optionally determine if a timer has elapsed atblock 355 to reduce the risk of contamination and infection, for example. According to such embodiments, the timer may be started upon the determination that the barrier has been properly removed at block 310 (or may be started upon the determination that the barrier has been removed, according to still further embodiments), and if themethod 300 does not determine that the device has been triggered within a certain amount of time from that event, themethod 300 may return to block 312, for example, as illustrated inFIGS. 3B and 3A . If it is determined atblock 350 that the trigger has occurred, then the method proceeds to block 356, where the user may be notified of the triggering of the device and/or the date, time and location of the delivery may be stored or recorded. Optionally, this information may also be communicated to local and/or remote devices in communication with the system. Themethod 300 then continued toFIG. 3C . - A further determination may be made at
block 358 whether the system is enabled to determine if the device has remained properly positioned on or oriented relative to the body. If the system is so adapted, then themethod 300 continues to block 360, and a determination is made if the device is properly positioned on or oriented relative to the body. If the device is not properly positioned or oriented, then themethod 300 may continue to block 362, where the user is alerted to reposition or reorient the device, and block 364, where a time delay is provided for the user to reposition or reorient the device, before returning to block 360 wherein the position or orientation of the device on the patient's body is determined. If the device is properly positioned or oriented, themethod 300 may proceed to block 366. Optionally, themethod 300 may repeat block 360 periodically during the time the device is administering the drug product to ensure that the device remains correctly positioned. - At
block 366, a determination is made whether the system is enabled to determine if the administration is complete. If the system is so adapted, then themethod 300 continues to block 368, and a determination is made if the delivery is complete. In some embodiments, it may be determined that the medicament has been successfully delivered to the patient in response to sensor data indicating that: (i) a needle shield (e.g.,needle shield 526 described below) has been moved in the distal direction relative to a delivery cannula (e.g.,delivery cannula 514 described below); and/or (ii) a plunger (e.g.,plunger 531 descrbied below) has completed its delivery stroke by having moved from its proximal position to its distal position. If the determination is made atblock 368 that the delivery is not complete, then a further determination is made atblock 370 whether the delivery can be completed. If the delivery is not complete but may be completed, then themethod 300 returns to block 368 viablock 372, where the device is permitted to continue to administer the drug product. If the delivery is not complete and cannot be completed (e.g., the device has been removed from the patient's skin), then themethod 300 continues to block 374, and information regarding the drug and drug delivery may be communicated to a local and/or remote device. For example, information regarding whether certain operational states occurred (cannula inserted, delivery started, delivery partially completed), the timing of the operational states, and the amount of drug product that was administered may be communicated. - If the determination is made at
block 368 that the delivery has been completed, then the method proceeds to block 376, where the system indicates to the user that the delivery is complete. Furthermore, themethod 300 communicates information regarding the drug delivery, the drug delivery device, and the drug product to local and/or remote devices atblock 378. For example, the information may include that certain operational states occurred and the timing of the operational states. Themethod 300 may also verify that the device was correctly positioned throughout, where the system is enabled to make this determination. Themethod 300 may also pass to block 378 if the system is not enabled to determine if the administration of the drug product is complete, the assumption made that the drug delivery device having been determined to have passed through one or more of the preceding operational states necessarily leads to the conclusion that the delivery was completed. - Again, it should be noted that while the above description relates to a method including a series of states of the devices and alternative actions that may depend on those states, the device need not determine each and every state or perform each and every action illustrated in
FIG. 3A-3C . Rather, it will be recognized that one of ordinary skill in the art may omit or eliminate the determination of certain states or performance of certain actions, so as to result in a system that may control the device based on or communicate a subset of the states described. - Having discussed the possible methods of operating the drug delivery system in the context of the illustrated methods of
FIGS. 2 and 3A-3C , the possible methods of operating one or more computing devices in communication with the drug delivery system is now discussed in the context of amethod 400 illustrated inFIG. 4 . It will be recognized that themethod 400 may be carried out by a single computing device, such as theserver 104 illustrated inFIG. 1 , or theremote computing device 506 described below in connection withFIG. 5 . Alternatively, the actions discussed with respect toFIG. 4 may be carried out by multiple computing devices, such as themobile device 110 and/or thecomputing device 114 in conjunction with theserver 104 illustrated inFIG. 1 , or thelocal computing device 504 and theremote computing device 506 illustrated inFIG. 5 . - The
method 400 begins atblock 402 with a determination as to whether a report has been received from the drug delivery system. If no report has been received, themethod 400 waits atblock 402 Once it is determined that a report has been received atblock 402, themethod 400 proceeds to block 404. - At
block 404, the report received from the drug delivery system is used to update one or more records. In this regard, the one or more computing devices adapted or programmed to carry out themethod 400 may perform the actions of retrieving the one or more records from storage in one or more memory storage devices, writing the information received from the drug delivery device into the one or more records, and then storing the one or more records in the one or more memory storage devices. The one or more memory storage devices may be part of the one or more computing devices, may be separate from the one or more computing devices, or may include one or more of the memory storage devices that are part of the one or more computing devices and one or more memory storage devices that are separate from the one or more computing devices (i.e., the record is stored at the computing device and in backup storage separate and possibly remote from the computing device). - As mentioned above, the report may be used to update one or more records. For example, there may be one record for the individual patient that is stored in a patient record database. The patient record may be used, for example, to track the compliance of the individual patient (e.g., patient 102) with his or her regimen(s). There may also be a record for the drug delivery system used by the individual patient that is stored in a drug delivery system database. The drug delivery system record may be used to store information regarding the drug delivery system throughout the life of the drug delivery system. The drug delivery system record may be accessed by the drug delivery system manufacturer or the drug provider for quality control purposes (e.g., to monitor individual instances of the drug delivery system for faults or failures attributable for to the drug delivery system, or to track the environmental condition histories of one or more drug delivery systems for patterns that may assist in determining improvements in the design, packaging, shipment or handling of the drug delivery systems). There may also be record for drug used in the drug delivery system that is stored in a drug database. This record may be used in a similar fashion to the drug delivery system record for quality control purposes.
- In addition to the updating the records at
block 404, the computing device adapted or programmed to carry out themethod 400 may be adapted or programmed to carry out one or more actions based on the information in the report received from the drug delivery system. For example, the computing device may be adapted or programmed to carry out an action atblock 406. This action may require not only the information received in the report and/or stored previously in the record updated atblock 404, but may require additional information such as from other patient records, drug system delivery records and/or drug records. If this is the case, the determination may be made atblock 408 that these other records need to be accessed, and the information retrieved at block 410 (e.g., by retrieving these other records from the patient, drug delivery system and drug databases and reading the information from these records once retrieved). The action may then be carried out atblock 412. - As one example, the one or more computing devices adapted or programmed to carry out the
method 400 may be adapted or programmed to use the information received in the report to prepare a compliance history for the patient, which compliance history tracks uses of instances of the drug delivery system by the individual patient relative to his or her treatment regimen to determine how successful the patient has been in following the treatment regimen and which compliance history may be stored in the patient record. In addition, the one or more computing devices may determine if a pharmacy should be contacted to order delivery of additional drug delivery devices for the individual patient, and may generate a communication to be sent to the pharmacy to order the delivery of additional drug delivery systems. Further, the one or more computing devices may determine if a reminder should be sent to the patient, via themobile device 110 for example, to improve or support compliance with the individual patient's treatment regime, in which case the one or more computing devices may generate a communication to be sent to the patient or user of the device. Further, the one or more computing devices may determine that the operation of the drug delivery device should be modified because of a conditional state received from the drug delivery device, for example. For example, the one or more computing devices may determine that the drug delivery system should be locked to prevent its use because of the temperature history of the drug in the drug delivery system, for example. In this case, the one or more computing devices may generate a communication, in the form of a signal for example, to be sent to the drug delivery system to lock the drug delivery device that is part of the drug delivery system. Other possible actions are discussed in detail below, although this discussion is for illustrative purposes only and is not intended to be limiting. - Depending on the action taken at
block 412, or even if it is determined atblock 406 that no action need be taken, themethod 400 may proceed toblocks block 412 may involve the generation of communications or signals to be sent to third parties, such as the pharmacy, to the patient, or to the drug delivery device. In such a case, the one or more computing devices may carry out the actions ofblock blocks blocks block 406. For example, the one or more computing devices may forward certain information tothird parties 420 based solely on the receipt of the information in a report from the drug delivery device, such that there is no need to separately determine that an action need be taken in regard to the information received (i.e., the communication is automatically sent based on the fact that the information has been received, with the one or more computing devices acting as a repeater station for such information). The receipt of information from the drug delivery device may also prompt communications to be sent to the patient/user or control signals to be sent to the drug delivery system without a separate determination that such action need be taken, the communication or control signal being sent simply because certain information and/or reports were received from the drug delivery system. - Having made the determinations at
blocks blocks method 400 may return to block 402 to await the next report. It will be recognized that the one or more computing devices may perform the actions of themethod 400 in parallel for each of the reports received from different instances of the drug delivery system, or may perform this steps in sequence for each report. If performed in parallel, the one or more computing devices may determine if action is to be taken in regard to one report, while the one or more computing devices may be interacting with another patient in regard to the information contained in the report received from that patient. Furthermore, the one or more computing devices carrying out themethod 400 need not be adapted or programmed to carry out each of the actions described above according to every embodiment of the one or more computing devices. For example, one of the one or more computing devices may be adapted or programmed to update records for each patient and to determine if an interaction with that patient is required, while another of the one or more computing devices may be adapted or programmed to update records for each drug delivery device and to determine is a control signal should be sent to the drug delivery device, while another one of the one or more computing devices does not update any record, but is adapted or programmed to access, for example, a patient record and determine if the pharmacy needs to be contacted to order additional instances of the drug delivery system for the patient associated with the patient record accessed and to generate the communication if the order of additional instances of the system is required. - It will be appreciated that the
methods - For example, a non-limiting matrix of state and identity information may include the following:
- Condition State Information:
-
- Temperature
- Shock or vibration exposure
- Light exposure
- Color and/or turbidity (as relates to the drug)
- Orientation
- Geographic position
- Temporal information
- Operational State Information:
-
- Device removed from package
- Device removed from cold storage (e.g., refrigerator)
- Device/drug temperature ready for administration
- Delivery triggered
- Device applied to patient
- Device applied at correct location/orientation on patient
- Cannula inserted into patient and/or inserted into correct tissue
- Delivery in progress
- Delivery complete
- Error has occurred
- Device Identity Information:
-
- Drug name or identification, concentration, and/or amount
- Security and/or anti-counterfeiting information
- Patient prescription/therapeutic regime
- Patient Identity Information:
-
- Point of Care diagnostics on patient
- Self-analyzed measure of progress
- Fingerprint, pin, or other secure identification information
- This information may be used to control the drug delivery system or device, to be communicated to other computing devices, or otherwise to be used, and an exemplary listing of certain additional uses is included below. The listing and additional comments below is not intended to supersede, but to augment the discussion above, and is intended to be non-limiting.
- As one example, the drug delivery system or the one or more computing devices may make a determination regarding the authenticity of the drug and its compliance with manufacturing standards. Such a determination may be made by the drug delivery device at
block 220 ofmethod 200 or block 318 ofmethod 300, or by the one or more computing devices atblock 406 ofmethod 400, for example. The determination may be made based on the temperature, shock or vibration exposure, and/or light exposure of the drug delivery device/drug (or a history of one or more of these conditions) and color and/or turbidity of the drug (as determined by an optical inspection). This determination may result in control of the drug delivery device to either lock or unlock the device, according to the determination made. Seeblocks method 220, blocks 318, 312, 314 ofmethod 300, and blocks 406-412 and 418, 424 ofmethod 400. - As another example, the drug delivery system or the one or more computing devices may make a determination whether the drug is appropriate for the patient. See
block 220 ofmethod 200, block 322 ofmethod 300, and block 406-412 ofmethod 400. The determination may be made based on one or more of the items of device of patient identity information listed above, and may also result in control of the drug delivery device to either lock or unlock the device, according to the determination made. Seeblocks method 220, blocks 322, 324, 326 ofmethod 300, and blocks 406-412 and 418, 424 ofmethod 400. - As a further example, the drug delivery system or the one or more computing devices may make a determination whether the dose has been correctly administered. This determination may be carried out after determining that the drug is appropriate for the patient and/or that the drug is authentic (e.g., not counterfeit) and is in compliance with manufacturing standards. See the preceding paragraphs. The determination whether the dose has been correctly administered may depend on one or more of the types of operational state information listed above. See blocks 220-260 of
method 200, and blocks 328-378 ofmethod 300. This information may be used to update the patient record, determine the patient compliance or therapy progress, and may prompt communication with the pharmacy regarding a refill, or with the payer (e.g., insurance company) to authorize payment for the drug delivery device. See blocks 404-414 ofmethod 400, andservers FIG. 1 . - As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination regarding the operational state of the drug delivery device, and to generate instructional messages to guide the user through the actions required for the proper use of the drug delivery device. The determination may be based on any of the operational state information listed above, and the instructions generated may be dictated by the actions that need to be performed after the operational state that has just occurred. Implementation of interactive instructions that follow the changing states of the drug delivery device may help the user have confidence in administration of the drug.
- As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination that the patient needs more medication (a refill). See blocks 406-412 of
method 400. The determination may be based in part on the drug identity information, such as the prescribed treatment regime, and in part on the operational state information, such as where the drug delivery has been completed. Based on this information, the one or more computing devices may generate a communication that is sent to the payer and/or pharmacy to request a prescription refill. Seeblocks method 400. - As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination that the injection was not performed correctly. See blocks 406-412 of
method 400. The determination may be based in part on operational state information, in comparison with information that may be collected and stored regarding conventional norms in operation. Alternatively or additionally, a comparison between the determined, reported or received operational states may permit a determination to be made that the injection was not performed correctly. For example, the determination, reporting or receipt of operational state information indicating that the drug delivery is complete without operation state information indicating that device was triggered, that the device was applied to the patient, and/or that the cannula was inserted may indicate that the drug delivery device has failed to perform correctly, is faulty or was operated incorrectly. - As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination that patient's condition is improving. The determination may be based in part on patient identity information, such as point-of-care diagnostics performed on the patient (e.g., blood glucose test or other testing) or self-analysis reporting, and in part on the determination, reporting or receipt of operational state information, such as where the drug delivery has been completed. The determination may rely upon an overall trend as opposed to individual determinations or reports, as it is believed that data or reporting trends are usually more indicative of improvement in a patient's condition than the patient's condition as determined at individual instances for serious diseases. As such, the information gathered regarding the patient and the operational state of the drug delivery system/device may be combined with combined with therapy compliance history. This determination may result in individualized interventions to be generated, which interventions (such as encouraging messages and other forms of positive reinforcement) may increase persistence in therapy.
- As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination of the time of day (or week, month, etc.) that the patient usually takes their medication. This determination may be based, in part, on the patient record in which time information is associated with operational state information, such as relates to the triggering of the drug delivery device or the completion of the drug delivery. This determination may also rely on device identity information, such as the prescribed treatment regimen. Based on this determination, the one or more computing devices may generate a reminder communication that is sent, for example, to the
mobile device 110 to alert the patient that the time is approaching for them to administer their next dose. As the usefulness of reminders is enhanced when there is reasonable access to the drug delivery device and an opportunity for its use, it is beneficial to reinforce a patients decision to take their medication at a particular time during the day, week, month, etc. Based on this determination, the one or more computing devices may also generate a personalized intervention, such as a message of encouragement to be used as a positive reinforcement. - As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination where the patient usually takes their medication. This determination may be based, in part, on the patient record in which geographic position information is associated with operational state information, such as relates to the triggering of the drug delivery device or the completion of the drug delivery. This determination may also rely on device identity information, such as the prescribed treatment regimen. Based on this determination, the one or more computing devices may generate a reminder communication that is sent, for example, to the
mobile device 110 to alert the patient that the time is approaching for them to administer their next dose when they are at or near the geographic location where the patient usually uses the drug delivery system. As the usefulness of reminders is enhanced when there is reasonable access to the drug delivery device and an opportunity for its use, it is beneficial to reinforce a patient's decision to take their medication when they are in the usual location where they take their medication. Based on this determination, the one or more computing devices may also generate a personalized intervention, such as a message of encouragement to be used as a positive reinforcement. - Of course, the determinations regarding the usual time and location of the use of the drug delivery device may be combined, and the one or more computing devices may generate a message only when the patient or user is at or near their usual location of use at or near the time they usually use the drug delivery device.
- As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination that other people nearby are taking the same medication. See blocks 406-412 of
method 400. This determination may be made based on the drug identity information and the patient identity information, in combination with the drug delivery system geographic location information. This determination may prompt a communication with the patient (seeblocks blocks blocks - As a further alternative, the drug delivery system or the one or more computing devices may use the information to make a determination whether the patient is not in compliance with their treatment regimen. See blocks 406-412 of
method 400. The determination may be based in part on the drug identification information, such as the prescribed treatment regime, in part on condition state information, such as the passage of time, and in part on the operational state information, such as where the drug delivery device is removed from the packaging but where no additional operational state information is determined, reported or received during the passage of time from the removal from packaging operational state. Based on this information, the drug delivery system and/or the one or more computing devices may determine that an interaction with the patient should be generated, such as an alert may be displayed or sent to patient. Seeblocks method 400. Furthermore, the drug delivery system and/or one or more computing devices may determine that a communication should be generated to be displayed or sent to a healthcare provider, caregiver, support giver and/or payer to encourage adherence to the treatment regime. Seeblocks method 400. - Described below with reference to
FIGS. 5 and 6 are embodiments of a system and method for implementing the patient support network mentioned above in connection withFIG. 4 . -
FIG. 5 illustrates an embodiment of a system 500 including adrug delivery device 502, alocal computing device 504 and aremote computing device 506. While the system 500 includes both alocal computing device 504 and aremote computing device 506, not all embodiments according to this disclosure include both alocal computing device 504 and aremote computing device 506. Also, any one of thedrug delivery device 502, thelocal computing device 504 and theremote computing device 506 may be substituted for a corresponding element ofFIG. 1 . For example, thedrug delivery device 502, thelocal computing device 504, and theremote computing device 506 may be substituted for, respectively, thedrug delivery system 100, themobile device 110, and theserver 104 ofFIG. 1 . - The
drug delivery device 502 may be in the form of an autoinjector, and thus is adapted for hand-held use and application against the skin of the patient. Thedrug delivery device 502 includes ahousing 510 in which are disposed assemblies or structures that introduce a delivery cannula into the patient, and that eject a drug or medicament from areservoir 512 through the delivery cannula into the patient. According to certain embodiments, the same assemblies or structures that introduce the delivery cannula into the patient may also eject the drug or medicament from the reservoir through the delivery cannula into the patient. Thedrug delivery device 502 may also include assemblies or structures that connect the delivery cannula to the reservoir, that withdraw the delivery cannula into thehousing 510 through an opening in the housing 510 (not illustrated), or that deploy other structures that will prevent contact with the delivery cannula once the delivery cannula has been removed from the patient. Even additional assemblies and structures are possible. The specific embodiment of thedrug delivery device 502 discussed below is thus by way of example and not by way of limitation. - Accordingly, the
drug delivery device 502 includes areservoir 512 and adelivery cannula 514 having a first end 516 (e.g., a proximal end) that may be connected or connectable in fluid communication with thereservoir 512 and a second end 518 (e.g., a distal end) that may be inserted into a patient. Thedelivery cannula 514 may be, for example, a rigid needle having a beveled edge that may be sized such that thesecond end 518 of theneedle 514 is received under the skin so as to deliver a subcutaneous injection of the medicament within thereservoir 512. Thefirst end 516 of theneedle 514 may be disposed through awall 520 of thereservoir 512, and thus be connected in fluid communication with thereservoir 512. Alternatively, thefirst end 516 of theneedle 514 may be disposed only partially through the wall 520 (whichwall 520 may be a resalable septum or stopper, for example) such that the first end of theneedle 514 may not be connected in fluid communication until thesecond end 518 of theneedle 514 is inserted into the patient. In such a circumstance, thefirst end 516 of theneedle 514 may thus be described as connectable in fluid communication with thereservoir 512, although it will be recognized that there are other mechanisms by which thefirst end 516 of theneedle 514 may be connectable, but not connected, in fluid communication with thereservoir 512. - The
drug delivery device 502 includes a shield 522 (e.g., a needle shield) that may be deployed at least after the injection has been completed to limit access to thesecond end 518 of theneedle 514. According to certain embodiments, theshield 522 may have a biasing element 524 (such as a spring) that extends theshield 522 from thehousing 510 such that adistal end 526 of theshield 522 extends beyond thesecond end 518 of theneedle 514 except when theshield 522 is disposed against the skin and the insertion of theneedle 514 is actuated. In fact, the insertion of theneedle 514 may be actuated according to certain embodiments of thedrug delivery device 502 by disposing thedistal end 526 of theshield 522 on or against the skin of the patient. - The
drug delivery device 502 may also include a lock 528 (e.g., a ratchet) that is coupled to theshield 522 and configured to limit or prevent movement of theshield 522 relative to thehousing 510 of thedrug delivery device 502 such that thedistal end 526 of theshield 522 extends from the housing 510 a sufficient distance to limit or prevent contact with thesecond end 518 of theneedle 514, for example, after theneedle 514 has been removed or separated from the skin of the patient. In some embodiments, thelock 528 may be coupled to a controller (e.g.,controller 550 described in more detail below) which can selectively activate or deactivate thelock 528 based on different types of information regarding thedrug delivery device 502, including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above. When thelock 528 is activated by thecontroller 550, thelock 528 may be configured to limit or prevent movement of theneedle shield 522 relative to thehousing 510. When thelock 528 is deactivated by thecontroller 550, thelock 528 may be configured to allow movement of theneedle shield 522 relative to thehousing 510. - The
drug delivery device 502 also includes at least onedrive 530 that may be used to insert thesecond end 518 of theneedle 514 into the skin of the patient, and to eject the drug or medicament from thereservoir 512 through thedelivery cannula 514 into the patient. Thedrive 530 may include one or more springs, according to certain embodiments. According to other embodiments, thedrive 530 may include a source of pressurized gas or a source of a material that undergoes a phase change, such that the escaping gas or phase changing material provides a motive force that may be applied to thereservoir 512 to eject the drug therefrom. According to still other embodiments, thedrive 530 may include an electromechanical system, such as may include a motor for example, although such an electromechanical system may be more appropriate for the on-body autoinjector or infuser described above. Other embodiments of thedrive 530 are also possible. - In one embodiment, the
drive 530 may be coupled to aplunger 531 and/or a stopper 532 (e.g., a wall) disposed in thereservoir 512 to move thatstopper 532 in a distal direction toward thedelivery cannula 514. In accordance with such an embodiment, thestopper 532 may be a stopper that is fixed to a distal end of theplunger 531 and received within abore 534. Theplunger 531, in conjunction with thedrive 530, may move thestopper 532 along a longitudinal axis of thedrug delivery device 502 through thebore 534 from a proximal end of thebore 534 to a distal end of thebore 534, and thereby eject the medicament from thereservoir 512. - In some embodiments, the
drive 530 may also cooperate with thestopper 532 and/or thebore 534 to move thereservoir 512 relative to thehousing 510 so as to move thesecond end 518 of theneedle 514 relative to thehousing 510 and into the patient. According to those embodiments wherein thedrive 530 cooperates with thestopper 532, this may occur before thefirst end 516 of theneedle 514 is in fluid communication with thereservoir 512. According to those embodiments wherein the drive cooperates with thebore 534, the drive may include one component (e.g., first spring) that cooperates with thebore 534 to move thereservoir 512 andneedle 514 relative to thehousing 510, and a second component (e.g., second spring) that cooperates with thestopper 532 to move thestopper 532 relative to thebore 534. - The
drug delivery device 502 may also include alock 535 that is coupled to theplunger 531 and configured to limit or prevent movement of theplunger 531 relative to thehousing 510 of thedrug delivery device 502 so that thestopper 532 cannot be advanced to discharge the medicament from thereservoir 512 to the patient. In some embodiments, thelock 535 may be coupled to a controller (e.g.,controller 550 described in more detail below) which can selectively activate or deactivate thelock 535 based on different types of information regarding thedrug delivery device 502, including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above. When thelock 535 is activated by thecontroller 550, thelock 535 may be configured to limit or prevent movement of theplunger 531 relative to thehousing 510. When thelock 535 is deactivated by thecontroller 550, thelock 528 may be configured to allow movement of theplunger 531 relative to thehousing 510. - The
drive 530 may be associated with anactuator 540. Theactuator 540 may activate thedrive 530 to cause thedrive 530 to insert theneedle 514 and eject the drug from thereservoir 512 through theneedle 514 into the patient. Theactuator 540 may, according to certain embodiments, be theneedle shield 522, as explained above. According to other embodiments, such as the one illustrated inFIG. 5 , theactuator 540 may be a button that may be manually depressed by the user or patient once thedrug delivery device 502 is placed disposed on or against the patient's skin. Alock 541 may be coupled to theactuator 540 and configured to limit or prevent movement of theactuator 540 so that theactuator 540 cannot be used to activate thedrive 530. In some embodiments, thelock 541 may be coupled to a controller (e.g.,controller 550 described in more detail below) which can selectively activate or deactivate thelock 541 based on different types of information regarding thedrug delivery device 502, including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above. When thelock 541 is activated by thecontroller 550, thelock 541 may be configured to limit or prevent movement of theactuator 540 relative to thehousing 510. When thelock 541 is deactivated by thecontroller 550, thelock 541 may be configured to allow movement of theactuator 540 relative to thehousing 510. - The
drug delivery device 502 may also include a removablesterile barrier 544 that is disposed about one or more of a distal end of thehousing 510, theneedle shield 522, and thesecond end 518 of thedelivery cannula 514. The removablesterile barrier 544 may be removably attached to the distal end of thehousing 510 as shown inFIG. 5 . In some embodiments, the removablesterile barrier 544 may form an interference or snap fit with the distal end of thehousing 510. A frictional force associated with the interference or snap fit may be overcome by manually pulling the removablesterile barrier 544 in a direction away from ahousing 510. The removablesterile barrier 544, when attached to thedrug delivery device 502, may reduce the risk of contamination of thedelivery cannula 514 and other elements disposed within thedrug delivery device 502. - Additionally, the
drug delivery device 502 may include aheating element 546 coupled to the exterior of thereservoir 512 and configured to warm the medicament inside thereservoir 512 through, for example, conductive heating. Theheating element 546 may be coupled to thecontroller 550 so that thecontroller 550 can selectively activate or deactivate theheating element 546 based on different types of information regarding thedrug delivery device 502, including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above. In some embodiments, theheating element 546 may include an electrically conductive coil that is wrapped around the exterior of thereservoir 512. Alternatively, or additionally, a cooling element (not illustrated) may be coupled to thereservoir 512 and controllable by thecontroller 550 in a manner similar to theheating element 546. - The
drug delivery device 502 may also include anoutput unit 547 coupled to thehousing 510 and configured to notify the patient or user of information related to thedrug delivery device 502. Theoutput unit 547 may be coupled to thecontroller 550 so that thecontroller 550 can selectively activate or deactivate theoutput unit 547 based on different types of information regarding thedrug delivery device 502, including operational state information, condition information, and/or identity information, in accordance with one or more of the methods described above. Theoutput unit 547 may be any device suitable for conveying information to the patient or user including a display (e.g., a liquid crystal display), a touchscreen, a light (e.g., a light emitting diode), a vibrator (e.g., an electro-mechanical vibrating element), a speaker, and/or an alarm, among other devices. - The
drug delivery device 502 may also include aninput unit 548 coupled to thehousing 510 and configured to allow a user or patient to input information (e.g., password information) to be used by thecontroller 550. In some embodiments, theinput unit 548, theoutput unit 547, and even thefingerprint sensor 565, may be a single device such as a touchscreen. In other embodiments, theinput unit 548 may be a separate device from theoutput unit 547 such as a keyboard or button. - As illustrated in
FIG. 5 , thereservoir 512, the biasingelement 524, thelocks plunger 531, thestopper 532, and thedrive 530, and theheating element 546 are disposed within thehousing 510, along with at least part of thedelivery cannula 514. Also disposed within thehousing 510 is acontroller 550, a communication module 552 (e.g., a wireless transmitter), and at least one sensor or switch. According to the embodiment illustrated inFIG. 5 , four sensors are included: atemperature sensor 560, askin sensor 562, at least oneorientation sensor 564, and afingerprint sensor 565. Thesensors drug delivery device 502. The sensor data may be representative of at least one of a condition or operational state of thedrug delivery device 502. Additionally, thedrug delivery device 502 includes aswitch 566. Thecontroller 550 is coupled to thecommunication module 552, thelocks sensors heating element 546, thefingerprint sensor 565, theoutput unit 547, theinput unit 548, and theswitch 566. Thecontroller 550 may be configured to process the sensor data generated by thesensors drug delivery device 502. Thecontroller 550, thecommunication module 552, one or more of thesensors switch 566 may be packaged together as a single module, or each component may be fabricated separately and coupled once the components are disposed within thehousing 510. According to certain embodiments, each electrical component may be integrated into the structure of thedevice 502 associated with that electrical component (e.g., thesensors controller 550, thecommunication module 552, one or more of thesensors switch 566 may be packaged together inside the removablesterile barrier 544 - The
controller 550 may include at least one processor 570 (e.g., a microprocessor) and a memory 572 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.). Thecontroller 550 may also include or be coupled to a power supply, e.g. a battery. Theprocessor 570 may be programmed to carry out the actions that thecontroller 550 is adapted to perform and thememory 572 may include one or more tangible non-transitory readable memories having executable, computer-readable, non-transitory instructions stored thereon, which instructions when executed by the at least oneprocessor 570 may cause the at least oneprocessor 570 to carry out the actions that thecontroller 550 is adapted to perform. Alternatively, thecontroller 550 may include other circuitry that carries out the actions that the controller is adapted to perform. - The
memory 572 may store the identity information discussed above. The identity information may be stored in thememory 572 prior to the start of execution of any of the methods discussed above. The identity information may include, by way of example and not by way of limitation, a unique identifier, the name of the drug, the dosage, an expiration date, and information regarding the identity of the patient for whom the drug was prescribed. With this information, thecontroller 550 or a local computing device (e.g., a smartphone) may make a determination regarding the patient that is about to receive the drug, and provide appropriate informational and/or instructional prompts. As an alternative tomemory 572, the identity information may be contained in a QR code label or RFID tag associated with thedrug delivery device 502. - The
communication module 552 may be any of a number of different communication modules used to communicate with a local computing device (e.g., a smartphone) and/or a remote computing device (e.g., a server operated by the device manufacturer). According to one embodiment, thecommunication module 552 may be a Bluetooth and/or Bluetooth Low Energy module that is on-board with thecontroller 550. Thecommunication module 552 is used to transmit information from thedrug delivery device 502 to thelocal computing device 504. Alternatively, other wireless protocols may be used by thecommunication module 552, such as radio-frequency identification (RFID), Zigbee, Wi-Fi, near field communication (NFC), and others. In fact, the communication may be sent along a hardwired connection, rather than using the electromagnetic (EM) spectrum. As defined herein, a communication transmitted and/or received between themodule 552, the local computing device, and/or the remote computing device may be in the form of a hardwired signal or EM signal or a pattern of such signals, for example. - The
temperature sensor 560 may be disposed proximate to thereservoir 512 so that the temperature of the drug in thereservoir 512 may be determined. Alternatively, thetemperature sensor 560 may simply be disposed in thehousing 510, so that an approximate temperature of the drug in thereservoir 512 and of thedrug delivery device 502 generally may be determined. According to an embodiment, thetemperature sensor 560 may be an on-board temperature sensor 560 attached to theprocessor 570. - The
skin sensor 562 may be attached to or associated with theshield 522 to determine when thedrug delivery device 502 is disposed on or against the patient's skin. According to one embodiment, theskin sensor 562 is a pressure sensor. According to other embodiments, theskin sensor 562 may be a capacitance sensor, resistance sensor, or inductance sensor. Theskin sensor 562 or the switch 566 (which is attached to or associated with the actuator 540) may be used to determine when thedrug delivery device 502 is activated or actuated, depending on the design and operation of thedrug delivery device 502 that is used to actuate thedrive 530, in accordance with the discussion above. It may also be the case that a signal from theskin sensor 560 is used to determine that thedrug delivery device 502 has been activated even when theshield 522 is not used as the actual actuator, the underlying assumption being that the movement of theshield 522 is necessarily related to the actuation of thedevice 502. - The
orientation sensors 564, of which there may be at least two as illustrated, may be associated with the shield 522 (or that portion of thehousing 510 adjacent the shield 522) and the controller 550 (which may be, as illustrated, disposed at the other end of thedrug delivery device 502 or thehousing 510 from the shield 522). Theorientation sensors 564 may be magnetometers, for example. In particular, theorientation sensor 564 associated with thecontroller 550 may be an on-board magnetometer. Theorientation sensors 564 may be used to determine the orientation of the drug delivery device 502 (in particular, the housing 510) relative to the injection site (or more particularly, relative to the placement of thedrug delivery device 502 on or against the patient's skin). - Still referring to
FIG. 5 , thelocal computing device 504 may be in the form of at least one computing device including at least one processor 620 (e.g., microprocessor) and a memory 622 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.). The at least oneprocessor 620 and thememory 622 may be incorporated into a controller 623 of thelocal computing device 504 and/or may be configured separately. Likewise, theremote computing device 506 may be in the form of at least one computing device including at least one processor 624 (e.g., microprocessor) and memory 626 (e.g., a random access memory (RAM), a non-volatile memory such as a hard disk, a flash memory, a removable memory, a non-removable memory, etc.). The at least oneprocessor 624 and thememory 626 may be incorporated into acontroller 627 of thelocal computing device 504 and/or may be configured separately. Theprocessors FIG. 6 and thememories processors processors FIG. 6 . - In some embodiments, the computer-executable instructions may be included in a software application (e.g., a mobile software application, also commonly referred to as a “mobile app”) stored in the
memory 622 of thelocal computing device 504. The software application may be installed onlocal computing device 504 as one or more downloaded files, such as an executable package installation file downloaded from a suitable application store via a connection to the Internet. Examples of package download files may include downloads via the iTunes store, the Google Play Store, the Windows Phone Store, downloading a package installation file from another computing device, etc. The software application may be developed for a mobile operating system such as Android™ or iOS®, developed by Google and Apple, respectively. In some embodiments, the application may be initiated by a user selecting an icon shown on a home screen of a display 632 (e.g., a touchscreen) of thelocal computing device 504. Various displays, including messages received from a support group, may be generated in the application and displayed to a user and/or patient via thedisplay 632 of thelocal computing device 504. - According to certain embodiments of this disclosure, the
local computing device 504 may carry out the actions ofFIG. 6 independent of theremote computing device 506. According to other embodiments, thelocal computing device 504 may carry out certain of the actions ofFIG. 6 , while theremote computing device 506 carries out other of the actions ofFIG. 6 . For example, according to certain embodiments the processor(s) 620 may control components of thelocal computing device 504 permitting communication with thecontroller 550 and/or the user, but may not make the determinations as to the content of those communications, the determinations relative to the content of the communications being made at theremote computing device 506. - According to the illustrated embodiment, the
local computing device 504 is a mobile computing device (e.g., a smartphone, a smartwatch, a smart wearable device, a personal computer, a laptop computer, or a tablet computer, etc.) while theremote computing device 506 is a server. In some embodiments, thelocal computing device 504 can include generally any computing device capable of processing data and being synched to and in communication with thedrug delivery device 502 such as, for example, a smart wearable device, a personal computer, a laptop computer, a smart television, a smart appliance, a smart automobile, a networked computer, etc. According to other embodiments, thelocal computing device 504 may be a dedicated device such as a hub or gateway that can establish a communication link with thecommunication module 552 and potentially theremote computing device 506, where communication with theremote computing device 506 is necessary or desirable. - To carry out the actions of the methods described in
FIG. 6 , thelocal computing device 504 may further include acommunication module 630 for wireless communication with thecommunication module 552 of thedrug delivery device 502, for example by using Bluetooth or Bluetooth Low Energy protocol. Alternatively, other wireless protocols may be used by thecommunication module 552, such as radio-frequency identification (RFID), Zigbee, Wi-Fi, near field communication (NFC), and others. Thelocal computing device 504 may also include the display 632 (e.g., a touchscreen) to be used to display information (e.g., instructional prompts and/or informational prompts) to the user. Thelocal computing device 504 may include other output devices other than thedisplay 632 to communicate with the user, such as aspeaker 634 for example. Thespeaker 634 may be controlled by the processor(s) 620 to provide an audible form of the instructions displayed in written form on thedisplay 632. - The
local computing device 504 may also include one or more communication modules, which may be the same as or different from thecommunication module 630, that may be used to communicate with one or more networks 640, 642. For example, the network 640 may be a wireless radio frequency network, such as a cellular mobile device network, while the network 642 may be a network of computing devices, such as the Internet. As is illustrated inFIG. 6 , the networks 640, 642 may be in communication with each other, such that thelocal computing device 504 may communicate with theremote computing device 506 over the network 640, the network 642 or a combination of the networks 640, 642. Theremote computing device 624 may include acommunication module 636 to receive communications from the networks 640, 642. - While the terms “local” and “remote” have been used to describe the
local computing device 504 and theremote computing device 506, these terms have not been selected to require a particular spatial or geographical distance between thedevices remote computing device 506 is not required to be at the same physical location as the user and thedrug delivery device 502. According to certain embodiments, it is possible, even likely, that theremote computing device 506 may be located in a different geographic location than the user and thedrug delivery device 502, for example a different city, state or country. - Also, it is noted that each of the
local computing device 504 and theremote computing device 506 is separate from, and spaced apart from, thedrug delivery device 502, and therefore each may be considered to be an “external computing device” relative to thedrug delivery device 502. - Turning to
FIG. 6 , illustrated is a flow diagram of one embodiment of amethod 700 of providing social support to a patient associated with thedrug delivery device 502. Thememory 622 of thelocal computing device 504 and/or thememory 626 of theremote computing device 506 may store one or more computer-executable instructions that, when executed by theprocessor 620 of thelocal computing device 504 and/or the processor of the 624 of theremote computing device 506, cause theprocessor 620 of thelocal computing device 504 and/or the processor of the 624 of theremote computing device 506 to carry out the actions described below relative to themethod 700. Also, as described below in more detail, themethod 700 may leverage social networking services (e.g., Facebook, Twitter, etc.) that provide access to groups of users who are already connected, or who can easily be connected, to the patient. By providing the patient with support (e.g., encouragement, praise, coaching, advice, reminders, etc.), the patient may be more likely to comply with a treatment regimen (e.g., a therapeutic regimen) for treating a medical condition of the patient withdrug delivery device 502. - The
method 700 may begin with associating the patient with a support group or multiple support groups (see block 710). The support group may be a group of people and/or organizations having an interest in the patient complying with the treatment regimen. The support group may include a healthcare provider (e.g., a doctor, nurse, etc.), a caregiver, a family member, a friend, a medical device manufacturer, an insurance company, and/or another individual using a similar drug delivery device and/or having a similar medical condition. In some embodiments, the support group may be a pre-existing online community of individuals connected through a social networking service, such as a Facebook group. In some embodiments, the support group may consist of the patient's Facebook friends. - The association of the patient with the support group may be accomplished in a variety of different manners. In some embodiments, the patient may select (via, for example, a mobile application executing on the local computing device 504) a pre-existing group (e.g., the patient's Facebook friends) to be the support group. The patient's selection may be transmitted to the
remote computing device 506 which subsequently associates the patient with the patient-selected support group. In other embodiments, theremote computing device 506 may register identity information about the patient (e.g., age, height, weight, medical condition, etc.) and then associate the patient with individuals sharing similar identity information. In still further embodiments, the associating the patient with a support group may include initially collecting data (e.g., GPS data) from thelocal computing device 504 about the geographic location of the patient and/or thedrug delivery device 502. Based on this data, theremote computing device 506 may choose individuals who are physically near the geographic location of the patient as the support group. The geographic-based method of associating the patient with a support group may be combined with any of the foregoing methods of association, such that the geographic location of the patient is only one factor in the selection of an appropriate support group. In some embodiments, the patient may be presented with map of nearby support groups from which the patient can selected a desired support group. - Next, the
method 700 may involve receiving, at thelocal computing device 504 and/or at theremote computing device 506, data representative of a condition and/or an operational state of the drug delivery device 502 (see block 720). The data may be in the form of one or more of the reports similar to those described above in connection with themethod 200 and/or themethod 300. In some embodiments, thedrug delivery device 502 may transmit sensor data, collected by the sensors onboard thedrug delivery device 502, to thelocal computing device 504, which in turn, may analyze the sensor data to generate a report representative of a condition and/or an operational state of thedrug delivery device 502 and then transmit that report to theremote computing device 506. In other embodiments, the sensor data may be transmitted directly to theremote computing device 506, which may then analyze the sensor data to determine the condition and/or operational state of thedrug delivery device 502. In still further embodiments, thedrug delivery device 502 may analyze the sensor data and generate the report representative the condition and/or an operational state of adrug delivery device 502, and then transmit that report to thelocal computing device 504 and/or theremote computing device 506. - Once in possession of the data representative of the condition and/or the operational state of the
drug delivery device 502, thelocal computing device 504 and/or theremote computing device 506 may analyze the data to determine if the patient has complied with a treatment regimen (see block 730). This determination may involve a comparison of the data representative of the condition and/or the operational state of thedrug delivery device 502 with a predefined criteria stored in thememory 622 of thelocal computing device 504 and/or thememory 626 of theremote computing device 506. The predefined criteria may specify, for example, the frequency with which the patient is to receive an injection of a medicament, the amount or dose of medicament to be received by the patient, the temperature of the medicament at the time of injection, the type of medicament to be received by the patient, and/or the sequence in which a medicament is to be injected along with other medicaments. In some embodiments, the predefined criteria may indicate that the patient is to receive an injection of the medicament every day before noon. - In some embodiments, compliance with the treatment regimen may be involve a determination that the operational state of the
drug delivery device 502 corresponds to thedrug delivery device 502 having completed delivery of the medicament to the patient. Judging whether delivery of the medicament to the patient has been successful may accomplished in a manner consistent with themethod 200 and/or themethod 300. In some embodiments, successful drug delivery may be determined if both theneedle shield 522 has been moved in the distal direction relative to thedelivery cannula 514 and theplunger 531 has completed its delivery stroke by moving from its proximal position to its distal position. Other conditions or states that may be considered to confirm successful delivery of the medicament to the patient include an indication that theactuator 540 has been triggered (e.g., depressed) and/or the amount of medicament remaining in thereservoir 512. - In response to a determination at
block 720 that the patient's use of thedrug delivery device 502 complies with the treatment regimen, themethod 700 may return to block 720, where thelocal computing device 504 and/or theremote computing device 506 waits for the reception of new data representative of at least one of a condition or an operational state of adrug delivery device 502. In an alternative embodiment (not illustrated), in response to a determination atblock 720 is compliant with the treatment regimen, thelocal computing device 504 and/or theremote computing device 506 may transmit a communication to the support group associated with the patient requesting the support group to send a message of praise or congratulation to the patient. - In response to a determination at
block 720 that the patient is not compliant with the treatment regimen, thelocal computing device 504 and/or theremote computing device 506 may transmit a communication to the support group associated with the patient in order to initiate an intervention with the patient (see block 740). The communication may be sent through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.). The communication may request the support group to counsel the patient about the treatment regimen. In some embodiments, the request may suggest that the support group send a message to the patient encouraging the patient to comply with the treatment regimen. In some embodiments, the request may include pre-written message and/or an ideogram (e.g., an emoji) which can be sent, on demand, by a member of the support group to the patient. In addition to asking the support group to counsel the patient, the request may ask the support group to actively intervene by, for example, meeting with the patient in-person, physically assisting the patient with their use of the drug delivery device, and/or actually administering the medicament to the patient with the drug delivery device. Active intervention may be especially beneficial for patients suffering from dementia and other forms of cognitive decline. In some embodiments, the message asking the support group to intervene may include an indication of the patient's limited cognitive abilities so that the support group appreciates the patient's vulnerability to forget their medication schedule. - Next, the
method 700 may include thelocal computing device 504 and/or theremote computing device 506 receiving a communication from the support group providing the requested counseling (see block 750). The communication may in the form of a message sent through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.). The message may include words of encouragement, coaching, advice, a reminder, or any other communication likely to urge the patient to comply with the treatment regimen. - After receiving the communication from the support group, the
method 700 may forward the communication to the patient (block 760). This may involve displaying the communication on thedisplay 632 of thelocal computing device 504 and/or generating a sound with thespeaker 634 of thelocal computing device 504. - In general, the support provided to the patient by the
method 700 is reactive support since it is provided in response to the patient's failure to comply with the treatment regimen. In addition to reactive support, or as a substitute for reactive support, the methods and systems disclosed herein may be configured to provide the patient with proactive support. This type of support reduces the likelihood that the patient will fail to comply with the treatment regimen by taking preventative measures before a violation of the treatment regimen occurs. In one implementation, thelocal computing device 504 and/or theremote computing device 506 may evaluate the treatment region to determine if the patient is scheduled to receive a dose of the medicament in the near future (e.g., tomorrow, tonight, in the next hour, etc.). In response to a determination that the patient is scheduled to receive a dose of the medicament, thelocal computing device 504 and/or theremote computing device 506 may transmit a communication to the support group associated with the patient. This communication may include a request for support group to remind the patient to take their upcoming dose of the medicament. Similar to themethod 700, these steps may be performed by executing non-transitory, computer-executable instructions included in a mobile software application, or other module, stored in thememory 622 of thelocal computing device 504 and/or thememory 626 of theremote computing device 506. Upon receipt of the communication asking for support, members of the support group may send one or more messages through a social networking service or some other mechanism (e.g., email, SMS message, push notification, telephone, etc.) to the patient reminding him or her to take their medication. By providing the patient with proactive support, the patient may be less likely to miss a scheduled dose of the medicament. - Additionally, while the foregoing embodiments provide support that is not actively solicited by the patient, the scope of the present disclosure is not limited to unsolicited support. In some embodiments, the
local computing device 504 and/or theremote computing device 506 may be configured to receive a request from the patient for help and/or support, and in response to that request, automatically contact an appropriate individual or organization. In one implementation, a mobile software application executing on thelocal computing device 504 may display a help button or icon that, when selected by the patient, causes thelocal computing device 504 to transmit a help request to a healthcare provider (e.g., doctor, nurse practitioner, nurse, etc.), caregiver, medical device manufacturer, support group, or any other individual or organization capable helping the patient. The help request may solicit technical support for proper use of the drug delivery device, emotional support, information about the medicament and its side effects, and/or any other type of support. In an embodiment where thelocal computing device 504 is a smartphone, selecting the help button may cause the smartphone to automatically call a support hotline, call a member of a support group, and/or open a website (e.g., a website including a list a frequently asked questions) in a web browser executing on the smartphone. Accordingly, the patient may be able to obtain immediate support for his or her questions or concerns. - In addition to the various medical benefits discussed above, the methods and systems disclosed herein have several technical effects on the process of monitoring the use of a drug delivery device and ensuring patient compliance with a treatment regimen. One technical effect is the computer-implemented determination of the condition and/or operational state of the drug delivery device and the automatic distribution of this information to a social network for further processing and/or notification of a support group. Accordingly, a caregiver is not required to manually determine, or manually notify a support group of, the condition and/or operational state of the drug delivery device to ensure patient compliance. Another technical effect is that the presently disclosed systems and methods streamline the process of identifying an appropriate support group for the patient. For example, the systems and methods may automatically associate the patient with a support group located geographically nearby the patient and/or a support group including members with whom the patient has a personal and/or professional relationship. Automating the process of associating the patient with a support group reduces the search burden on the patient or caregiver. In some embodiments, the patient may be associated with a support group based upon the patient's pre-existing social networking based relationships (e.g., Facebook friendships), which may further simplify the process of identifying appropriate members for the support group. Yet another technical effect of the presently disclosed methods and systems is that they automatically send a help request to the support group in response to a determination of the patient's non-compliance with the treatment regimen. Accordingly, the systems and methods provide a relatively simplistic trigger for notifying the support group, which can help minimize the amount of data processing needed to alert the support group. While the foregoing mentions several technical effects associated with the invention, other technical effects will be readily apparent to one of ordinary skill in the art upon a review of this disclosure.
- The above description describes various systems and methods for use with a drug delivery device. It should be clear that the system, drug delivery device or methods can further comprise use of a medicament listed below with the caveat that the following list should neither be considered to be all inclusive nor limiting. The medicament will be contained in a reservoir. In some instances, the reservoir is a primary container that is either filled or pre-filled for treatment with the medicament. The primary container can be a cartridge or a pre-filled syringe.
- For example, the drug delivery device or more specifically the reservoir of the device may be filled with colony stimulating factors, such as granulocyte colony-stimulating factor (G-CSF). Such G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim). In various other embodiments, the drug delivery device may be used with various pharmaceutical products, such as an erythropoiesis stimulating agent (ESA), which may be in a liquid or a lyophilized form. An ESA is any molecule that stimulates erythropoiesis, such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, and epoetin delta, as well as the molecules or variants or analogs thereof as disclosed in the following patents or patent applications, each of which is herein incorporated by reference in its entirety: U.S. Pat. Nos. 4,703,008; 5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078; 5,773,569; 5,955,422; 5,986,047; 6,583,272; 7,084,245; and 7,271,689; and PCT Publication Nos. WO 91/05867; WO 95/05465; WO 96/40772; WO 00/24893; WO 01/81405; and WO 2007/136752.
- An ESA can be an erythropoiesis stimulating protein. As used herein, “erythropoiesis stimulating protein” means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor. Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor. Erythropoiesis stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, pegylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1/hematide), and mimetic antibodies. Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoetin, erythropoietin agonist variants, and peptides or antibodies that bind and activate erythropoietin receptor (and include compounds reported in U.S. Publication Nos. 2003/0215444 and 2006/0040858, the disclosures of each of which is incorporated herein by reference in its entirety) as well as erythropoietin molecules or variants or analogs thereof as disclosed in the following patents or patent applications, which are each herein incorporated by reference in its entirety: U.S. Pat. Nos. 4,703,008; 5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078; 5,773,569; 5,955,422; 5,830,851; 5,856,298; 5,986,047; 6,030,086; 6,310,078; 6,391,633; 6,583,272; 6,586,398; 6,900,292; 6,750,369; 7,030,226; 7,084,245; and 7,217,689; U.S. Publication Nos. 2002/0155998; 2003/0077753; 2003/0082749; 2003/0143202; 2004/0009902; 2004/0071694; 2004/0091961; 2004/0143857; 2004/0157293; 2004/0175379; 2004/0175824; 2004/0229318; 2004/0248815; 2004/0266690; 2005/0019914; 2005/0026834; 2005/0096461; 2005/0107297; 2005/0107591; 2005/0124045; 2005/0124564; 2005/0137329; 2005/0142642; 2005/0143292; 2005/0153879; 2005/0158822; 2005/0158832; 2005/0170457; 2005/0181359; 2005/0181482; 2005/0192211; 2005/0202538; 2005/0227289; 2005/0244409; 2006/0088906; and 2006/0111279; and PCT Publication Nos. WO 91/05867; WO 95/05465; WO 99/66054; WO 00/24893; WO 01/81405; WO 00/61637; WO 01/36489; WO 02/014356; WO 02/19963; WO 02/20034; WO 02/49673; WO 02/085940; WO 03/029291; WO 2003/055526; WO 2003/084477; WO 2003/094858; WO 2004/002417; WO 2004/002424; WO 2004/009627; WO 2004/024761; WO 2004/033651; WO 2004/035603; WO 2004/043382; WO 2004/101600; WO 2004/101606; WO 2004/101611; WO 2004/106373; WO 2004/018667; WO 2005/001025; WO 2005/001136; WO 2005/021579; WO 2005/025606; WO 2005/032460; WO 2005/051327; WO 2005/063808; WO 2005/063809; WO 2005/070451; WO 2005/081687; WO 2005/084711; WO 2005/103076; WO 2005/100403; WO 2005/092369; WO 2006/50959; WO 2006/02646; and WO 2006/29094.
- Examples of other pharmaceutical products for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), Xgeva™ (denosumab) and Prolia™ (denosamab); other biological agents such as Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim , G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet). The device may also be used with a therapeutic antibody, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose. The pharmaceutical product may be in liquid form, or reconstituted from lyophilized form.
- Among particular illustrative proteins are the specific proteins set forth below, including fusions, fragments, analogs, variants or derivatives thereof:
- OPGL specific antibodies, peptibodies, and related proteins, and the like (also referred to as RANKL specific antibodies, peptibodies and the like), including fully humanized and human OPGL specific antibodies, particularly fully humanized monoclonal antibodies, including but not limited to the antibodies described in PCT Publication No. WO 03/002713, which is incorporated herein in its entirety as to OPGL specific antibodies and antibody related proteins, particularly those having the sequences set forth therein, particularly, but not limited to, those denoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including the OPGL specific antibodies having either the light chain of SEQ ID NO:2 as set forth therein in
FIG. 2 and/or the heavy chain of SEQ ID NO:4, as set forth therein inFIG. 4 , each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication; - Myostatin binding proteins, peptibodies, and related proteins, and the like, including myostatin specific peptibodies, particularly those described in U.S. Publication No. 2004/0181033 and PCT Publication No. WO 2004/058988, which are incorporated by reference herein in their entirety particularly in parts pertinent to myostatin specific peptibodies, including but not limited to peptibodies of the mTN8-19 family, including those of SEQ ID NOS:305-351, including TN8-19-1 through TN8-19-40, TN8-19 coni and TN8-19 con2; peptibodies of the mL2 family of SEQ ID NOS:357-383; the mL15 family of SEQ ID NOS:384-409; the mL17 family of SEQ ID NOS:410-438; the mL20 family of SEQ ID NOS:439-446; the mL21 family of SEQ ID NOS:447-452; the mL24 family of SEQ ID NOS:453-454; and those of SEQ ID NOS:615-631, each of which is individually and specifically incorporated by reference herein in their entirety fully as disclosed in the foregoing publication;
- IL-4 receptor specific antibodies, peptibodies, and related proteins, and the like, particularly those that inhibit activities mediated by binding of IL-4 and/or IL-13 to the receptor, including those described in PCT Publication No. WO 2005/047331 or PCT Application No. PCT/US2004/37242 and in U.S. Publication No. 2005/112694, which are incorporated herein by reference in their entirety particularly in parts pertinent to IL-4 receptor specific antibodies, particularly such antibodies as are described therein, particularly, and without limitation, those designated therein: L1H1; L1H2; L1H3; L1H4; L1H5; L1H6; L1H7; L1H8; L1H9; L1H10; L1H11; L2H1; L2H2; L2H3; L2H4; L2H5; L2H6; L2H7; L2H8; L2H9; L2H10; L2H11; L2H12; L2H13; L2H14; L3H1; L4H1; L5H1; L6H1, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in U.S. Publication No. 2004/097712, which is incorporated herein by reference in its entirety in parts pertinent to IL1-R1 specific binding proteins, monoclonal antibodies in particular, especially, without limitation, those designated therein: 15CA, 26F5, 27F2, 24E12, and 10H7, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the aforementioned publication;
- Ang2 specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in PCT Publication No. WO 03/057134 and U.S. Publication No. 2003/0229023, each of which is incorporated herein by reference in its entirety particularly in parts pertinent to Ang2 specific antibodies and peptibodies and the like, especially those of sequences described therein and including but not limited to: L1(N); L1(N) WT; L1(N) 1K WT; 2xL1(N); 2xL1(N) WT; Con4 (N), Con4 (N) 1K WT, 2xCon4 (N) 1K; L1C; L1C 1K; 2xL1C; Con4C; Con4C 1K; 2xCon4C 1K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8-8(N); TN8-14 (N); Con 1 (N), also including anti-Ang 2 antibodies and formulations such as those described in PCT Publication No. WO 2003/030833 which is incorporated herein by reference in its entirety as to the same, particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565; AbF1AbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12; AblA1; AblF; AblK, AblP; and AblP, in their various permutations as described therein, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- NGF specific antibodies, peptibodies, and related proteins, and the like including, in particular, but not limited to those described in U.S. Publication No. 2005/0074821 and U.S. Pat. No. 6,919,426, which are incorporated herein by reference in their entirety particularly as to NGF-specific antibodies and related proteins in this regard, including in particular, but not limited to, the NGF-specific antibodies therein designated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- CD22 specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 5,789,554, which is incorporated herein by reference in its entirety as to CD22 specific antibodies and related proteins, particularly human CD22 specific antibodies, such as but not limited to humanized and fully human antibodies, including but not limited to humanized and fully human monoclonal antibodies, particularly including but not limited to human CD22 specific IgG antibodies, such as, for instance, a dimer of a human-mouse monoclonal hLL2 gamma-chain disulfide linked to a human-mouse monoclonal hLL2 kappa-chain, including, but limited to, for example, the human CD22 specific fully humanized antibody in Epratuzumab, CAS registry number 501423-23-0;
- IGF-1 receptor specific antibodies, peptibodies, and related proteins, and the like, such as those described in PCT Publication No. WO 06/069202, which is incorporated herein by reference in its entirety as to IGF-1 receptor specific antibodies and related proteins, including but not limited to the IGF-1 specific antibodies therein designated L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50HSO, L51H51, L52H52, and IGF-1R-binding fragments and derivatives thereof, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- Also among non-limiting examples of anti-IGF-1R antibodies for use in the methods and compositions of the present invention are each and all of those described in:
-
- (i) U.S. Publication No. 2006/0040358 (published Feb. 23, 2006), 2005/0008642 (published Jan. 13, 2005), 2004/0228859 (published Nov. 18, 2004), including but not limited to, for instance, antibody 1A (DSMZ Deposit No. DSM ACC 2586), antibody 8 (DSMZ Deposit No. DSM ACC 2589), antibody 23 (DSMZ Deposit No. DSM ACC 2588) and antibody 18 as described therein;
- (ii) PCT Publication No. WO 06/138729 (published Dec. 28, 2006) and WO 05/016970 (published Feb. 24, 2005), and Lu et al. (2004), J. Biol. Chem. 279:2856-2865, including but not limited to antibodies 2F8, A12, and IMC-A12 as described therein;
- (iii) PCT Publication No. WO 07/012614 (published Feb. 1, 2007), WO 07/000328 (published Jan. 4, 2007), WO 06/013472 (published Feb. 9, 2006), WO 05/058967 (published Jun. 30, 2005), and WO 03/059951 (published Jul. 24, 2003);
- (iv) U.S. Publication No. 2005/0084906 (published Apr. 21, 2005), including but not limited to antibody 7C10, chimaeric antibody C7C10, antibody h7C10, antibody 7H2M, chimaeric antibody *7C10, antibody GM 607, humanized antibody 7C10 version 1, humanized antibody 7C10 version 2, humanized antibody 7C10 version 3, and antibody 7H2HM, as described therein;
- (v) U.S. Publication Nos. 2005/0249728 (published Nov. 10, 2005), 2005/0186203 (published Aug. 25, 2005), 2004/0265307 (published Dec. 30, 2004), and 2003/0235582 (published Dec. 25, 2003) and Maloney et al. (2003), Cancer Res. 63:5073-5083, including but not limited to antibody EM164, resurfaced EM164, humanized EM164, huEM164 v1.0, huEM164 v1.1, huEM164 v1.2, and huEM164 v1.3 as described therein;
- (vi) U.S. Pat. No. 7,037,498 (issued May 2, 2006), U.S. Publication Nos. 2005/0244408 (published Nov. 30, 2005) and 2004/0086503 (published May 6, 2004), and Cohen, et al. (2005), Clinical Cancer Res. 11:2063-2073, e.g., antibody CP-751,871, including but not limited to each of the antibodies produced by the hybridomas having the ATCC accession numbers PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, and antibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2, and 4.17.3, as described therein;
- (vii) U.S. Publication Nos. 2005/0136063 (published Jun. 23, 2005) and 2004/0018191 (published Jan. 29, 2004), including but not limited to antibody 19D12 and an antibody comprising a heavy chain encoded by a polynucleotide in plasmid 15H12/19D12 HCA (γ4), deposited at the ATCC under number PTA-5214, and a light chain encoded by a polynucleotide in plasmid 15H12/19D12 LCF (κ), deposited at the ATCC under number PTA-5220, as described therein; and
- (viii) U.S. Publication No. 2004/0202655 (published Oct. 14, 2004), including but not limited to antibodies PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-12A5, as described therein; each and all of which are herein incorporated by reference in their entireties, particularly as to the aforementioned antibodies, peptibodies, and related proteins and the like that target IGF-1 receptors;
- B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like (“B7RP-1,” also is referred to in the literature as B7H2, ICOSL, B7h, and CD275), particularly B7RP-specific fully human monoclonal IgG2 antibodies, particularly fully human IgG2 monoclonal antibody that binds an epitope in the first immunoglobulin-like domain of B7RP-1, especially those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells in particular, especially, in all of the foregoing regards, those disclosed in U.S. Publication No. 2008/0166352 and PCT Publication No. WO 07/011941, which are incorporated herein by reference in their entireties as to such antibodies and related proteins, including but not limited to antibodies designated therein as follow: 16H (having light chain variable and heavy chain variable sequences SEQ ID NO:1 and SEQ ID NO:7 respectively therein); 5D (having light chain variable and heavy chain variable sequences SEQ ID NO:2 and SEQ ID NO:9 respectively therein); 2H (having light chain variable and heavy chain variable sequences SEQ ID NO:3 and SEQ ID NO:10 respectively therein); 43H (having light chain variable and heavy chain variable sequences SEQ ID NO:6 and SEQ ID NO:14 respectively therein); 41H (having light chain variable and heavy chain variable sequences SEQ ID NO:5 and SEQ ID NO:13 respectively therein); and 15H (having light chain variable and heavy chain variable sequences SEQ ID NO:4 and SEQ ID NO:12 respectively therein), each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- IL-15 specific antibodies, peptibodies, and related proteins, and the like, such as, in particular, humanized monoclonal antibodies, particularly antibodies such as those disclosed in U.S. Publication Nos. 2003/0138421; 2003/023586; and 2004/0071702; and U.S. Pat. No. 7,153,507, each of which is incorporated herein by reference in its entirety as to IL-15 specific antibodies and related proteins, including peptibodies, including particularly, for instance, but not limited to, HuMax IL-15 antibodies and related proteins, such as, for instance, 146B7;
- IFN gamma specific antibodies, peptibodies, and related proteins and the like, especially human IFN gamma specific antibodies, particularly fully human anti-IFN gamma antibodies, such as, for instance, those described in U.S. Publication No. 2005/0004353, which is incorporated herein by reference in its entirety as to IFN gamma specific antibodies, particularly, for example, the antibodies therein designated 1118; 1118*; 1119; 1121; and 1121*. The entire sequences of the heavy and light chains of each of these antibodies, as well as the sequences of their heavy and light chain variable regions and complementarity determining regions, are each individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication and in Thakur et al. (1999), Mol. Immunol. 36:1107-1115. In addition, description of the properties of these antibodies provided in the foregoing publication is also incorporated by reference herein in its entirety. Specific antibodies include those having the heavy chain of SEQ ID NO:17 and the light chain of SEQ ID NO:18; those having the heavy chain variable region of SEQ ID NO:6 and the light chain variable region of SEQ ID NO:8; those having the heavy chain of SEQ ID NO:19 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:10 and the light chain variable region of SEQ ID NO:12; those having the heavy chain of SEQ ID NO:32 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:30 and the light chain variable region of SEQ ID NO:12; those having the heavy chain sequence of SEQ ID NO:21 and the light chain sequence of SEQ ID NO:22; those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:16; those having the heavy chain of SEQ ID NO:21 and the light chain of SEQ ID NO:33; and those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:31, as disclosed in the foregoing publication. A specific antibody contemplated is antibody 1119 as disclosed in the foregoing U.S. publication and having a complete heavy chain of SEQ ID NO:17 as disclosed therein and having a complete light chain of SEQ ID NO:18 as disclosed therein;
- TALL-1 specific antibodies, peptibodies, and the related proteins, and the like, and other TALL specific binding proteins, such as those described in U.S. Publication Nos. 2003/0195156 and 2006/0135431, each of which is incorporated herein by reference in its entirety as to TALL-1 binding proteins, particularly the molecules of Tables 4 and 5B, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publications;
- Parathyroid hormone (“PTH”) specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 6,756,480, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind PTH;
- Thrombopoietin receptor (“TPO-R”) specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Pat. No. 6,835,809, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TPO-R;
- Hepatocyte growth factor (“HGF”) specific antibodies, peptibodies, and related proteins, and the like, including those that target the HGF/SF:cMet axis (HGF/SF:c-Met), such as the fully human monoclonal antibodies that neutralize hepatocyte growth factor/scatter (HGF/SF) described in U.S. Publication No. 2005/0118643 and PCT Publication No. WO 2005/017107, huL2G7 described in U.S. Pat. No. 7,220,410 and OA-5d5 described in U.S. Pat. Nos. 5,686,292 and 6,468,529 and in PCT Publication No. WO 96/38557, each of which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind HGF;
- TRAIL-R2 specific antibodies, peptibodies, related proteins and the like, such as those described in U.S. Pat. No. 7,521,048, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TRAIL-R2;
- Activin A specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Publication No. 2009/0234106, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind Activin A;
- TGF-beta specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Pat. No. 6,803,453 and U.S. Publication No. 2007/0110747, each of which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TGF-beta;
- Amyloid-beta protein specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in PCT Publication No. WO 2006/081171, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind amyloid-beta proteins. One antibody contemplated is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6 as disclosed in the foregoing publication;
- c-Kit specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Publication No. 2007/0253951, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind c-Kit and/or other stem cell factor receptors;
- OX40L specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Publication No. 2006/0002929, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind OX40L and/or other ligands of the OX40 receptor; and
- Other exemplary proteins, including Activase® (alteplase, tPA); Aranesp® (darbepoetin alfa); Epogen® (epoetin alfa, or erythropoietin); GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (alemtuzumab, anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti-α4β7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cetuximab, anti-EGFR/HER1/c-ErbB-1); Genotropin® (somatropin, Human Growth Hormone); Herceptin® (trastuzumab, anti-HER2/neu (erbB2) receptor mAb); Humatrope® (somatropin, Human Growth Hormone); Humira® (adalimumab); insulin in solution; Infergen® (interferon alfacon-1); Natrecor® (nesiritide; recombinant human B-type natriuretic peptide (hBNP); Kineret® (anakinra); Leukine® (sargamostim, rhuGM-CSF); LymphoCide® (epratuzumab, anti-CD22 mAb); Benlysta™ (lymphostat B, belimumab, anti-BlyS mAb); Metalyse® (tenecteplase, t-PA analog); Mircera® (methoxy polyethylene glycol-epoetin beta); Mylotarg® (gemtuzumab ozogamicin); Raptiva® (efalizumab); Cimzia® (certolizumab pegol, CDP 870); Soliris™ (eculizumab); pexelizumab (anti-C5 complement); Numax® (MEDI-524); Lucentis® (ranibizumab); Panorex® (17-1A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem® (IDM-1); OvaRex® (B43.13); Nuvion® (visilizumab); cantuzumab mertansine (huC242-DM1); NeoRecormon® (epoetin beta); Neumega® (oprelvekin, human interleukin-11); Neulasta® (pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF); Neupogen® (filgrastim, G-CSF, hu-MetG-CSF); Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody); Procrit® (epoetin alfa); Remicade® (infliximab, anti-TNFα monoclonal antibody); Reopro® (abciximab, anti-GP IIb/Ilia receptor monoclonal antibody); Actemra® (anti-IL6 Receptor mAb); Avastin® (bevacizumab), HuMax-CD4 (zanolimumab); Rituxan® (rituximab, anti-CD20 mAb); Tarceva® (erlotinib); Roferon-A®-(interferon alfa-2a); Simulect® (basiliximab); Prexige® (lumiracoxib); Synagis® (palivizumab); 146B7-CHO (anti-IL15 antibody, see U.S. Pat. No. 7,153,507); Tysabri® (natalizumab, anti-α4integrin mAb); Valortim® (MDX-1303, anti-B. anthracis protective antigen mAb); ABthrax™; Vectibix® (panitumumab); Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portion of human IgG1 and the extracellular domains of both IL-1 receptor components (the Type I receptor and receptor accessory protein)); VEGF trap (Ig domains of VEGFR1 fused to IgG1 Fc); Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2Rα mAb); Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal antibody (galiximab); anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3/huFc fusion protein, soluble BAFF antagonist); CNTO 148 (golimumab, anti-TNFα mAb); HGS-ETR1 (mapatumumab; human anti-TRAIL Receptor-1 mAb); HuMax-CD20 (ocrelizumab, anti-CD20 human mAb); HuMax-EGFR (zalutumumab); M200 (volociximab, anti-α5β1 integrin mAb); MDX-010 (ipilimumab, anti-CTLA-4 mAb and VEGFR-1 (IMC-18F1); anti-BR3 mAb; anti-C. difficile Toxin A and Toxin B C mAbs MDX-066 (CDA-1) and MDX-1388); anti-CD22 dsFv-PE38 conjugates (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax-TAC); anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333 (anti-IFNAR); anti-CD38 mAb (HuMax CD38); anti-CD4OL mAb; anti-Cripto mAb; anti-CTGF Idiopathic Pulmonary Fibrosis Phase I Fibrogen (FG-3019); anti-CTLA4 mAb; anti-eotaxinl mAb (CAT-213); anti-FGF8 mAb; anti-ganglioside GD2 mAb; anti-ganglioside GM2 mAb; anti-GDF-8 human mAb (MYO-029); anti-GM-CSF Receptor mAb (CAM-3001); anti-HepC mAb (HuMax HepC); anti-IFNα mAb (MEDI-545, MDX-1103); anti-IGF1R mAb; anti-IGF-1R mAb (HuMax-Inflam); anti-IL12 mAb (ABT-874); anti-IL12/IL23 mAb (CNTO 1275); anti-IL13 mAb (CAT-354); anti-IL2Ra mAb (HuMax-TAC); anti-IL5 Receptor mAb; anti-integrin receptors mAb (MDX-018, CNTO 95); anti-IP10 Ulcerative Colitis mAb (MDX-1100); anti-LLY antibody; BMS-66513; anti-Mannose Receptor/hCGβ mAb (MDX-1307); anti-mesothelin dsFv-PE38 conjugate (CAT-5001); anti-PD1mAb (MDX-1106 (ONO-4538)); anti-PDGFRα antibody (IMC-3G3); anti-TGFβ mAb (GC-1008); anti-TRAIL Receptor-2 human mAb (HGS-ETR2); anti-TWEAK mAb; anti-VEGFR/Flt-1 mAb; anti-ZP3 mAb (HuMax-ZP3); NVS Antibody #1; and NVS Antibody #2.
- Also included can be a sclerostin antibody, such as but not limited to romosozumab, blosozumab, or BPS 804 (Novartis). Further included can be therapeutics such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA. Additionally, included in the device can be a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), e.g. U.S. Pat. No. 8,030,547, U.S. Publication No. 2013/0064825, WO2008/057457, WO2008/057458, WO2008/057459, WO2008/063382, WO2008/133647, WO2009/100297, WO2009/100318, WO2011/037791, WO2011/053759, WO2011/053783, WO2008/125623, WO2011/072263, WO2009/055783, WO2012/0544438, WO2010/029513, WO2011/111007, WO2010/077854, WO2012/088313, WO2012/101251, WO2012/101252, WO2012/101253, WO2012/109530, and WO2001/031007.
- Also included can be talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers. Examples of oncolytic HSV include, but are not limited to talimogene laherparepvec (U.S. Pat. Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669); OrienX010 (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143); G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002), Cancer Gene Ther., 9(12):967-978).
- Also included are TIMPs. TIMPs are endogenous tissue inhibitors of metalloproteinases (TIMPs) and are important in many natural processes. TIMP-3 is expressed by various cells or and is present in the extracellular matrix; it inhibits all the major cartilage-degrading metalloproteases, and may play a role in role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions. The amino acid sequence of TIMP-3, and the nucleic acid sequence of a DNA that encodes TIMP-3, are disclosed in U.S. Pat. No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated by reference herein. Description of TIMP mutations can be found in U.S. Publication No. 2014/0274874 and PCT Publication No. WO 2014/152012.
- Also included are antagonistic antibodies for human calcitonin gene-related peptide (CGRP) receptor and bispecific antibody molecule that target the CGRP receptor and other headache targets. Further information concerning these molecules can be found in PCT Application No. WO 2010/075238.
- Additionally, a bispecific T cell engager antibody (BiTe), e.g. Blinotumomab can be used in the device. Alternatively, included can be an APJ large molecule agonist e.g., apelin or analogues thereof in the device. Information relating to such molecules can be found in PCT Publication No. WO 2014/099984.
- In certain embodiments, the medicament comprises a therapeutically effective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody. Examples of anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Pat. Nos. 7,982,016, and 8,232,372, and U.S. Publication No. 2009/0186022. Examples of anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Pat. No. 8,101,182. In particularly preferred embodiments, the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated as AS within U.S. Pat. No. 7,982,016.
- It should be noted that the configurations of the various embodiments of the drug delivery devices and drug delivery systems described herein are illustrative only. Although only a few embodiments of the of the drug delivery devices and drug delivery systems have been described in detail in this disclosure, those skilled in the art who review this disclosure will readily appreciate that many modifications are possible (e.g., variations in sizes, dimensions, structures, shapes and proportions of the various elements, values of parameters, mounting arrangements, use of materials, orientations, etc.) without materially departing from the novel teachings and advantages of the subject matter of this disclosure. For example, any combination of one or more of the sensors and sensor systems described herein may be incorporated into one or more of the drug delivery systems and drug delivery devices described herein. Also, the order or sequence of any process or method steps described herein may be varied or re-sequenced, in any combination, according to alternative embodiments. Furthermore, any combination of one or more of the elements of one or more of the claims set forth at the end of this disclosure is possible.
- Although the preceding text sets forth a detailed description of different embodiments of the invention, it should be understood that the legal scope of the invention is defined by the words of the claims set forth at the end of this patent. The detailed description is to be construed as exemplary only and does not describe every possible embodiment of the invention because describing every possible embodiment would be impractical, if not impossible. Numerous alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, that would still fall within the scope of the claims defining the invention.
- It should also be understood that, unless a term is expressly defined in this patent using the sentence “As used herein, the term ‘______’ is hereby defined to mean . . . ” or a similar sentence, there is no intent to limit the meaning of that term, either expressly or by implication, beyond its plain or ordinary meaning, and such term should not be interpreted to be limited in scope based on any statement made in any section of this patent (other than the language of the claims). To the extent that any term recited in the claims at the end of this patent is referred to in this patent in a manner consistent with a single meaning, that is done for sake of clarity only so as to not confuse the reader, and it is not intended that such claim term be limited, by implication or otherwise, to that single meaning. Finally, unless a claim element is defined by reciting the word “means” and a function without the recital of any structure, it is not intended that the scope of any claim element be interpreted based on the application of 35 U.S.C. §112, sixth paragraph.
Claims (43)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/315,954 US20170103186A1 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for supporting patient use of a drug delivery device |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462007007P | 2014-06-03 | 2014-06-03 | |
PCT/US2015/033946 WO2015187805A2 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for supporting patient use of a drug delivery device |
US15/315,954 US20170103186A1 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for supporting patient use of a drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170103186A1 true US20170103186A1 (en) | 2017-04-13 |
Family
ID=53385997
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/315,896 Abandoned US20170098058A1 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for remotely processing data collected by a drug delivery device |
US15/315,922 Pending US20170124285A1 (en) | 2014-06-03 | 2015-06-03 | Devices and methods for assisting a user of a drug delivery device |
US15/315,817 Active 2035-06-28 US10695492B2 (en) | 2014-06-03 | 2015-06-03 | Drug delivery system and method of use |
US15/315,954 Abandoned US20170103186A1 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for supporting patient use of a drug delivery device |
US15/315,829 Active 2035-07-17 US10646652B2 (en) | 2014-06-03 | 2015-06-03 | Controllable drug delivery system and method of use |
US16/843,622 Active US11213624B2 (en) | 2014-06-03 | 2020-04-08 | Controllable drug delivery system and method of use |
US15/931,364 Active US11738146B2 (en) | 2014-06-03 | 2020-05-13 | Drug delivery system and method of use |
US17/534,173 Pending US20220257862A1 (en) | 2014-06-03 | 2021-11-23 | Controllable drug delivery system and method of use |
US17/940,422 Pending US20230098606A1 (en) | 2014-06-03 | 2022-09-08 | Devices and methods for assisting a user of a drug delivery device |
US18/111,064 Pending US20230201461A1 (en) | 2014-06-03 | 2023-02-17 | Systems and methods for remotely processing data collected by a drug delivery device |
US18/218,782 Pending US20230355877A1 (en) | 2014-06-03 | 2023-07-06 | Drug delivery system and method of use |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/315,896 Abandoned US20170098058A1 (en) | 2014-06-03 | 2015-06-03 | Systems and methods for remotely processing data collected by a drug delivery device |
US15/315,922 Pending US20170124285A1 (en) | 2014-06-03 | 2015-06-03 | Devices and methods for assisting a user of a drug delivery device |
US15/315,817 Active 2035-06-28 US10695492B2 (en) | 2014-06-03 | 2015-06-03 | Drug delivery system and method of use |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/315,829 Active 2035-07-17 US10646652B2 (en) | 2014-06-03 | 2015-06-03 | Controllable drug delivery system and method of use |
US16/843,622 Active US11213624B2 (en) | 2014-06-03 | 2020-04-08 | Controllable drug delivery system and method of use |
US15/931,364 Active US11738146B2 (en) | 2014-06-03 | 2020-05-13 | Drug delivery system and method of use |
US17/534,173 Pending US20220257862A1 (en) | 2014-06-03 | 2021-11-23 | Controllable drug delivery system and method of use |
US17/940,422 Pending US20230098606A1 (en) | 2014-06-03 | 2022-09-08 | Devices and methods for assisting a user of a drug delivery device |
US18/111,064 Pending US20230201461A1 (en) | 2014-06-03 | 2023-02-17 | Systems and methods for remotely processing data collected by a drug delivery device |
US18/218,782 Pending US20230355877A1 (en) | 2014-06-03 | 2023-07-06 | Drug delivery system and method of use |
Country Status (11)
Country | Link |
---|---|
US (11) | US20170098058A1 (en) |
EP (6) | EP3151884A1 (en) |
JP (11) | JP6817074B2 (en) |
KR (6) | KR102416904B1 (en) |
CN (7) | CN106663139A (en) |
AU (13) | AU2015271767B2 (en) |
CA (4) | CA2948003C (en) |
IL (7) | IL297356A (en) |
MX (8) | MX2016015851A (en) |
SG (6) | SG11201609963PA (en) |
WO (5) | WO2015187805A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180308571A1 (en) * | 2015-10-09 | 2018-10-25 | Duke University | Medication administration and adherence systems and related methods |
US10182969B2 (en) | 2015-03-10 | 2019-01-22 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
US10646652B2 (en) | 2014-06-03 | 2020-05-12 | Amgen Inc. | Controllable drug delivery system and method of use |
US20210398664A1 (en) * | 2016-03-14 | 2021-12-23 | Fenwal, Inc. | Cell processing method |
US11547801B2 (en) | 2017-05-05 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE480278T1 (en) | 2005-09-12 | 2010-09-15 | Unomedical As | INTRODUCTION SYSTEM FOR AN INFUSION SET WITH A FIRST AND SECOND SPRING UNIT |
EP2552513B1 (en) | 2010-03-30 | 2014-03-19 | Unomedical A/S | Medical device |
US10194938B2 (en) | 2011-03-14 | 2019-02-05 | UnoMedical, AS | Inserter system with transport protection |
CN103957962B (en) | 2011-10-05 | 2017-07-07 | 犹诺医药有限公司 | Insert for inserting multiple percutaneous parts simultaneously |
EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
US10441717B2 (en) | 2014-04-15 | 2019-10-15 | Insulet Corporation | Monitoring a physiological parameter associated with tissue of a host to confirm delivery of medication |
US11478583B2 (en) | 2014-10-03 | 2022-10-25 | Enable Injections, Inc. | Medical fluid transfer and injection apparatus and method |
SI3265152T1 (en) | 2015-03-06 | 2020-08-31 | Attila Berey | Data acquisiton means, especially for a pen-type drug delivery devices |
EP3103491A1 (en) * | 2015-06-10 | 2016-12-14 | Sanofi-Aventis Deutschland GmbH | A device for attachment to a drug delivery device |
JP7082568B2 (en) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | Automatic syringe with signal transduction cap |
US11207460B2 (en) | 2015-12-14 | 2021-12-28 | Amgen Inc. | Drug delivery storage device and system |
EP3184135A1 (en) * | 2015-12-22 | 2017-06-28 | Carebay Europe Ltd. | Communication device for transmitting information from a medicament delivery device |
EP3397318B1 (en) | 2015-12-30 | 2021-11-10 | Ascendis Pharma A/S | Auto injector with adaptable air-shot mechanism |
PL3397324T3 (en) | 2015-12-30 | 2022-10-24 | Ascendis Pharma A/S | Auto injector with cartridge retention system |
AU2016383026B2 (en) | 2015-12-30 | 2021-06-17 | Ascendis Pharma A/S | Auto injector with detection of used cartridge and associated method |
PL3397321T3 (en) * | 2015-12-30 | 2023-01-23 | Ascendis Pharma A/S | Auto injector with temperature control |
CA3006638C (en) | 2015-12-30 | 2024-03-05 | Ascendis Pharma A/S | Auto injector with charger safety |
WO2017120178A1 (en) * | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017125817A1 (en) | 2016-01-19 | 2017-07-27 | Unomedical A/S | Cannula and infusion devices |
US20170237486A1 (en) * | 2016-02-11 | 2017-08-17 | West Pharmaceutical Services, Inc. | Visual communication between mobile communication devices and drug delivery devices |
JOP20170042B1 (en) | 2016-02-12 | 2022-09-15 | Amgen Inc | Drug Delivery Device, Method of Manufacture and Method of Use |
KR101957963B1 (en) * | 2016-03-11 | 2019-07-04 | 이오플로우 주식회사 | Apparatus for Infusing medical liquid |
US10747850B2 (en) * | 2016-03-29 | 2020-08-18 | International Business Machines Corporation | Medication scheduling and alerts |
JP7074684B2 (en) | 2016-04-08 | 2022-05-24 | アムジエン・インコーポレーテツド | Drug delivery device, manufacturing method, and usage |
US10953155B2 (en) | 2016-04-29 | 2021-03-23 | Verily Life Sciences Llc | Pressure sensor in plunger head to wake up electronics |
US10518039B2 (en) * | 2016-04-29 | 2019-12-31 | Verily Life Sciences Llc | Apparatus and methods for tracking administering of medication by medication injection devices |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11173247B2 (en) | 2016-07-14 | 2021-11-16 | Sanofi | Medicament delivery device |
JP7007358B2 (en) * | 2016-08-09 | 2022-02-10 | エフ ホフマン-ラ ロッシュ アクチェン ゲゼルシャフト | Portable injection device |
JP6826392B2 (en) * | 2016-08-10 | 2021-02-03 | 持田製薬株式会社 | Automatic syringe |
JP6415498B2 (en) * | 2016-08-24 | 2018-10-31 | 株式会社スズケン | Pharmaceutical inventory management system and pharmaceutical inventory management method |
CN109789277B (en) * | 2016-10-13 | 2022-03-29 | 艾斯曲尔医疗公司 | Controller for a medicament delivery device |
EP3526913A1 (en) * | 2016-10-14 | 2019-08-21 | SHL Medical AG | A self-administrative medicament device configured to send data through the human body |
WO2018096534A1 (en) | 2016-11-22 | 2018-05-31 | Sorrel Medical Ltd. | Apparatus for delivering a therapeutic substance |
EP3326671A1 (en) | 2016-11-29 | 2018-05-30 | Carebay Europe Ltd. | Activation assembly for a medicament delivery device |
EP3549374A4 (en) * | 2016-12-05 | 2020-07-08 | Quio Technologies LLC | Communication and tracking system for disposable drug delivery devices |
US20180165422A1 (en) * | 2016-12-08 | 2018-06-14 | Verily Life Sciences Llc | Systems and methods for controlling the operational state of a medical device |
KR102354959B1 (en) | 2016-12-28 | 2022-01-24 | 제넨테크, 인크. | injection monitoring device |
EP3685868A1 (en) * | 2017-01-09 | 2020-07-29 | Verily Life Sciences LLC | Systems and methods for wearable emergency drug injection devices |
CN106964014B (en) * | 2017-02-13 | 2020-03-10 | 深圳麦科田生物医疗技术有限公司 | Infusion management method and system |
MX2019010214A (en) | 2017-02-28 | 2019-10-09 | Lilly Co Eli | Dose detection and drug identification for a medication delivery device. |
CN116531613A (en) | 2017-03-31 | 2023-08-04 | 贝克顿·迪金森公司 | Intelligent wearable injection and/or infusion device |
AU2018254481A1 (en) * | 2017-04-19 | 2019-12-05 | Medimmune, Llc | E-connected auto-injectors |
US9993209B1 (en) * | 2017-04-24 | 2018-06-12 | International Business Machines Corporation | Dynamically monitoring environmental and physiological characteristics to generate a medicine ingestion alarm |
US10223248B2 (en) | 2017-05-15 | 2019-03-05 | Bank Of America Corporation | Conducting automated software testing using centralized controller and distributed test host servers |
US10489287B2 (en) | 2017-05-15 | 2019-11-26 | Bank Of America Corporation | Conducting automated software testing using centralized controller and distributed test host servers |
US10845955B2 (en) | 2017-05-15 | 2020-11-24 | Apple Inc. | Displaying a scrollable list of affordances associated with physical activities |
KR102526705B1 (en) | 2017-05-23 | 2023-04-27 | 아센디스 파마 에이에스 | Automatic injector with variable plunger force |
EP3630231B1 (en) * | 2017-05-25 | 2023-11-01 | West Pharmaceutical Services, Inc. | Smart syringe using nfc communication and capacitance detection |
JP7063920B2 (en) * | 2017-05-25 | 2022-05-09 | イネイブル インジェクションズ、インコーポレイテッド | Methods involving drug transfer and injection equipment and compliance monitoring |
EP3630238B1 (en) * | 2017-05-30 | 2021-01-20 | West Pharma. Services Il, Ltd. | Vertical assembly of pcb |
EP3630226A1 (en) | 2017-05-30 | 2020-04-08 | West Pharma. Services Il, Ltd. | Modular drive train for wearable injector |
CA3067243A1 (en) | 2017-06-13 | 2018-12-20 | Irenix Medical, Inc. | Active agent delivery devices and methods for using the same |
WO2018237225A1 (en) * | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
AU2018294519B2 (en) | 2017-06-29 | 2023-10-12 | Ascendis Pharma A/S | Auto injector with reconstitution handling support |
IL308235A (en) | 2017-06-30 | 2024-01-01 | Regeneron Pharma | Auto-injector with anti-roll features |
CA3079664A1 (en) | 2017-07-14 | 2019-01-17 | Valeritas, Inc. | Communication accessory for a drug delivery device |
US11672923B2 (en) | 2017-07-14 | 2023-06-13 | Sanofi | Packaging assembly |
US20190053981A1 (en) * | 2017-08-17 | 2019-02-21 | Qualcomm Incorporated | Temperature thresholding in drug dispensing devices |
JP7313337B2 (en) * | 2017-08-31 | 2023-07-24 | ベクトン・ディキンソン・アンド・カンパニー | System for detecting force applied during injection |
JP2021501616A (en) * | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | Drug delivery device with placement and flow detection |
US11191904B2 (en) * | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
EP3710091A2 (en) | 2017-11-14 | 2020-09-23 | Sanofi | Conserving power in an injection device |
CN111511425B (en) * | 2017-11-15 | 2023-10-27 | 戴斯维柯公司 | drug delivery device |
MA50904A (en) * | 2017-11-16 | 2020-09-23 | Amgen Inc | NEEDLE INSERTION MECHANISM FOR DRUG DELIVERY DEVICE |
CN107998488A (en) * | 2017-11-28 | 2018-05-08 | 广东嘉博制药有限公司 | A kind of infusion system of Clevidipine butyrate fat emulsion injection |
CA3085972A1 (en) * | 2017-12-19 | 2019-06-27 | Biocorp Production S.A. | Auto-injector drug delivery device |
CN111712285B (en) * | 2017-12-21 | 2022-08-12 | 赛诺菲 | Determining injection status |
EP3727519A1 (en) | 2017-12-21 | 2020-10-28 | Sanofi | Supplementary device for attachment to an injection device |
CN108154909A (en) * | 2017-12-22 | 2018-06-12 | 广东康之家云健康医药股份有限公司 | A kind of customer's medicine consumes tracking system |
WO2019136163A1 (en) | 2018-01-03 | 2019-07-11 | Irenix Medical, Inc. | Therapeutic agent delivery devices having integrated pain mitigation, and methods for using the same |
JP7069330B2 (en) | 2018-02-22 | 2022-05-17 | イーライ リリー アンド カンパニー | Drug delivery device with a device to be detected |
US11058605B2 (en) * | 2018-03-08 | 2021-07-13 | Flex Ltd. | Sterilization fluid path with barrier removal |
DK201870599A1 (en) | 2018-03-12 | 2019-10-16 | Apple Inc. | User interfaces for health monitoring |
WO2019190647A1 (en) * | 2018-03-30 | 2019-10-03 | Amgen Inc. | Camera-based drug container inspection |
JP7079893B2 (en) * | 2018-04-19 | 2022-06-02 | イーライ リリー アンド カンパニー | Status sensing system for injection devices |
US11278670B2 (en) * | 2018-04-26 | 2022-03-22 | Carefusion 303, Inc. | Semi-autonomous hot-swap infusion module |
DK201870378A1 (en) | 2018-05-07 | 2020-01-13 | Apple Inc. | Displaying user interfaces associated with physical activities |
US11317833B2 (en) | 2018-05-07 | 2022-05-03 | Apple Inc. | Displaying user interfaces associated with physical activities |
US11664107B2 (en) * | 2018-05-08 | 2023-05-30 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods using a prescription-regulated software application |
WO2019222140A1 (en) * | 2018-05-15 | 2019-11-21 | Quio Technologies Llc | Systems and methods for delivering a substance to a living being |
KR20200021794A (en) * | 2018-08-21 | 2020-03-02 | 삼성전자주식회사 | Method of controlling electronic apparatus and computer-readable recording medium |
US11324887B2 (en) * | 2018-09-14 | 2022-05-10 | Datadose, Llc | Reporting syringe |
CA3112914A1 (en) * | 2018-09-28 | 2020-04-02 | Becton, Dickinson And Company | Universal smart cap for pen injectors |
RS63595B1 (en) * | 2018-10-03 | 2022-10-31 | Lilly Co Eli | Status sensing systems within an injection device assembly |
EP3744368A1 (en) | 2018-10-05 | 2020-12-02 | Sorrel Medical Ltd. | Triggering sequence |
US10705891B2 (en) * | 2018-10-26 | 2020-07-07 | International Business Machines Corporation | Cognitive agent for persistent multi-platform reminder provision |
KR102623506B1 (en) * | 2018-11-14 | 2024-01-11 | 메디허브 주식회사 | Automatic injection apparatus and control method |
CN109472515A (en) * | 2018-11-26 | 2019-03-15 | 复旦大学附属中山医院 | It is a kind of for ensureing the monitoring method and system of cold stored medicine quality safety |
KR20210130137A (en) | 2018-12-20 | 2021-10-29 | 스카이랜드 애널리틱스 인크. | Dynamic Placement Limit Validation |
US11458292B2 (en) | 2019-05-20 | 2022-10-04 | Unomedical A/S | Rotatable infusion device and methods thereof |
US11209957B2 (en) | 2019-06-01 | 2021-12-28 | Apple Inc. | User interfaces for cycle tracking |
US11234077B2 (en) | 2019-06-01 | 2022-01-25 | Apple Inc. | User interfaces for managing audio exposure |
US11228835B2 (en) | 2019-06-01 | 2022-01-18 | Apple Inc. | User interfaces for managing audio exposure |
US11152100B2 (en) | 2019-06-01 | 2021-10-19 | Apple Inc. | Health application user interfaces |
DK201970534A1 (en) | 2019-06-01 | 2021-02-16 | Apple Inc | User interfaces for monitoring noise exposure levels |
US11094407B2 (en) * | 2019-06-13 | 2021-08-17 | International Business Machines Corporation | Electronics miniaturization platform for medication verification and tracking |
JP2022536471A (en) * | 2019-06-20 | 2022-08-17 | アムジエン・インコーポレーテツド | Wireless communicable drug delivery device and method |
WO2021007355A1 (en) * | 2019-07-10 | 2021-01-14 | Verily Life Sciences Llc | Systems and methods for wearable emergency drug injection devices |
CN112057705B (en) * | 2019-07-30 | 2023-04-18 | 嘉兴森迈医疗科技有限公司 | Injection device |
CA3148032A1 (en) * | 2019-08-01 | 2021-02-04 | Amgen Inc. | Drug delivery device with temperature measurement and related method |
EP4004702A1 (en) | 2019-09-09 | 2022-06-01 | Apple Inc. | Research study user interfaces |
US11738154B2 (en) * | 2019-09-11 | 2023-08-29 | Altaviz, Llc | Micro-volume injectors with dose guidance and methods for use |
MX2022003646A (en) * | 2019-09-25 | 2022-07-12 | Janssen Pharmaceuticals Inc | Interconnection of drug administration systems. |
BR112022005657A2 (en) * | 2019-09-25 | 2022-07-19 | Janssen Pharmaceuticals Inc | DRUG DISTRIBUTION DEVICE |
WO2021059200A1 (en) * | 2019-09-25 | 2021-04-01 | Janssen Pharmaceuticals, Inc. | Drug delivery systems and methods |
CA3156032A1 (en) * | 2019-09-25 | 2021-04-01 | Janssen Pharmaceuticals, Inc. | Measuring parameters associated with drug administration and drug administration devices incorporating same |
EP4037738A1 (en) * | 2019-10-01 | 2022-08-10 | SHL Medical AG | A cap assembly |
CN110841149A (en) * | 2019-12-18 | 2020-02-28 | 苏州嘉树医疗科技有限公司 | Low-temperature locking automatic injector |
CN114727783A (en) * | 2019-12-23 | 2022-07-08 | 费森尤斯医疗保健控股公司 | Drug delivery system for the attachment of an erythropoietin stimulating agent |
WO2021180494A1 (en) | 2020-03-11 | 2021-09-16 | Shl Medical Ag | System for evaluating a batch of medicament delivery devices, and method |
CA3077844A1 (en) * | 2020-04-03 | 2021-10-03 | Duoject Medical Systems Inc. | Method of sanitizing a medical device |
DE102020110112A1 (en) * | 2020-04-10 | 2021-10-14 | Fresenius Medical Care Deutschland Gmbh | Medical set for cannulation |
US20210345953A1 (en) * | 2020-05-06 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | Monitoring and communicating information using drug administration devices |
US11607216B2 (en) | 2020-05-06 | 2023-03-21 | Janssen Pharmaceuticals, Inc. | Adaptive responses from smart packaging of drug delivery absorbable adjuncts |
DK181037B1 (en) | 2020-06-02 | 2022-10-10 | Apple Inc | User interfaces for health applications |
USD955566S1 (en) | 2020-07-01 | 2022-06-21 | Zealand Pharma A/S | Medicament delivery device |
WO2022032024A1 (en) * | 2020-08-07 | 2022-02-10 | West Pharmaceutical Services, Inc. | Injection device and method of indicating an injection status for an injection device |
CA3190317A1 (en) * | 2020-08-27 | 2022-03-03 | David Nazzaro | Systems and methods for activating drug delivery devices |
US11698710B2 (en) | 2020-08-31 | 2023-07-11 | Apple Inc. | User interfaces for logging user activities |
JP2023543702A (en) * | 2020-09-16 | 2023-10-18 | イオフロー・カンパニー・リミテッド | Needle assembly and liquid drug injection device including the same |
US11737954B1 (en) | 2020-10-06 | 2023-08-29 | Verily Life Sciences Llc | Network-connected containers having medication stored therein |
US20220222734A1 (en) * | 2020-12-21 | 2022-07-14 | Beta Bionics, Inc. | Cloud-connected ambulatory pump integration |
US11311666B1 (en) | 2021-02-18 | 2022-04-26 | Fresenius Kabi Deutschland Gmbh | Modular wearable medicament delivery device and method of use thereof |
US11872369B1 (en) | 2021-02-18 | 2024-01-16 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof |
US11464902B1 (en) | 2021-02-18 | 2022-10-11 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with compressible reservoir and method of use thereof |
US11497847B1 (en) | 2021-02-19 | 2022-11-15 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive substrate |
US11406755B1 (en) | 2021-02-19 | 2022-08-09 | Fresenius Kabi Deutschland Gmbh | Sensing fluid flow irregularities in an on-body injector |
US11413394B1 (en) | 2021-02-19 | 2022-08-16 | Fresenius Kabi Deutschland Gmbh | Display for wearable drug delivery device |
US11607505B1 (en) * | 2021-02-19 | 2023-03-21 | Fresenius Kabi Deutschland Gmbh | Wearable injector with sterility sensors |
US11426523B1 (en) | 2021-02-19 | 2022-08-30 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a removable cartridge |
US11344682B1 (en) | 2021-02-19 | 2022-05-31 | Fresenius Kabi Deutschland Gmbh | Drug supply cartridge with visual use indicator and delivery devices that use the same |
US11633537B1 (en) | 2021-02-19 | 2023-04-25 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a pre-filled cartridge |
US20220313256A1 (en) * | 2021-03-30 | 2022-10-06 | Cilag Gmbh International | Passively powered packaging for tissue adjuncts |
US11786240B2 (en) * | 2021-03-30 | 2023-10-17 | Cilag Gmbh International | Using smart packaging in adjusting use of tissue adjuncts |
US11849950B2 (en) | 2021-03-30 | 2023-12-26 | Cilag Gmbh International | Compressible adjuncts with drug dosage control features |
US11864765B2 (en) | 2021-03-30 | 2024-01-09 | Cilag Gmbh International | Compressible adjuncts with fluid control features |
US11850332B2 (en) | 2021-03-30 | 2023-12-26 | Cilag Gmbh International | Method for treating tissue |
US11627961B2 (en) | 2021-03-30 | 2023-04-18 | Cilag Gmbh International | Compressible adjuncts with different behavioral zones |
US11504125B2 (en) | 2021-03-30 | 2022-11-22 | Cilag Gmbh International | Tissue thickness compensating adjuncts having regions of differential expansion |
US11839374B2 (en) | 2021-03-30 | 2023-12-12 | Cilag Gmbh International | Compressible adjuncts with drug release features |
US11896226B2 (en) | 2021-03-30 | 2024-02-13 | Cilag Gmbh International | Compressible adjuncts with healing-dependent degradation profile |
US11602341B2 (en) | 2021-03-30 | 2023-03-14 | Cilag Gmbh International | Compressible adjuncts with drug release features |
JP2022157793A (en) | 2021-03-31 | 2022-10-14 | 三菱重工業株式会社 | Control system, processing device, and control method |
EP4070832A1 (en) | 2021-04-07 | 2022-10-12 | medmix Switzerland AG | Keyed connectors |
US11504470B1 (en) | 2021-04-30 | 2022-11-22 | Fresenius Kabi Deutschland Gmbh | Deformable drug reservoir for wearable drug delivery device |
US11351300B1 (en) | 2021-04-30 | 2022-06-07 | Fresenius Kabl Deutschland GmbH | Drug dispensing system with replaceable drug supply cartridges |
US11419976B1 (en) | 2021-04-30 | 2022-08-23 | Fresenius Kabi Deutschland Gmbh | Wearable drug delivery device with pressurized fluid dispensing |
US11529459B1 (en) | 2021-04-30 | 2022-12-20 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive module |
US11717608B1 (en) | 2021-05-03 | 2023-08-08 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including an adhesive pad |
US11484646B1 (en) | 2021-05-04 | 2022-11-01 | Fresenius Kabi Deutschland Gmbh | Sealing systems for a reservoir of an on-body injector |
WO2023276090A1 (en) * | 2021-06-30 | 2023-01-05 | シンクランド株式会社 | Transdermal administration apparatus and transdermal administration system |
WO2023147158A1 (en) * | 2022-01-31 | 2023-08-03 | Noble International, Llc | Interrogatable delivery device and associated status module |
GB2612154C (en) * | 2022-04-14 | 2023-11-08 | Kilnmark Ltd | Medication auto-injectors |
US20230405351A1 (en) * | 2022-06-10 | 2023-12-21 | Alucent Biomedical Inc. | Sterilizable catheter and light fiber for use therewith and methods of sterilization |
DE202023107090U1 (en) | 2022-12-01 | 2024-01-24 | Nuova Ompi S.R.L. Unipersonale | Device for subcutaneous administration of a medicament |
Family Cites Families (427)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US3485239A (en) | 1967-11-02 | 1969-12-23 | Becton Dickinson Co | Self-contained sterile syringe |
US4386606A (en) | 1979-12-26 | 1983-06-07 | Waters Instruments, Inc. | Syringe lock |
US4417889A (en) | 1980-12-31 | 1983-11-29 | Choi Soo Bong | Device for a portable automatic syringe |
KR850004274A (en) | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4559038A (en) | 1984-10-19 | 1985-12-17 | Deltec Systems, Inc. | Drug delivery system |
US4654034A (en) | 1986-02-03 | 1987-03-31 | Masters Edwin J | Safety needle cap |
US5222362A (en) | 1989-01-10 | 1993-06-29 | Maus Daryl D | Heat-activated drug delivery system and thermal actuators therefor |
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
AU7323994A (en) | 1993-07-13 | 1995-02-13 | Sims Deltec, Inc. | Medical pump and method of programming |
CN1057534C (en) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | Erythropoietin analogs |
US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5582593A (en) | 1994-07-21 | 1996-12-10 | Hultman; Barry W. | Ambulatory medication delivery system |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
IE77523B1 (en) | 1995-09-11 | 1997-12-17 | Elan Med Tech | Medicament delivery device |
US5858001A (en) | 1995-12-11 | 1999-01-12 | Elan Medical Technologies Limited | Cartridge-based drug delivery device |
US5879143A (en) | 1996-04-26 | 1999-03-09 | Sims Deltec, Inc. | Reservoir enclosure adaptors and methods |
US6355019B1 (en) | 1996-12-18 | 2002-03-12 | Science Incorporated | Variable rate infusion apparatus with indicator and adjustable rate control |
US6176845B1 (en) | 1996-12-18 | 2001-01-23 | Science Incorporated | Fluid delivery apparatus with flow indicator and vial fill |
US6183441B1 (en) | 1996-12-18 | 2001-02-06 | Science Incorporated | Variable rate infusion apparatus with indicator and adjustable rate control |
US20010039397A1 (en) | 1996-12-18 | 2001-11-08 | Kriesell Marshall S. | Fluid delivery apparatus with flow indicator and vial fill |
US5991655A (en) * | 1997-03-03 | 1999-11-23 | Drug Delivery Systems, Inc. | Iontophoretic drug delivery device and method of manufacturing the same |
US6186982B1 (en) * | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
EP1881005B1 (en) | 1997-07-14 | 2013-04-03 | Bolder Biotechnology, Inc. | Derivatives of G-CSF and related proteins |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
SE9702872D0 (en) * | 1997-08-06 | 1997-08-06 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
US6171276B1 (en) | 1997-08-06 | 2001-01-09 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
US5957895A (en) | 1998-02-20 | 1999-09-28 | Becton Dickinson And Company | Low-profile automatic injection device with self-emptying reservoir |
US6030086A (en) | 1998-03-02 | 2000-02-29 | Becton, Dickinson And Company | Flash tube reflector with arc guide |
ATE254938T1 (en) | 1998-03-23 | 2003-12-15 | Elan Corp Plc | DEVICE FOR DRUG ADMINISTRATION |
US6310078B1 (en) | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US8480580B2 (en) * | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
DE69933216T2 (en) | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
DE19840965A1 (en) | 1998-09-08 | 2000-03-09 | Disetronic Licensing Ag | Device for self-administration of a product fluid |
MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
AR020848A1 (en) | 1998-10-23 | 2002-05-29 | Amgen Inc | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ANEMIA |
US7621893B2 (en) | 1998-10-29 | 2009-11-24 | Medtronic Minimed, Inc. | Methods and apparatuses for detecting occlusions in an ambulatory infusion pump |
US7766873B2 (en) | 1998-10-29 | 2010-08-03 | Medtronic Minimed, Inc. | Method and apparatus for detecting occlusions in an ambulatory infusion pump |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
JP2002544123A (en) | 1999-04-14 | 2002-12-24 | スミスクライン・ビーチャム・コーポレイション | Erythropoietin receptor antibody |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
AU1099601A (en) | 1999-10-22 | 2001-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules derived from rat brain and programmed cell death models |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
JP2003514552A (en) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Erythropoietin morphology with improved properties |
US6564105B2 (en) | 2000-01-21 | 2003-05-13 | Medtronic Minimed, Inc. | Method and apparatus for communicating between an ambulatory medical device and a control device via telemetry using randomized data |
ES2233600T5 (en) | 2000-01-21 | 2009-06-22 | Biovex Limited | VIRUSES OF HERPES. |
US20010049608A1 (en) * | 2000-01-25 | 2001-12-06 | Hochman Mark N. | Injection tracking and management system |
AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
AU5551601A (en) | 2000-04-21 | 2001-11-07 | Amgen Inc | Methods and compositions for the prevention and treatment of anemia |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US6968179B1 (en) | 2000-07-27 | 2005-11-22 | Microsoft Corporation | Place specific buddy list services |
US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
GB2366705B (en) | 2000-08-29 | 2004-07-14 | Motorola Inc | Communications system, communications unit and method of operation |
US6740059B2 (en) | 2000-09-08 | 2004-05-25 | Insulet Corporation | Devices, systems and methods for patient infusion |
AU2001273385B2 (en) | 2000-09-08 | 2005-04-07 | Gryphon Therapeutics, Inc. | Polymer-modified synthetic proteins |
AU2001289589A1 (en) * | 2000-09-22 | 2002-04-02 | Novo-Nordisk A/S | A medication delivery device |
US20020040208A1 (en) * | 2000-10-04 | 2002-04-04 | Flaherty J. Christopher | Data collection assembly for patient infusion system |
US7271689B1 (en) | 2000-11-22 | 2007-09-18 | Fonar Corporation | Magnet structure |
ATE505204T1 (en) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG) |
HUP0302525A2 (en) | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Antibodies to insulin-like growth factor i receptor |
WO2002056822A1 (en) | 2001-01-19 | 2002-07-25 | Raimo Juselius | Device for monitoring the administration of doses and system for monitoring the administration of doses |
JP2005503127A (en) | 2001-04-04 | 2005-02-03 | ジェンオディセ | Novel polynucleotides and polypeptides of erythropoietin gene |
US6817986B2 (en) | 2001-04-13 | 2004-11-16 | Avant Medical Corp. | Jet injector with data logging system for use in compliance and dose monitoring programs |
CA2446189C (en) | 2001-05-11 | 2011-10-18 | Amgen, Inc. | Peptides and related molecules that bind to tall-1 |
US20120209197A1 (en) | 2002-01-04 | 2012-08-16 | Lanigan Richard J | Infusion pump assembly |
US8034026B2 (en) | 2001-05-18 | 2011-10-11 | Deka Products Limited Partnership | Infusion pump assembly |
CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
AU2002332628B2 (en) | 2001-08-23 | 2007-07-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
WO2003055526A2 (en) | 2001-12-21 | 2003-07-10 | Maxygen Aps | Erythropoietin conjugates |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
CA2473039C (en) | 2002-01-18 | 2014-09-23 | Pierre Fabre Medicament | Novel anti-igf-ir antibodies and uses thereof |
EP1470232A1 (en) | 2002-01-31 | 2004-10-27 | Oxford Biomedica (UK) Limited | Physiologically regulated erythropoietin-expressing vector for the treatment of anaemia |
GB0202252D0 (en) | 2002-01-31 | 2002-03-20 | Oxford Biomedica Ltd | Anemia |
US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
EP2077130A3 (en) | 2002-02-18 | 2009-09-23 | CeQur ApS | Device for administering of medication in fluid form |
US20050027264A1 (en) | 2002-02-28 | 2005-02-03 | Fleury Michael T. | Huber needle with anti-rebound safety mechanism |
US6918894B2 (en) | 2002-02-28 | 2005-07-19 | Medical Product Specialists | Huber needle with anti-rebound safety mechanism |
US7033338B2 (en) | 2002-02-28 | 2006-04-25 | Smiths Medical Md, Inc. | Cartridge and rod for axially loading medication pump |
US6878136B2 (en) | 2002-02-28 | 2005-04-12 | Medical Product Specialists | Huber needle with anti-rebound safety mechanism |
JP4109204B2 (en) | 2002-03-26 | 2008-07-02 | レツク・フアーマシユーテイカルズ・デー・デー | Method for producing desired erythropoietin glycoisoform profile |
WO2003084477A2 (en) | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Mammalian cdr mimetibodies, compositions, methods and uses |
CN102212537B (en) | 2002-03-29 | 2013-08-14 | 组合化学工业株式会社 | Genes encoding acetolactate synthase |
US6960192B1 (en) | 2002-04-23 | 2005-11-01 | Insulet Corporation | Transcutaneous fluid delivery system |
US6656158B2 (en) | 2002-04-23 | 2003-12-02 | Insulet Corporation | Dispenser for patient infusion device |
US6656159B2 (en) | 2002-04-23 | 2003-12-02 | Insulet Corporation | Dispenser for patient infusion device |
US20050256035A1 (en) | 2002-05-13 | 2005-11-17 | Irving Boime | Ctp-extended erythropoietin |
NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7241733B2 (en) | 2002-06-28 | 2007-07-10 | Centocor, Inc. | Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
AU2003280130B2 (en) | 2002-06-28 | 2009-06-11 | Centocor, Inc. | Mammalian CH1 deleted mimetibodies, compositions, methods and uses |
WO2004004809A1 (en) | 2002-07-02 | 2004-01-15 | Matsushita Electric Industrial Co., Ltd. | Medical automatic medicator |
US7018360B2 (en) | 2002-07-16 | 2006-03-28 | Insulet Corporation | Flow restriction system and method for patient infusion device |
AU2003246486A1 (en) | 2002-07-19 | 2004-02-09 | Cangene Corporation | Pegylated erythropoietic compounds |
JP2005536273A (en) | 2002-08-26 | 2005-12-02 | ペンジェット・コーポレーション | Device for needle-free injection with deaerated fluid |
JP4406607B2 (en) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | Peptide and pharmaceutical containing the same |
DK2213685T3 (en) | 2002-09-06 | 2014-03-03 | Medarex Llc | Therapeutic anti-IL-1R1 monoclonal antibody |
WO2005025606A1 (en) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
WO2004024776A1 (en) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
WO2004024211A2 (en) | 2002-09-12 | 2004-03-25 | Children's Hospital Medical Center | Method and device for painless injection of medication |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
US20050075670A1 (en) | 2002-10-07 | 2005-04-07 | Henrik Bengtsson | Signal device with electro-muscle stimulation feature |
US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
ATE496938T1 (en) | 2002-12-20 | 2011-02-15 | Amgen Inc | MYOSTATIN INHIBITING BINDERS |
JP2006520251A (en) * | 2003-03-06 | 2006-09-07 | ライフスキャン・インコーポレイテッド | System and method for piercing skin tissue |
BRPI0408317A (en) | 2003-03-14 | 2006-03-07 | Pharmacia Corp | igf-i receptor antibodies for cancer treatment |
JP4473257B2 (en) | 2003-04-02 | 2010-06-02 | エフ.ホフマン−ラ ロシュ アーゲー | Antibodies against insulin-like growth factor I receptor and uses thereof |
AU2004232289A1 (en) * | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
CA2522855A1 (en) | 2003-04-23 | 2004-11-04 | Vasogen Ireland Limited | Dispensing systems |
EP1622942B1 (en) | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DE602004028725D1 (en) | 2003-05-12 | 2010-09-30 | Affymax Inc | NEW POLY (ETHYLENGLYCOL) MODIFIED ERYTHROPOIETINAGONISTS AND THEIR USES |
MXPA05012313A (en) | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptides that bind to the erythropoietin receptor. |
KR101163683B1 (en) | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | Novel peptides that bind to the erythropoietin receptor |
US7074755B2 (en) | 2003-05-17 | 2006-07-11 | Centocor, Inc. | Erythropoietin conjugate compounds with extended half-lives |
KR20060032140A (en) | 2003-05-30 | 2006-04-14 | 센토코 인코포레이티드 | Formation of novel erythropoietin conjugates using transglutaminase |
DE10325106A1 (en) | 2003-06-03 | 2004-12-30 | Disetronic Licensing Ag | Device and method for recognizing a user of a medical device |
US20050037390A1 (en) | 2003-06-04 | 2005-02-17 | Irm Llc, A Delaware Limited Liability Company | Methods and compositions for modulating erythropoietin expression |
WO2005000384A1 (en) | 2003-06-05 | 2005-01-06 | University Of Florida | Auto-injection devices and methods for intramuscular administration of medications |
JP2007511252A (en) | 2003-06-09 | 2007-05-10 | ニプロ ダイアビティーズ システムズ,インコーポレイテッド | Coupling system in infusion pump |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Specific binding agents to hepatocyte growth factor |
US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
EP2609946B1 (en) | 2003-08-12 | 2018-05-16 | Becton, Dickinson and Company | Patch-like infusion device with shielding member |
JP2007512001A (en) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | EPO mimetic peptides and fusion proteins |
UA89481C2 (en) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
EP1687452A4 (en) | 2003-09-30 | 2008-08-06 | Centocor Inc | Human hinge core mimetibodies, compositions, methods and uses |
WO2005046559A2 (en) * | 2003-11-06 | 2005-05-26 | Lifescan, Inc. | Drug delivery pen with event notification means |
TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
KR20060120141A (en) | 2003-11-24 | 2006-11-24 | 네오스 테크놀로지스, 인크. | Glycopegylated erythropoietin |
WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
EP1548031A1 (en) | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
WO2005065239A2 (en) | 2003-12-31 | 2005-07-21 | Centocor, Inc. | Novel recombinant proteins with n-terminal free thiol |
ES2387028T3 (en) | 2003-12-31 | 2012-09-12 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with enhanced pharmacokinetics |
US7423139B2 (en) | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
WO2005070451A1 (en) | 2004-01-22 | 2005-08-04 | Zafena Aktiebolag | Pharmaceutical composition comprising non-glycosylated erythropoietin |
WO2005084711A1 (en) | 2004-03-02 | 2005-09-15 | Chengdu Institute Of Biological Products | A pegylated recombinant erythropoietin that has in vivo activity |
TW200603818A (en) | 2004-03-11 | 2006-02-01 | Fresenius Kabi De Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
JP2007530045A (en) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | Human OX40L (CD134L) specific monoclonal antibody |
US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
US20080194475A1 (en) | 2004-04-23 | 2008-08-14 | Andrew Buchanan | Erythropoietin Protein Variants |
US7220245B2 (en) | 2004-05-26 | 2007-05-22 | Kriesel Marshall S | Infusion apparatus |
PT1781697E (en) | 2004-07-07 | 2009-06-25 | Lundbeck & Co As H | Novel carbamylated epo and method for its production |
FR2873699B1 (en) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
US20060073563A1 (en) | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
EP1640029A1 (en) | 2004-09-24 | 2006-03-29 | Novo Nordisk A/S | Injection device with cap |
CA2586915A1 (en) | 2004-11-10 | 2006-05-18 | Aplagen Gmbh | Molecules which promote hematopoiesis |
EP1830699A2 (en) | 2004-12-22 | 2007-09-12 | Novo Nordisk A/S | Sensor system and method for detecting problems with mounting of skin mountable medical devices |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
US8361026B2 (en) * | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US8231573B2 (en) * | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
CA2762072C (en) | 2005-02-01 | 2017-08-29 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
GB2462209A (en) | 2005-02-11 | 2010-02-03 | Stryker Corp | A fluid delivery system with fluid flow detection means |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
WO2006123329A2 (en) | 2005-05-17 | 2006-11-23 | Medingo Ltd. | Disposable dispenser for patient infusion |
US20060263839A1 (en) | 2005-05-17 | 2006-11-23 | Isense Corporation | Combined drug delivery and analyte sensor apparatus |
EP1893256B1 (en) | 2005-06-16 | 2012-09-26 | Novo Nordisk A/S | Method and apparatus for assisting patients in self administration of medication |
US8128929B2 (en) | 2005-06-17 | 2012-03-06 | Imclone Llc | Antibodies against PDGFRa |
WO2007002052A2 (en) | 2005-06-21 | 2007-01-04 | Eli Lilly And Company | Apparatus and method for injecting a pharmaceutical |
WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
JP5142998B2 (en) | 2005-07-18 | 2013-02-13 | アムジエン・インコーポレーテツド | Human anti-B7RP1 neutralizing antibody |
FR2888850B1 (en) | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
US20070038181A1 (en) | 2005-08-09 | 2007-02-15 | Alexander Melamud | Method, system and device for delivering a substance to tissue |
US20070060870A1 (en) | 2005-08-16 | 2007-03-15 | Tolle Mike Charles V | Controller device for an infusion pump |
PE20071101A1 (en) | 2005-08-31 | 2007-12-21 | Amgen Inc | POLYPEPTIDES AND ANTIBODIES |
WO2007035666A2 (en) | 2005-09-19 | 2007-03-29 | Lifescan, Inc. | Electrokinetic infusion pump system |
DE102005052502A1 (en) | 2005-11-03 | 2007-05-16 | Tecpharma Licensing Ag | Auto-injector activation trigger element |
US7935104B2 (en) * | 2005-11-07 | 2011-05-03 | Medingo, Ltd. | Systems and methods for sustained medical infusion and devices related thereto |
US20150057615A1 (en) | 2005-11-08 | 2015-02-26 | Asante Solutions | Infusion Pump System |
EP1962947A4 (en) | 2005-12-20 | 2017-06-28 | Antares Pharma, Inc. | Needle-free injection device |
EA200870212A1 (en) * | 2006-01-31 | 2009-12-30 | Арес Трейдинг С.А. | INJECTION DEVICE WITH CAPACITIVE NON-CONTACT SENSOR |
CA2641569C (en) | 2006-02-09 | 2015-10-06 | Deka Products Limited Partnership | Fluid delivery systems and methods |
US9839743B2 (en) | 2006-02-09 | 2017-12-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
US9008764B2 (en) | 2006-03-20 | 2015-04-14 | Novo Nordisk A/S | Determination of position of injection needle |
NZ570731A (en) | 2006-03-29 | 2011-07-29 | Intelliject Inc | Device to deliver medication with circuit producing recorded speech output and movable structure to effectuate delivery and circuit |
TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
US8348885B2 (en) * | 2006-04-28 | 2013-01-08 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US20070270744A1 (en) | 2006-05-17 | 2007-11-22 | Bruno Dacquay | Limited Reuse Assembly For Ophthalmic Injection Device |
US7851438B2 (en) | 2006-05-19 | 2010-12-14 | GlycoFi, Incorporated | Erythropoietin compositions |
US20070282269A1 (en) | 2006-05-31 | 2007-12-06 | Seattle Medical Technologies | Cannula delivery apparatus and method for a disposable infusion device |
WO2007149514A2 (en) | 2006-06-19 | 2007-12-27 | Corium International, Inc. | Methods, devices, and kits for microjet drug delivery |
TWI527603B (en) * | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | Automatic injection device |
US8044778B2 (en) | 2007-07-12 | 2011-10-25 | Henry Schein, Inc. | Injection device and case with reporting ability |
US20080014550A1 (en) | 2006-07-13 | 2008-01-17 | Henry Schein, Inc. | Dental handpiece performance sensor |
WO2008082704A2 (en) * | 2006-08-08 | 2008-07-10 | Insulet Corporation | Interactive training system and method |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
US20100010418A1 (en) | 2006-09-29 | 2010-01-14 | Koninklijke Philips Electronics N. V. | Electrically activated gel array for transdermal drug delivery |
US20080234625A1 (en) | 2006-10-16 | 2008-09-25 | Bruno Dacquay | Fuse Assembly For Single Use Medical Device |
WO2008047373A2 (en) | 2006-10-19 | 2008-04-24 | Mfs Medical Flow Systems Ltd. | Device and method for patient activated bolus administration |
US20100040611A1 (en) | 2006-11-07 | 2010-02-18 | Sparrow Carl P | Antagonists of pcsk9 |
JP5588175B2 (en) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | PCSK9 antagonist |
CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
US20080119705A1 (en) | 2006-11-17 | 2008-05-22 | Medtronic Minimed, Inc. | Systems and Methods for Diabetes Management Using Consumer Electronic Devices |
CA2671538A1 (en) | 2006-12-14 | 2008-06-26 | Leonard G. Presta | Engineered anti-tslp antibody |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
IL185737A0 (en) | 2007-09-05 | 2008-01-06 | Sindolor Medical Ltd | A device and method for piercing a patient's skin with an injector whilst reducing pain caused by the piercing |
WO2008091838A2 (en) | 2007-01-22 | 2008-07-31 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
MX2009009999A (en) * | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Method and device for drug delivery. |
WO2008114220A2 (en) | 2007-03-19 | 2008-09-25 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
EP2129415B1 (en) | 2007-03-22 | 2018-10-24 | Tecpharma Licensing AG | Injection device with controlled needle retraction |
CN101679527A (en) | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
WO2008139464A1 (en) | 2007-05-10 | 2008-11-20 | Nilimedix Ltd | Infusion set self-occlusion mechanism |
US7794426B2 (en) | 2007-05-21 | 2010-09-14 | Asante Solutions, Inc. | Infusion pump system with contamination-resistant features |
US7981102B2 (en) | 2007-05-21 | 2011-07-19 | Asante Solutions, Inc. | Removable controller for an infusion pump |
KR20100034015A (en) | 2007-06-20 | 2010-03-31 | 아이알엠 엘엘씨 | Methods and compositions for treating allergic diseases |
CN101801438B (en) | 2007-07-20 | 2013-08-07 | 梅丁格有限公司 | Manually operable portable infusion device |
US8683381B2 (en) | 2007-08-09 | 2014-03-25 | Alfred E. Mann Foundation For Scientific Research | Drug delivery safety system |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US20090082730A1 (en) | 2007-09-24 | 2009-03-26 | Li Nguyen | Needle injection assembly |
US8062256B2 (en) | 2007-09-28 | 2011-11-22 | Calibra Medical, Inc. | Disposable infusion device with medicament level indicator |
US7771391B2 (en) | 2007-09-28 | 2010-08-10 | Calibra Medical, Inc. | Disposable infusion device with snap action actuation |
TWI451862B (en) * | 2007-10-09 | 2014-09-11 | Alcon Res Ltd | Thermal coefficient driven drug pellet size for ophthalmic injection |
US20090099525A1 (en) | 2007-10-11 | 2009-04-16 | Animas Corporation | Drug Delivery System with Breakaway Plunger Extractor |
SG2013014352A (en) | 2007-10-26 | 2014-09-26 | Merck Sharp & Dohme | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
WO2009059187A1 (en) * | 2007-11-02 | 2009-05-07 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US7875022B2 (en) | 2007-12-12 | 2011-01-25 | Asante Solutions, Inc. | Portable infusion pump and media player |
US8409133B2 (en) * | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US7976505B2 (en) | 2007-12-19 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device negative pressure filling apparatus and method |
US10188787B2 (en) | 2007-12-31 | 2019-01-29 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
EP2254621A2 (en) | 2008-02-04 | 2010-12-01 | Nilimedix Ltd. | Drug delivery system with wireless monitor |
AR070315A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
US8540673B2 (en) | 2008-03-18 | 2013-09-24 | Calibra Medical, Inc. | Disposable infusion device with actuation lock-out |
WO2009120692A2 (en) | 2008-03-25 | 2009-10-01 | Animal Innovations, Inc. | Syringe mechanism for detecting syringe status |
US8801679B2 (en) | 2008-04-10 | 2014-08-12 | Panasonic Healthcare Co., Ltd. | Medication administering device |
US20090259194A1 (en) | 2008-04-11 | 2009-10-15 | Raffi Pinedjian | Keyed Safety Cap and Receptacle for Two Piece Injection Device |
JP5836120B2 (en) * | 2008-05-20 | 2015-12-24 | アヴァント・メディカル・コーポレーション | Auto injector system |
US9295786B2 (en) * | 2008-05-28 | 2016-03-29 | Medtronic Minimed, Inc. | Needle protective device for subcutaneous sensors |
US7976500B2 (en) | 2008-06-26 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device with redundant valved safety |
US8361030B2 (en) | 2008-06-26 | 2013-01-29 | Calibra Medical, Inc. | Disposable infusion device with occlusion detector |
US8231577B2 (en) | 2008-06-26 | 2012-07-31 | Calibra Medical, Inc. | Disposable infusion device with automatically releasable cannula driver |
GB0814747D0 (en) | 2008-08-13 | 2008-09-17 | Owen Mumford Ltd | Autoinjection devices |
KR101251152B1 (en) * | 2008-09-10 | 2013-04-05 | 에프. 호프만-라 로슈 아게 | Delivery device for use with a therapeutic drug |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
US9427529B2 (en) | 2008-09-15 | 2016-08-30 | Medimop Medical Projects Ltd. | Safeguard mechanism for autoinjector needle |
CA3132517C (en) * | 2008-09-15 | 2024-04-30 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
EP2349412B1 (en) * | 2008-10-01 | 2019-07-24 | Novo Nordisk A/S | Medical assembly with monitoring device |
US20090192443A1 (en) | 2008-10-06 | 2009-07-30 | Collins Jr James F | Ophthalmic fluid delivery device and method of operation |
US8262616B2 (en) | 2008-10-10 | 2012-09-11 | Deka Products Limited Partnership | Infusion pump assembly |
US8223028B2 (en) | 2008-10-10 | 2012-07-17 | Deka Products Limited Partnership | Occlusion detection system and method |
US8016789B2 (en) | 2008-10-10 | 2011-09-13 | Deka Products Limited Partnership | Pump assembly with a removable cover assembly |
EP2345893B1 (en) | 2008-11-04 | 2016-05-04 | Panasonic Healthcare Holdings Co., Ltd. | Measurement device, measurement method, and program |
US20100121274A1 (en) | 2008-11-12 | 2010-05-13 | Baxter International Inc. | Prefillable constant pressure ambulatory infusion pump |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
US9370621B2 (en) | 2008-12-16 | 2016-06-21 | Medtronic Minimed, Inc. | Needle insertion systems and methods |
JO3382B1 (en) | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
CN107412916A (en) | 2009-02-27 | 2017-12-01 | 生命扫描有限公司 | Delivery system |
US8496623B2 (en) | 2009-03-02 | 2013-07-30 | Becton, Dickinson And Company | Bi-directional cannula feature capture mechanism |
WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
DE102009002537A1 (en) | 2009-04-21 | 2010-10-28 | Robert Bosch Gmbh | Medical device to be used by a patient |
US7976493B2 (en) | 2009-05-05 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device with resettable last dose lock-out |
WO2010135184A1 (en) * | 2009-05-18 | 2010-11-25 | Telcordia Technologies, Inc. | A mobile enabled social networking application to support closed, moderated group interactions for purpose of facilitating therapeutic care |
US8777897B2 (en) | 2009-07-06 | 2014-07-15 | Carefusion 303, Inc. | Fluid delivery systems and methods having wireless communication |
US8344847B2 (en) | 2009-07-09 | 2013-01-01 | Medtronic Minimed, Inc. | Coordination of control commands in a medical device system having at least one therapy delivery device and at least one wireless controller device |
US8882710B2 (en) | 2009-09-02 | 2014-11-11 | Medtronic Minimed, Inc. | Insertion device systems and methods |
US10071198B2 (en) | 2012-11-02 | 2018-09-11 | West Pharma. Servicees IL, Ltd. | Adhesive structure for medical device |
ES2393278T3 (en) | 2009-09-25 | 2012-12-20 | Carebay Europe Limited | Medical administration device |
EP2480576A4 (en) | 2009-09-25 | 2013-04-10 | Merck Sharp & Dohme | Antagonists of pcsk9 |
US9035744B2 (en) | 2009-10-01 | 2015-05-19 | Blackberry Limited | Method and apparatus for monitoring and controlling a medical device using a wireless mobile communication device |
US7967773B2 (en) | 2009-10-13 | 2011-06-28 | Smiths Medical Asd, Inc. | Two piece medication cassette closure apparatus and method |
SG179126A1 (en) | 2009-10-13 | 2012-04-27 | Valeritas Inc | Fluid delivery device |
JP2013509191A (en) | 2009-10-30 | 2013-03-14 | メルク・シャープ・エンド・ドーム・コーポレイション | AX1 and AX189PCSK9 antagonists and variants |
WO2011053783A2 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax213 and ax132 pcsk9 antagonists and variants |
US8945066B2 (en) | 2009-11-06 | 2015-02-03 | Crisi Medical Systems, Inc. | Medication injection site and data collection system |
US8449504B2 (en) | 2009-11-11 | 2013-05-28 | Calibra Medical, Inc. | Wearable infusion device and system |
AR079336A1 (en) | 2009-12-11 | 2012-01-18 | Irm Llc | ANTAGONISTS OF THE PRO-PROTEIN CONVERTASE-SUBTILISINE / TYPE 9 QUEXINE (PCSK9) |
IN2012DN05228A (en) | 2009-12-16 | 2015-10-23 | Becton Dickinson Co | |
DK3527239T3 (en) | 2009-12-16 | 2021-04-26 | Becton Dickinson Co | SELF-INJECTION DEVICE |
IN2012DN05230A (en) | 2009-12-16 | 2015-10-23 | Becton Dickinson Co | |
US10195340B2 (en) | 2009-12-16 | 2019-02-05 | Becton, Dickinson And Company | Self-injection device |
EP2512579B1 (en) | 2009-12-16 | 2016-11-30 | Becton, Dickinson and Company | Self-injection device |
US8070723B2 (en) | 2009-12-31 | 2011-12-06 | Medtronic Minimed, Inc. | Activity guard |
US20110160696A1 (en) | 2009-12-31 | 2011-06-30 | Abbott Diabetes Care Inc. | Injection port device adapted for use with insulin pump |
US10911515B2 (en) | 2012-05-24 | 2021-02-02 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
US9662438B2 (en) * | 2010-02-05 | 2017-05-30 | Deka Products Limited Partnership | Devices, methods and systems for wireless control of medical devices |
US9492607B2 (en) | 2010-02-05 | 2016-11-15 | Deka Products Limited Partnership | Infusion pump apparatus, method and system |
EP2536451B1 (en) | 2010-02-18 | 2018-03-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector with a torsion spring |
WO2011106030A1 (en) | 2010-02-25 | 2011-09-01 | Lifescan Scotland Limited | Analyte testing method and system with safety warnings for insulin dosing |
CN102844332B (en) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
TW201200190A (en) | 2010-03-26 | 2012-01-01 | Sanofi Aventis Deutschland | Electro-mechanical drug delivery device |
US20130184640A1 (en) | 2010-04-20 | 2013-07-18 | Minipumps, Llc | Accurate flow control in drug pump devices |
US20110275987A1 (en) * | 2010-04-20 | 2011-11-10 | Minipumps, Llc | Piston-driven drug pump devices |
JP5809242B2 (en) | 2010-04-21 | 2015-11-10 | アッヴィ バイオテクノロジー リミテッド | Wearable automatic infusion device for controlled delivery of therapeutic agents |
US9737659B2 (en) | 2010-05-12 | 2017-08-22 | Bioq Pharma Incorporated | Apparatus for dispensing medicinal fluids and method of making same |
US8821454B2 (en) | 2010-05-12 | 2014-09-02 | Bioquiddity, Inc. | Apparatus for dispensing medicinal fluids and method of making same |
EA032537B1 (en) * | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Method of operation of a drug delivery device |
US11462321B2 (en) * | 2010-08-12 | 2022-10-04 | Fenwal, Inc. | Mobile applications for blood centers |
CA2808457C (en) * | 2010-08-17 | 2018-09-04 | University Of Florida Research Foundation, Inc. | Intelligent drug and/or fluid delivery system to optimize medical treatment or therapy using pharmacodynamic and/or pharmacokinetic data |
WO2012032411A2 (en) | 2010-09-07 | 2012-03-15 | Tecpharma Licensing Ag | Automatic injection device |
US20120066140A1 (en) | 2010-09-14 | 2012-03-15 | Nokia Corporation | Method and apparatus for monitoring adherence to prescribed regimens |
US8915879B2 (en) | 2010-09-24 | 2014-12-23 | Perqflo, Llc | Infusion pumps |
US9498573B2 (en) * | 2010-09-24 | 2016-11-22 | Perqflo, Llc | Infusion pumps |
US9308320B2 (en) | 2010-09-24 | 2016-04-12 | Perqflo, Llc | Infusion pumps |
US9216249B2 (en) | 2010-09-24 | 2015-12-22 | Perqflo, Llc | Infusion pumps |
EP2438945A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Reusable engine for an auto-injector |
US8707392B2 (en) * | 2010-10-15 | 2014-04-22 | Roche Diagnostics Operations, Inc. | Systems and methods for disease management |
WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
US9211378B2 (en) | 2010-10-22 | 2015-12-15 | Cequr Sa | Methods and systems for dosing a medicament |
CN103347555B (en) | 2010-11-03 | 2015-02-18 | 赛诺菲-安万特德国有限公司 | Medicated module with interlock |
US8905972B2 (en) | 2010-11-20 | 2014-12-09 | Perqflo, Llc | Infusion pumps |
GB201020472D0 (en) * | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | A drive assembly for an autoinjector |
GB201020475D0 (en) | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | Delivery mechanism for an autoinjector |
US20130261561A1 (en) | 2010-12-17 | 2013-10-03 | Sanofi-Aventis Deutschland Gmbh | Medicament Administration |
EA201390929A1 (en) | 2010-12-22 | 2013-12-30 | Дженентек, Инк. | ANTIBODIES TO PCSK9 AND METHODS OF THEIR APPLICATION |
KR102423708B1 (en) * | 2011-01-19 | 2022-07-20 | 프랙틸 헬쓰, 인코포레이티드 | Devices and methods for the treatment of tissue |
PL3395836T3 (en) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
KR20140006022A (en) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 antagonists |
US8639288B1 (en) | 2011-02-22 | 2014-01-28 | Medavie Technologies | Injector device |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
DK2689359T3 (en) | 2011-03-24 | 2021-02-08 | Sanofi Aventis Deutschland | APPARATUS AND METHOD FOR DETECTING AN ACTIVATION ACTION THAT CAN BE PERFORMED WITH A MEDICAL DEVICE |
DK2691131T3 (en) | 2011-03-30 | 2015-11-16 | Sanofi Aventis Deutschland | Injection device |
EP2700424B1 (en) | 2011-04-19 | 2018-01-10 | Terumo Kabushiki Kaisha | Infusion pump |
JP6038884B2 (en) * | 2011-04-20 | 2016-12-07 | アムゲン・インコーポレーテッド | Automatic injection device |
ES2605817T3 (en) | 2011-04-21 | 2017-03-16 | Abbvie Inc. | Portable automatic injection device |
WO2012152628A1 (en) | 2011-05-06 | 2012-11-15 | Novo Nordisk A/S | System for optimizing a drug dosage regimen over time |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
JP2014519374A (en) | 2011-05-10 | 2014-08-14 | インスリン メディカル リミテッド | Device, system and method for facilitating syringe-type drug delivery and management thereof |
DK2714152T3 (en) | 2011-05-25 | 2018-03-26 | Sanofi Aventis Deutschland | COVER MEDICINE ADMINISTRATION DEVICE |
JP6050331B2 (en) * | 2011-05-25 | 2016-12-21 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drug delivery device with medication interface sensor and method for controlling the device |
EP2537546A1 (en) | 2011-06-21 | 2012-12-26 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with dose control mechanism |
EP2731644B1 (en) | 2011-07-15 | 2019-02-20 | Sanofi-Aventis Deutschland GmbH | Drug delivery device with electro-mechanic drive mechanism |
US9821116B2 (en) | 2011-07-25 | 2017-11-21 | Preciflex Sa | Fluid dispenser |
WO2013029999A1 (en) | 2011-09-02 | 2013-03-07 | F. Hoffmann-La Roche Ag | Dosing unit for an ambulatory infusion device |
US9707335B2 (en) | 2011-09-02 | 2017-07-18 | Unitract Syringe Pty Ltd | Drive mechanism for drug delivery pumps with integrated status indication |
WO2013030000A1 (en) | 2011-09-02 | 2013-03-07 | F. Hoffmann-La Roche Ag | Dosing unit for an ambulatory infusion device |
US8905944B2 (en) | 2011-09-07 | 2014-12-09 | Vlv Associates, Inc. | Protective cover assembly for a needle assembly |
AU2012306063B2 (en) | 2011-09-09 | 2017-05-25 | Merck Patent Gmbh | Reloadable auto-injector |
WO2013050535A2 (en) * | 2011-10-07 | 2013-04-11 | Novo Nordisk A/S | System for determining position of element |
IL216158A0 (en) | 2011-11-06 | 2011-12-29 | Medimop Medical Projects Ltd | Electronic autoinjector apparatus and cassettes for use therewith |
WO2013070715A1 (en) | 2011-11-07 | 2013-05-16 | Battelle Memorial Institute | Injection devices with ergonomic enhancements |
DE102011119000A1 (en) | 2011-11-21 | 2013-05-23 | Liebherr-Verzahntechnik Gmbh | Gear cutting machine and method for producing or machining gears |
US10058655B2 (en) | 2011-11-22 | 2018-08-28 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device with controller and time lock-out mechanism for its drive |
US20140108031A1 (en) | 2011-12-29 | 2014-04-17 | Daniel Ferrara | System and method for increasing medication adherence rates |
US10335545B2 (en) | 2012-01-31 | 2019-07-02 | West Pharma. Services IL, Ltd. | Time dependent drug delivery apparatus |
CN104245022A (en) | 2012-01-31 | 2014-12-24 | 普雷斯弗雷克斯股份公司 | Injection device using dry carrier |
EP2628494A1 (en) | 2012-02-17 | 2013-08-21 | Sensile Pat AG | Liquid storage and delivery system |
WO2013127428A1 (en) | 2012-02-27 | 2013-09-06 | F. Hoffmann-La Roche Ag | Spring force assembly for biasing or actuating stoppers of syringes, injection pen cartridges and the like |
US20130226608A1 (en) | 2012-02-28 | 2013-08-29 | Christopher Di Lascia | System for identifying, monitoring, influencing and rewarding healthcare behavior |
MX347426B (en) | 2012-03-02 | 2017-04-26 | Abbvie Inc | Automatic injection training device. |
WO2013136185A2 (en) | 2012-03-13 | 2013-09-19 | Becton Dickinson France | Method of manufacture for a miniaturized drug delivery device |
US9072827B2 (en) | 2012-03-26 | 2015-07-07 | Medimop Medical Projects Ltd. | Fail safe point protector for needle safety flap |
WO2013155426A1 (en) | 2012-04-13 | 2013-10-17 | Becton, Dickinson And Company | Infusion device with safety feature for preventing inadvertent activation |
US9335910B2 (en) | 2012-04-23 | 2016-05-10 | Tandem Diabetes Care, Inc. | System and method for reduction of inadvertent activation of medical device during manipulation |
EP2656865A1 (en) | 2012-04-24 | 2013-10-30 | Sanofi-Aventis Deutschland GmbH | Syringe carrier with needle shield and data storage device for use in a medical auto-injection device |
US8817258B2 (en) | 2012-05-21 | 2014-08-26 | Common Sensing Inc. | Dose measurement system and method |
AU2013266864B2 (en) * | 2012-05-24 | 2017-04-06 | Deka Products Limited Partnership | Apparatus for infusing fluid |
US9715327B2 (en) | 2012-06-07 | 2017-07-25 | Tandem Diabetes Care, Inc. | Preventing inadvertent changes in ambulatory medical devices |
EP2674179A1 (en) | 2012-06-15 | 2013-12-18 | Ares Trading S.A. | Injection device |
US8700133B2 (en) * | 2012-06-18 | 2014-04-15 | Smart Iv Llc | Apparatus and method for monitoring catheter insertion |
RU2649473C2 (en) * | 2012-07-05 | 2018-04-03 | Юнитрект Сириндж Пти Лтд | Automatic injectors for injectable cartridges and drive control mechanism therefor |
EP2682141A1 (en) | 2012-07-06 | 2014-01-08 | Sanofi-Aventis Deutschland GmbH | Injection system |
US20140012118A1 (en) | 2012-07-09 | 2014-01-09 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
CN109497960B (en) * | 2012-07-10 | 2021-06-25 | 贝克顿迪金森法国两合公司 | Integrated injection system, integrated injection device and method of monitoring an injection event |
US8454557B1 (en) | 2012-07-19 | 2013-06-04 | Asante Solutions, Inc. | Infusion pump system and method |
CN104619368B (en) | 2012-07-31 | 2018-11-30 | 三伟达保健系统有限责任公司 | For the device and method from infusion pump distribution fluid |
US9867929B2 (en) | 2012-08-15 | 2018-01-16 | Becton, Dickinson And Company | Pump engine with metering system for dispensing liquid medication |
EP2698180A1 (en) | 2012-08-15 | 2014-02-19 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
AU2013308699B2 (en) * | 2012-08-29 | 2018-03-01 | Unl Holdings Llc | Controlled delivery drive mechanisms for drug delivery pumps |
WO2014037331A1 (en) | 2012-09-06 | 2014-03-13 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration |
US20140088554A1 (en) | 2012-09-24 | 2014-03-27 | Po-Ying Li | Drug-delivery pump with intelligent control |
US9782538B2 (en) | 2012-09-27 | 2017-10-10 | Becton, Dickinson And Company | Angled inserter for drug infusion |
EP2716317A1 (en) | 2012-10-04 | 2014-04-09 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with trigger button |
US9789250B2 (en) | 2012-10-05 | 2017-10-17 | Becton, Dickinson And Company | Infusion set with safety device |
JP2014079325A (en) * | 2012-10-15 | 2014-05-08 | Seiko Epson Corp | Fluid injection apparatus |
EP2722065A1 (en) | 2012-10-18 | 2014-04-23 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
JP6205701B2 (en) | 2012-10-22 | 2017-10-04 | セイコーエプソン株式会社 | Fluid injection device |
GB201218913D0 (en) | 2012-10-22 | 2012-12-05 | Ucb Pharma Sa | Auto-injector and drive unit therefor |
WO2014064691A2 (en) | 2012-10-23 | 2014-05-01 | Insuline Medical Ltd. | Drug dispensing-tracking device, system and method |
JP2014087449A (en) | 2012-10-30 | 2014-05-15 | Seiko Epson Corp | Liquid transport device and method for determining catheter drop-out |
JP6426107B2 (en) | 2012-12-20 | 2018-11-21 | アムジエン・インコーポレーテツド | APJ receptor agonists and uses thereof |
GB2523512A (en) | 2012-12-27 | 2015-08-26 | Kaleo Inc | Devices, systems and methods for locating and interacting with medicament delivery systems |
DE202013000411U1 (en) | 2013-01-16 | 2013-01-24 | H & B Electronic Gmbh & Co. Kg | Continuous infusion device |
JP6273655B2 (en) | 2013-01-25 | 2018-02-07 | ユーエヌエル ホールディングス エルエルシーUNL Holdings LLC | Integrated fluid pathway connection and drug container |
US10617820B2 (en) | 2013-01-25 | 2020-04-14 | Unl Holdings Llc | Fluid restriction mechanisms for drug delivery pumps |
EP2764881B1 (en) | 2013-02-06 | 2017-09-13 | Medirio SA | System for medical treatment |
US9446186B2 (en) | 2013-03-01 | 2016-09-20 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
US20140274874A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
CN111499733A (en) | 2013-03-14 | 2020-08-07 | 美国安进公司 | Variants, compositions and methods of tissue inhibitors of type three metalloprotease (TIMP-3) |
US20140276423A1 (en) | 2013-03-14 | 2014-09-18 | Tandem Diabetes Care, Inc. | Infusion system and methods |
ES2799305T3 (en) | 2013-03-15 | 2020-12-16 | Becton Dickinson Co | Smart adapter for infusion devices |
US10229607B2 (en) | 2013-04-30 | 2019-03-12 | Elwha Llc | Systems and methods for competency training and use authorization for dispensing an agent |
US9889252B2 (en) | 2013-06-14 | 2018-02-13 | Medtronic, Inc. | Infusion device assembly |
US20150005703A1 (en) | 2013-06-28 | 2015-01-01 | Animas Corporation | Drug infusion device with safety interlock |
EP2865325B1 (en) | 2013-10-23 | 2017-11-22 | F. Hoffmann-La Roche AG | Skin-adherable cradle for infusion pump or continuous blood glucose monitor having optical indication means |
US10130755B2 (en) | 2013-12-31 | 2018-11-20 | Abbvie Inc. | Devices and methods for delivering a beneficial agent to a user |
EP3177345B1 (en) | 2014-03-14 | 2021-11-10 | SHL Medical AG | A monitoring device |
US10195342B2 (en) | 2014-04-24 | 2019-02-05 | Becton, Dickinson And Company | Cannula deployment mechanism |
SG11201609963PA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Devices and methods for assisting a user of a drug delivery device |
-
2015
- 2015-06-03 SG SG11201609963PA patent/SG11201609963PA/en unknown
- 2015-06-03 US US15/315,896 patent/US20170098058A1/en not_active Abandoned
- 2015-06-03 CA CA2948003A patent/CA2948003C/en active Active
- 2015-06-03 KR KR1020167032415A patent/KR102416904B1/en active IP Right Grant
- 2015-06-03 EP EP15729033.9A patent/EP3151884A1/en active Pending
- 2015-06-03 EP EP15730345.4A patent/EP3152694B1/en active Active
- 2015-06-03 CN CN201580029198.9A patent/CN106663139A/en active Pending
- 2015-06-03 AU AU2015271767A patent/AU2015271767B2/en active Active
- 2015-06-03 SG SG10201806528QA patent/SG10201806528QA/en unknown
- 2015-06-03 WO PCT/US2015/033946 patent/WO2015187805A2/en active Application Filing
- 2015-06-03 WO PCT/US2015/033925 patent/WO2015187793A1/en active Application Filing
- 2015-06-03 KR KR1020167032417A patent/KR102506614B1/en active IP Right Grant
- 2015-06-03 SG SG11201609970VA patent/SG11201609970VA/en unknown
- 2015-06-03 CN CN202010550731.9A patent/CN111840696B/en active Active
- 2015-06-03 AU AU2015271763A patent/AU2015271763B2/en active Active
- 2015-06-03 MX MX2016015851A patent/MX2016015851A/en unknown
- 2015-06-03 KR KR1020167032416A patent/KR20170016335A/en active Application Filing
- 2015-06-03 SG SG10201806563QA patent/SG10201806563QA/en unknown
- 2015-06-03 JP JP2016570991A patent/JP6817074B2/en active Active
- 2015-06-03 EP EP15728736.8A patent/EP3151882B1/en active Active
- 2015-06-03 KR KR1020237007289A patent/KR20230037063A/en not_active Application Discontinuation
- 2015-06-03 KR KR1020167032414A patent/KR102506249B1/en active IP Right Grant
- 2015-06-03 JP JP2016571023A patent/JP6822843B2/en active Active
- 2015-06-03 CN CN201580029455.9A patent/CN106470716B/en active Active
- 2015-06-03 IL IL297356A patent/IL297356A/en unknown
- 2015-06-03 SG SG11201609966SA patent/SG11201609966SA/en unknown
- 2015-06-03 US US15/315,922 patent/US20170124285A1/en active Pending
- 2015-06-03 KR KR1020227035873A patent/KR20220143782A/en not_active Application Discontinuation
- 2015-06-03 WO PCT/US2015/033939 patent/WO2015187802A1/en active Application Filing
- 2015-06-03 JP JP2016570990A patent/JP6808494B2/en active Active
- 2015-06-03 CN CN202111156962.2A patent/CN113990437A/en active Pending
- 2015-06-03 MX MX2016015853A patent/MX2016015853A/en unknown
- 2015-06-03 WO PCT/US2015/033933 patent/WO2015187797A1/en active Application Filing
- 2015-06-03 CA CA2948005A patent/CA2948005C/en active Active
- 2015-06-03 MX MX2016015854A patent/MX2016015854A/en unknown
- 2015-06-03 JP JP2016571049A patent/JP6742248B2/en active Active
- 2015-06-03 CA CA2949846A patent/CA2949846C/en active Active
- 2015-06-03 CN CN202010825780.9A patent/CN112237662B/en active Active
- 2015-06-03 IL IL281354A patent/IL281354B1/en unknown
- 2015-06-03 US US15/315,817 patent/US10695492B2/en active Active
- 2015-06-03 AU AU2015271769A patent/AU2015271769A1/en not_active Abandoned
- 2015-06-03 AU AU2015271676A patent/AU2015271676A1/en not_active Abandoned
- 2015-06-03 EP EP15728737.6A patent/EP3151883A1/en not_active Ceased
- 2015-06-03 US US15/315,954 patent/US20170103186A1/en not_active Abandoned
- 2015-06-03 CN CN201580029453.XA patent/CN106488782B/en active Active
- 2015-06-03 EP EP22158912.0A patent/EP4036924A1/en active Pending
- 2015-06-03 US US15/315,829 patent/US10646652B2/en active Active
- 2015-06-03 CA CA2948525A patent/CA2948525A1/en active Pending
- 2015-06-03 WO PCT/US2015/033935 patent/WO2015187799A1/en active Application Filing
- 2015-06-03 EP EP24163506.9A patent/EP4362039A2/en active Pending
- 2015-06-03 MX MX2016015926A patent/MX2016015926A/en unknown
- 2015-06-03 SG SG11201609972RA patent/SG11201609972RA/en unknown
- 2015-06-03 CN CN201580028862.8A patent/CN106470717B/en active Active
-
2016
- 2016-11-03 IL IL248730A patent/IL248730B/en unknown
- 2016-11-03 IL IL248731A patent/IL248731B/en active IP Right Grant
- 2016-11-06 IL IL248756A patent/IL248756B/en active IP Right Grant
- 2016-11-06 IL IL248757A patent/IL248757B2/en unknown
- 2016-12-01 MX MX2023005376A patent/MX2023005376A/en unknown
- 2016-12-01 MX MX2021012555A patent/MX2021012555A/en unknown
- 2016-12-01 MX MX2023003211A patent/MX2023003211A/en unknown
- 2016-12-02 MX MX2023000722A patent/MX2023000722A/en unknown
-
2020
- 2020-03-04 AU AU2020201600A patent/AU2020201600C1/en active Active
- 2020-03-24 AU AU2020202096A patent/AU2020202096B2/en active Active
- 2020-04-08 US US16/843,622 patent/US11213624B2/en active Active
- 2020-05-13 US US15/931,364 patent/US11738146B2/en active Active
- 2020-06-26 AU AU2020204260A patent/AU2020204260A1/en not_active Abandoned
- 2020-10-22 AU AU2020257127A patent/AU2020257127A1/en not_active Abandoned
- 2020-10-26 JP JP2020178668A patent/JP2021035515A/en active Pending
- 2020-12-08 JP JP2020203182A patent/JP7100106B2/en active Active
- 2020-12-23 JP JP2020213220A patent/JP7126540B2/en active Active
-
2021
- 2021-03-09 IL IL281369A patent/IL281369B/en unknown
- 2021-11-05 AU AU2021261964A patent/AU2021261964B2/en active Active
- 2021-11-23 US US17/534,173 patent/US20220257862A1/en active Pending
-
2022
- 2022-01-05 AU AU2022200026A patent/AU2022200026B2/en active Active
- 2022-06-29 JP JP2022104384A patent/JP2022137121A/en active Pending
- 2022-08-15 JP JP2022129187A patent/JP2022172150A/en active Pending
- 2022-09-08 US US17/940,422 patent/US20230098606A1/en active Pending
- 2022-10-19 AU AU2022256116A patent/AU2022256116B2/en active Active
-
2023
- 2023-02-17 US US18/111,064 patent/US20230201461A1/en active Pending
- 2023-06-30 AU AU2023204188A patent/AU2023204188A1/en not_active Abandoned
- 2023-07-06 US US18/218,782 patent/US20230355877A1/en active Pending
- 2023-11-22 AU AU2023270272A patent/AU2023270272A1/en active Pending
- 2023-12-26 JP JP2023218940A patent/JP2024050546A/en active Pending
-
2024
- 2024-03-06 JP JP2024033584A patent/JP2024061771A/en active Pending
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10646652B2 (en) | 2014-06-03 | 2020-05-12 | Amgen Inc. | Controllable drug delivery system and method of use |
US11738146B2 (en) | 2014-06-03 | 2023-08-29 | Amgen Inc. | Drug delivery system and method of use |
US11213624B2 (en) | 2014-06-03 | 2022-01-04 | Amgen Inc. | Controllable drug delivery system and method of use |
IL281369A (en) * | 2014-06-03 | 2021-04-29 | Amgen Inc | Systems and methods for remotely processing data collected by a drug delivery device |
US10695492B2 (en) | 2014-06-03 | 2020-06-30 | Amgen Inc. | Drug delivery system and method of use |
US10182969B2 (en) | 2015-03-10 | 2019-01-22 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
US11406565B2 (en) | 2015-03-10 | 2022-08-09 | Regeneran Pharmaceuticals, Inc. | Aseptic piercing system and method |
US20180308571A1 (en) * | 2015-10-09 | 2018-10-25 | Duke University | Medication administration and adherence systems and related methods |
US11901068B2 (en) * | 2016-03-14 | 2024-02-13 | Fenwal, Inc. | Cell processing methods with process parameter control |
US20210398664A1 (en) * | 2016-03-14 | 2021-12-23 | Fenwal, Inc. | Cell processing method |
US11547801B2 (en) | 2017-05-05 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP4292576A2 (en) | 2017-07-21 | 2023-12-20 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
EP4257164A2 (en) | 2017-10-06 | 2023-10-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022256116B2 (en) | Systems and methods for remotely processing data collected by a drug delivery device | |
US11207460B2 (en) | Drug delivery storage device and system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMGEN INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GIBSON, SCOTT R.;BUSBY, DONALD;TAMTORO, FERRY;AND OTHERS;SIGNING DATES FROM 20151118 TO 20161231;REEL/FRAME:041556/0469 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |